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Summary 
In recent decades many developed countries have seen unprecedented increases in 
incidence of Human Papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma 
(OPSCC). HPV-positive OPSCC represents a new disease entity and preclinical assessment of 
novel therapies is hampered by a lack of relevant in vitro models. It is well-established that 
HPV-positive OPSCC patients generally survive longer than HPV-negative patients, and this may 
be partly attributable to defective repair of DNA double-strand-breaks in HPV-positive 
tumours. 
This study aimed to develop novel cell line models of HPV-OPSCC and use them, and 
previously validated lines, to test the hypothesis that defective DNA repair in HPV-positive cells 
could be exploited by synthetic lethal therapy using the Poly (ADP-ribose) polymerase (PARP) 
inhibitor Olaparib. 
Two novel HPV-positive OPSCC cell lines were derived and characterised. mRNA 
sequencing confirmed expression of the HPV oncogenes and HPV integration state, but did not 
show consistent differences in transcript levels of genes involved in DNA repair between HPV-
positive and negative lines. The effects of Olaparib were assessed in a panel of eight cell lines, 
including effects on colony formation, cell cycle distribution, DNA double-strand-break 
persistence and p53 activity. All lines were sensitive to high doses of Olaparib (10 μM), 
however at doses between 0.5-1 μM, the surviving fractions differed significantly between 
lines. Two HPV-positive lines were sensitive to Olaparib (Surviving Fraction (SF)<40%), and two 
were resistant (SF>80%). Neither HPV-status, nor basal levels of PARP correlated with Olaparib 
sensitivity. The data were not consistent with the original hypothesis, but did suggest that 
monotherapy with PARP inhibitors might be useful in some OPSCC patients. 
The study also included an investigation into the natural history of HPV in the 
oropharynx. This demonstrated that HPV infection is a rare event in non-malignant tonsil 
tissue (prevalence of 0%: 95% confidence interval (CI) 0-0.58%). 
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Chapter 1 - Introduction 
1.1 Human Papillomavirus  
Papillomaviruses are found in many species, but in higher vertebrates in particular. Over 
200 types have been described in human so far (Doorbar et al. 2016). Papillomaviruses are 
strictly species specific and display a tropism towards epithelial cells, both in cutaneous and 
mucosal epithelium, often in specific locations (Egawa et al. 2015). 
1.1.1 Taxonomy 
Papillomaviruses were originally classified in the phylogenic group papovaviridae 
together with the polyomaviruses with which they share the same basic structure, being non-
enveloped viruses with double stranded DNA. However their genomes and protein expression 
differ and two separate families, the polyamaviridae and the papillomaviridae, were classified 
in the 1970s (Fenner 1976). Papillomaviruses are classified genetically, based on the DNA 
sequence of the highly conserved L1 Open Reading Frame (ORF). The main subgroups, called 
genera, share less than 60% sequence similarity with one another.  
Human Papillomaviruses (HPV) are divided in to Alpha, Beta, Gamma, Mu and Nu genera 
with the majority in Alpha and Beta. Each genera is further divided into smaller groups or 
species, which comprise several types of papillomaviruses. Virus types differ in at least 10% of 
the L1 sequence whilst subtypes are defined by sequence variations smaller than 10% (2-10%). 
The numbering dates back to early research on HPV typing and corresponds to the order of 
discovery (de Villiers et al. 2004; Egawa et al. 2015). Phylogenetic tree representations do not 
usually correspond to any pathological features of the viruses, although the oncogenic HPV 
types, including HPV16 and 18, are all members of the Alpha genus (Doorbar et al. 2012). In 
humans an alternative classification, developed with regards to the 40 types which can infect 
the genital mucosa, and referring to pathological implications, is often used. HPV are 
separated in two categories, high risk and low risk, which describes their oncogenic potential. 
The high risk group comprises at least 14 types, the main ones being HPV16 and 18 
predominantly associated with anogenital cancers. The most common low risk types of HPV 
are HPV6 and 11, which are the main causal agents for genital warts (Muñoz et al. 2003). 
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1.1.2 Physical and genetic structure 
HPV are non-enveloped viruses, with a 55 nm diameter icosahedral capsid. The capsid is 
formed of two proteins: L1 (55 kDa), the major capsid protein, comprising about 80% of the 
capsid, and L2 (50 kDa) comprising the remaining 20%. The capsid is composed of 72 
pentameres of the L1 protein (capsomeres), at the centre of which a unit of the L2 protein can 
be present, there are between 12 and 72 units of L2 in a capsid. A notable feature of the HPV 
capsid, is the capacity for self-assembly of L1 into pentameres and then into a full capsid. This 
property is exploited for the production of virus-like-particle vaccines directed against the 
main oncogenic types of HPV and HPV6 and 11 which cause genital warts (Buck et al. 2008). 
The 7900 bp genome of HPV consists of double stranded DNA. It contains 8 overlapping 
ORF and is divided in to three regions (Figure 1.1). The early (E) region of around 4 kb, encodes 
6 proteins expressed at the beginning of the viral life cycle and involved in the replication and 
pathogenicity of the virus. The 3 kb late (L) region, encodes the capsid proteins L1 and L2 that 
are expressed towards the end of the viral cycle (Doorbar et al. 2016). The Long Control Region 
(LCR) is situated between the E and L sequences, and is a non-coding regulatory region 
involved in the control of genes expression as well as encapsidation, replication and 
transcription of the genome. This region also contains the promoter sequences of the E genes. 
High risk HPV have two promoters: P97, involved in the expression of E genes is situated 
upstream of the E6 open reading frame, and the P742 (P670) promoter, located in the E7 ORF 
which functions as the main promoter for late gene expression (Longworth and Laimins 2004). 
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Figure 1.1: HPV16 genomic structure 
HPV16 genome is composed of 6 early genes, whose products are involved in virus replication, 
and two late genes, encoding the capsid proteins. The LCR is involved in gene regulation. 
 
1.1.3 HPV life cycle and infection 
HPV is one of the most common sexually transmitted viruses. Most sexually active 
people will contract a genital HPV infection at some point in their life, however the majority of 
infections are transient, and few will persist and develop into a neoplasia (Moscicki et al. 
2010). HPV infection and life cycle are closely related to the differentiation and maturation of 
epithelial cells. The viral life cycle and subsequent infection can be divided in the steps 
described below. 
1.1.3.1 Cell entry 
The virus infects cells in the basal epithelial layer which are reached through micro 
abrasions. Alternatively, in some cases the nature of the epithelium, such as a reticulated 
epithelium in the tonsils, can facilitate the virus access to the basal layer. Once the virus 
reaches the basal layer of the epithelium, part of the L1 protein binds to heparan sulfate 
proteoglycans on the keratinocytes surface or the extracellular matrix (Culp et al. 2006). 
Several heparan sulfate proteoglycans, which could be involved in this process, have been 
described. The main one is syndecan-1 which is mainly expressed in epithelial cells and up-
regulated during wound healing (Elenius et al. 1991). The binding causes a conformational 
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change in L1 which exposes a highly conserved furin convertase site on L2 (Day et al. 2008). 
The exposed site leads to the furin mediated cleavage of the N-terminal region of L2. Another 
site in turn becomes exposed on L1, this neutralizing epitope is then able to bind to secondary 
cellular receptors (such as integrins α6 and β4) (Shafti-keramat et al. 2003) ). Following binding 
to the cellular surface, the virions are internalized into the host cell. Various mechanism of 
entry have been described, but recently the endocytosis has been shown to be independent of 
clathrin, caveolin, lipid raft, flotillin, cholesterol and dynamin (Schelhaas et al. 2012). The virus 
uncoats in the endosome and escapes through an L2 mediated mechanism. An L2 and HPV 
genome complex is formed and trafficked through the cytoplasm to the nucleus where RNA 
transcription begins (Raff et al. 2013). 
1.1.3.2 Maintenance phase 
After cellular entry, the viral genome is maintained in an episomal form at a low level, 
around 50-100 copies per cell, with low level expression of E genes (Flores et al. 1999). 
Transcription of the early genes is regulated by the P97 early promoter located on the 3’ end 
of the LCR region. Various cellular transcription factors and the E2 gene products are involved 
in its regulation (Kammer et al. 2000). Activation of P97 in the early stage of infection leads to 
the constant expression of low level E1 and E2 proteins (Wilson et al. 2005). E1 binds to the 
origin of replication site, and exhibits an Adenosine Triphosphate (ATP) dependent helicase 
activity, causing the unwinding and separation of the DNA double helix necessary for the 
initiation of replication (Lin et al. 2002; Longworth and Laimins 2004). E2 functions in 
conjunction with E1, binding to sequences in the LCR region close to the E1 binding site. The C 
terminal region of E2 facilitates E1 binding to the DNA (Sedman and Stenlund 1998). E2 also 
plays an important role in the establishment of a productive infection. During mitosis, E2 
ensures the efficient segregation of viral genomes into daughter cells (Van Tine et al. 2004). 
Another role of E2 is the regulation, both positive and negative, of gene expression. Its binding 
sites overlap with the sites of various transcription factors, with which E2 interacts. This 
includes P97 which is positively regulated by low E2 concentration and negatively by high level 
of E2, enabling the self-regulation of P97. This process ensures a balanced level of viral gene 
products such as E6 and E7 and promotes stable genome replication in undifferentiated cells 
(Steger and Corbach 1997; Longworth and Laimins 2004). E4 and E5 proteins are involved in 
the regulation of the later events of the cycle (Fehrmann et al. 2003). 
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1.1.3.3 Proliferation and amplification 
In epithelia, the basal layer cells divide, producing daughter cells which separate from 
the basal membrane, and differentiate as they progress through the layers. Fully differentiated 
cells are shed once they reach the epithelial surface. E6 and E7 activity is increased once this 
process begins. Together they enable cells to continue cycling which maintains a supply of the 
S-phase cellular factors necessary for genome replication, and prevents cellular differentiation.  
E7 causes the degradation of retinoblastoma protein (pRb), promoting entry into S-
phase (Dyson 1998). E7 is also able to interact with other types of proteins with roles related 
to cell proliferation such as histone deacetylases and cyclin dependent kinase inhibitors p21 
and p27 (Doorbar 2005). The activities of the E6 protein are complementary to E7, and are 
primarily involved with preventing apoptosis (zur Hausen 2002). In order to produce viral 
particles in the host cell, the viral genome is amplified. This amplification process results in 
accumulation of a higher number of genome copies in the upper layers of the epithelium 
(Middleton et al. 2003). During this phase of the viral cycle, the late promoter P670 (E2 
independent) is activated in terminally differentiated cells and favors the expression of the 
early proteins involved in DNA replication (E1, 2, 4 and 5). This results in an increase of viral 
copy number to about 1000 per cell (Flores et al. 1999).  
1.1.3.4 Assembly 
The last stages of the cycle consist of the encapsidation of the genomes to form full 
virions that are subsequently released. The late genes (L1 and L2) are expressed in the upper 
epithelial layers, followed by self-assembly of the capsid. Viral assembly involves the 
coordinated association between human proteins, HPV DNA, L1 L2 and E2 proteins (Doorbar et 
al. 2016). The viral particles are then released when the host cells naturally shed at the 
epithelial surface, this mechanism of release contributes to the low immune response against 
the virus, as there is no pathological cell death (Woodman et al. 2007). 
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1.1.4 Molecular biology of HPV mediated carcinogenesis 
The malignant transformation of HPV infected cells is a rare and accidental event (Ho 
1995). When it occurs, the pattern of HPV gene expression is disrupted and the virus loses the 
capacity to produce virions. This type of infection is therefore referred as non-productive 
(Münger and Howley 2002; Middleton et al. 2003). E6 and E7 are central to malignant 
transformation, their effects are described in more details below together with other factors 
promoting carcinogenesis. 
1.1.4.1 Cell cycle progression 
The c-terminal end of E6 protein comprises a PDZ binding domain enabling interaction 
with a range of human proteins containing a PDZ domain (Thomas et al. 2008; Pim et al. 2012). 
The PDZ binding activity is also involved in cell cycle regulation via the expression of cyclin B1, 
necessary for the G2/M transition (Russo et al. 2006). Other identified protein interactions are 
involved in the regulation of cell polarity, adhesion and differentiation (Elsum et al. 2012).  
E7 causes the degradation of pRb and pRb-related proteins, resulting in release of 
transcription factor E2F, which regulates the expression of genes involved in G1/S-phase 
progression (Figure 1.2), leading to inappropriate cell cycle progression (Dyson 1998). This 
includes increased expression of cyclin A and E, as well as modifications of cyclin dependent 
kinase 2 (CDK2) activity (Duensing and Münger 2004). One of the genes up-regulated by E2F 
activity encodes p16, which is involved in regulation of cell cycle progression via a negative 
feedback loop suppressing cyclinD/CDK4-6 mediated phosphorylation of pRb. During HPV 
infection, p16 levels increase but the feedback loop is ineffective, as release of E2F is no longer 
cyclinD/CDK4-6 dependent. Hence p16 is often used as a biomarker of HPV infection. E7 is also 
able to interact with other types of proteins with roles related to cell proliferation such as 
histone deacetylases and CDK inhibitors p21 and p27 (Doorbar 2005). CDK and their inhibitors 
are essential to cell cycle regulation. p21 and p27 are involved in preventing G1/S progression 
via the inhibition of CDK. Hence neutralization of p21 and p27 due to E7 binding results in 
constantly high levels of CDK activity and unregulated G1/S progression. 
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Figure 1.2: Effect of E6 and E7 on HPV infected epithelial cells 
The Rb tumour suppressor protein regulates progression through the G1/S cell cycle 
checkpoint. In normal epithelia E2F transcription factors are only released when Rb is 
phosphorylated by the cyclinD/CDK4 complex. Binding of E2F transcription factors to multiple 
promotors results in increased expression of genes involved in S-phase progression. E2F 
transcription factors also activate a negative feedback loop in which increased expression of 
p16 inhibits the activity of the cyclinD/CDK4 complex leading to reduced expression of E2F 
dependent genes. Additional feedback is achieved via p14/ARF, which inhibits Mdm2-
mediated degradation of p53 resulting in accumulation of p53 which promotes cell cycle 
arrest. In HPV infected epithelia, HPV E7 protein binds Rb and causes the release of E2F 
transcription factors, but negative feedback does not occur as release of E2F is no longer 
driven by cyclinD/CDK4. 
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1.1.4.2 p53 degradation 
E6 associates with the endogenous ubiquitin ligase E6-Apurine apyrimidic (AP), and this 
complex targets p53 for ubiquitinylation eventually leading to proteosomal degradation. This 
inhibits the apoptotic response which should be associated with forced entry into S-phase, and 
also facilitates the accumulation of mutations and consequent genomic instability (zur Hausen 
2002).  
1.1.4.3 Telomerase activity  
E6 has several p53 independent functions, and these include increasing the activity of 
the human telomerase reverse transcriptase (hTERT), the catalytic subunit of telomerase, by 
targeting its promoter repressor for proteosomal degradation. hTERT is also indirectly 
activated by E6 through the degradation of p53. E6 also directly interacts with the telomerase 
complex to increase telomerase activity. This enables the maintenance of telomere integrity 
following multiple divisions, and contributes to replicative immortality (Klingelhutz et al. 1996). 
The effects of loss of cell cycle control and p53 mediated, combined with telomerase activation 
are summarized in Figure 1.3.  
 
 
Figure 1.3: The combined effects of HPV gene expression 
The E7 protein deregulates the activity of Rb resulting in uncontrolled proliferation. This would 
ordinarily be associated with p53 mediated cell cycle arrest and apoptosis, but this is 
circumvented by reduced levels of p53 due to the activities of the HPV E6 protein. 
Uncontrolled proliferation normally results in replicative senescence associated with telomere 
shortening, but telomere length is maintained due to increased telomerase activity associated 
with presence of HPV E6 protein. 
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1.1.4.4 Genomic instability 
Expression of HPV E6 and E7, and consequent unregulated cell cycle progression, 
contribute to the accumulation of mutations and genomic instability in the host cell. E7, via its 
inhibiting effect on some protein kinases (e.g. cyclinE cyclinA/CDKD2 complexes), can lead to 
abnormal centrosome and centriole number. The joint effect of E6 and E7 can result in 
incorrect chromosome numbers and aberrant mitotic figures (Duensing et al. 2000; Duensing 
et al. 2001). Genomic instability also facilitates integration of the viral DNA into the host 
genome. Integration occurs mainly, but not exclusively, at common fragile sites in the human 
genome. Integration does not seem to be sequence specific and lots of variation can be seen in 
the integration sites (Thorland et al. 2003). During integration, viral DNA is often disrupted in 
or near the genes encoding E2 and E1 or other regions downstream of E6 and E7. This often 
disrupts the expression of E2 which, as mentioned earlier, is involved in the negative 
regulation of E6 and E7 expression. Loss of E2 control facilitates the high level and long term 
expression of E6 and E7, hence viral integration is thought to be an important factor in 
carcinogenesis (Choo et al. 1987). However, integration events are not present in all patients, 
implying that there are alternative reasons for dysregulation of viral gene expression (Moody 
and Laimins 2010). 
1.1.5 HPV and cancer 
Since the 1960s studies involving first animal, and then human, data indicated a 
probable association between papillomavirus and cancer (Olson et al. 1965). The link between 
HPV and cervical cancer was more firmly established in 1983, by work conducted in the 
laboratory of Prof. Harald zur Hausen. It showed the presence of HPV16 DNA in cervical 
cancers from women diagnosed in diverse geographical locations, including Germany, Kenya 
and Brazil (Dürst et al. 1983). HPV was subsequently identified in 99.7% of cervical cancers, 
with two types alone causing 70% of the lesions. HPV 16 was reported in c. 50% of cases and 
HPV 18 in c.20%; the remaining cases were caused by other high risks types of HPV 
(Walboomers et al. 1999). This lead to HPV being regarded as a “necessary, but not sufficient” 
factor in the aetiology of cervical cancer. Over the past two decades, other types of cancers, in 
both men and women have also been associated with high risk HPV infections. These include 
anogenital cancers (vulva, penis, anus) and head and neck cancers (IARC 2007). 
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1.2 Oropharyngeal squamous cells carcinoma 
1.2.1 Anatomy of the oropharynx 
Head and neck cancers refer to a variety of upper aerodigestive tract, craniofacial bone, 
skin and soft tissue neoplasms, i.e. they encompass several anatomical sites, in which the 
disease behaviour can differ markedly. The oropharynx is situated posterior to the oral cavity 
and connects it with the nasopharynx (above) and larynx (below). In the oral cavity, the 
oropharynx is delimited by the palatoglossal arch. The palatine tonsils, lingual tonsils and the 
posterior third of the tongue, soft palate and posterior pharyngeal wall are all part of the 
oropharynx (Figure 1.4). 
The aerodigestive tract represents a significant potential entry route for pathogens and 
therefore contains several lymphoid tissues located around the tract, described as Waldeyer’s 
ring. This includes the palatine and lingual tonsils, situated in the oropharynx. The tonsils are 
formed by a stratified squamous epithelium with invaginations that forming the crypts (Figure 
1.5). The tonsil crypts are covered by a reticulated (net-like) epithelium which facilitates the 
interaction between antigens and immune cells. Lymphoid nodules are present under the 
epithelial surface and the base of the tonsil is separated from surrounding tissue by a capsule. 
The oropharynx itself is predominantly covered by squamous epithelia. 
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Figure 1.4: Anatomy of the oropharynx 
The oropharynx is located posterior to the oral cavity and includes the soft palate (the back 
part of the roof of the mouth), the side and back wall of the throat, the tonsils and the back 
third of the tongue. Picture obtained from Cancer Research UK.  
 
 
Figure 1.5: Anatomy of the palatine tonsil 
The surface epithelia deeply invaginates forming crypts (highlighted in the black box). Drawing 
by Max Brödel, John Hopkins University.  
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1.2.2 Epidemiology 
 Head and neck cancers, which include oropharyngeal tumours, are estimated to be the 
10th most common cancers worldwide, but are the 7th highest cause of cancer related deaths. 
In 90% of cases these tumours are squamous cell carcinomas (SCC). The incidence of head and 
neck SCC (HNSCC) varies with geographical location, higher incidence rates are observed in the 
Indian subcontinent, Australia, France, Brazil, and Southern Africa. Nasopharyngeal cancer is 
disproportionately common in southern China. In recent years the incidence of oral, laryngeal, 
and other smoking related cancers has stabilised or declined in North America and Western 
Europe. Incidence also correlates with gender, with higher rates observed in men. Incidence 
also increases with age, in Europe, 98% are over 40 years of age, and 50% are over 60 years of 
age (Mehanna et al. 2010; Ferlay et al. 2015).  
Over recent decades, the epidemiology of HNSCC has changed. In the UK, the incidence 
of oral cavity, laryngeal, and hypopharyngeal cancers has remained relatively stable, and this 
has been attributed mostly to the tobacco prevention campaigns and the resulting decrease in 
its use.(Schache et al. 2016). In contrast, a significant increase in oropharyngeal cancer 
incidence has occurred. Similar trends have been observed in several countries including the 
USA, where oropharyngeal cancers rose by 2.5% a year between 2002 and 2012 (Mourad et al. 
2017). In the UK, the number of oropharyngeal cancers doubled during the last decade, the 
age-standardized rate in 2002 was 2.1 (95% Confidence Interval (CI), 1.9–2.2) and rose to 4.1 
(95% CI, 4.0–4.3) by 2011 (Schache et al. 2016).  
Historically, alcohol and tobacco consumption have been the primary risk factors in the 
development of Oropharyngeal Squamous Cell Carcinoma (OPSCC), with a synergistic effect 
when combined (Franceschi et al. 1990; Smith et al. 1998).The rise in oropharyngeal cancer 
incidence has been also been observed in non-tobacco and alcohol consumers of a younger 
age group. In the past two decades, HPV has been recognised as an important risk factor for 
head and neck cancers, and for OPSCC especially. A causal link has been established between 
the presence of HPV infected cells and SCC (Smith et al. 1998; Gillison et al. 2000). Since 2007, 
HPV has been recognised as a risk factor for OPSCC by the World Health Organisation (IARC 
2007). Distinct trends in incidence of HPV-positive compared to HPV-negative tumours have 
been reported depending on the geographical location, with higher rates of HPV-positive 
disease in western Europe compared to eastern Europe or Asia (Mehanna et al. 2016). In the 
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UK, the proportion of HPV-positive and negative OPSCC remained constant in the past decade 
(around 50% each) whilst the incidence of both doubled (Schache et al. 2016). In South Wales, 
the proportion of HPV-positive OPSCC was 55% during the 2001-2006 period (Evans et al. 
2013). Relative to HPV-negative tumours, HPV-positive OPSCC display characteristic 
pathological, molecular and clinical features, and hence can be regarded as a distinct disease 
entity (Gillison and Shah 2001).  
1.2.3 Risk factors 
The main risk factors for HNSCC in general are the consumption of tobacco and alcohol. 
The higher the consumption of tobacco, the higher the risk of head and neck cancer 
(Franceschi et al. 1990). Tobacco consumption is not limited to active smoking, passive 
smoking as well as smokeless tobacco products also contribute to carcinogenesis (Zhang et al. 
2000; Muwonge et al. 2008). Some components of tobacco smoke such as polycyclic 
hydrocarbons are known carcinogens, and when metabolised, some of the products formed 
can bind to DNA forming mutagenic DNA adducts (Gelboin 1980). Regarding ex-smokers, the 
associated risk of developing HNSCC decreases with cessation of smoking, but remains higher 
than for a non-tobacco user (Schlecht et al. 1999). Tobacco consumption is frequently 
associated with p53 mutations, which are a common feature of HPV-negative tumours 
(Brennan et al. 1995). 
The second major risk factor is consumption of alcohol, which is another known 
carcinogen involved in many types of cancer. The oncogenic effect of alcohol is mainly due to 
its metabolite acetaldehyde which directly damages DNA (Baan et al. 2007). Together, the 
effects of tobacco and alcohol are synergistic, as alcohol acts to increase the effect of the 
tobacco metabolites on the cell. This could be due to the fact that it is a solvent and could 
increase the time of exposure of tissues to those metabolites (Pai and Westra 2009). Clearly, 
many people who consume tobacco and alcohol do not develop head and neck cancers, but 
genetic polymorphisms or mutation in the enzymes metabolising alcohol and tobacco, and in 
the detoxification pathways, can increase the effect of alcohol and tobacco in some 
individuals. For instance, polymorphisms and/or mutations in the ALDH2 gene encoding 
acetaldehyde dehydrogenase, which detoxifies acetaldehyde produced during alcohol 
metabolism, increase the risk of heavy alcohol consumers to develop HNSCC (Hakenewerth et 
al. 2011). 
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As it is the case for most cancers, genetic factors can predispose to the development of 
head and neck neoplasms. People with a family member who developed a head and neck 
neoplasm have an increased risk of developing one too. Various genetic mutations could be 
linked to a higher risk of HNSCC. These include mutations in DNA Base Excision Repair (BER) 
genes and Single Nucleotide Polymorphism (SNP) such as one in the 10q23 region identified 
through genome wide association studies (Kowalski et al. 2009; Yuan et al. 2013). Other factors 
that have been associated with increased risk of developing head and neck cancers include 
diets poor in fruit and vegetables, poor dental hygiene, smoke and chemicals, immune system 
deficiency, and body mass index. These risk factors often occur in combination (Lissowska et al. 
2003; Hashim et al. 2016). 
Some patients do not present with any major risk factors but nonetheless develop 
HNSCC. Studies investigating this population led to the identification of HPV in different stages 
of the disease (invasive and lymph nodes) and as a causal agent for some head and neck 
cancers. HPV associated tumours are mostly located in the oropharynx (57%) compared to the 
other regions of the head and neck. The type distribution of HPV differs between cervical and 
HNSCC. In HNSCC, a higher proportion (over 90%) of  tumours are associated with HPV16, with 
other high risk types, mainly HPV 31, 33 and 18, present in the remainder (Gillison and Shah 
2001). The tumours originate mostly from the lingual and palatine tonsils crypts but can also 
originate from other areas of the oropharynx (Begum et al. 2005). As it is the case in cervical 
cancer, sexual behaviour influences risk of HPV-associated OPSCC. A high number of sexual 
partners increases the risks of infection by high risk types of HPV, and for OPSCC, oral sex is 
also considered a risk factor. People with 6 or more sexual partner throughout their life and 4 
or more oral sex partners have been shown to have an increased risk of developing HNSCC 
(Heck et al. 2010).  
1.2.4 Natural history 
The association between HPV and oropharyngeal cancer has only been convincingly 
established relatively recently, hence the natural history of HPV infection in the oropharynx 
and oral cavity, is not yet well defined. OPSCC appear to most commonly arise in the tonsillar 
crypts (Begum et al. 2005). Due to this localisation, pre-malignant and early stage lesions are 
very difficult to detect, hence screening protocols such as those used for cervical cancer are 
likely to be impractical (Franceschi et al. 2015).  
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OPSCC affects predominantly men, and rates are up to 4 fold higher in men compared to 
women. This disparity is observed for both HPV-negative and HPV-positive OPSCC. For HPV-
negative disease, this has been attributed to higher consumption of tobacco and alcohol in 
men than women (Evans et al. 2013; Schache et al. 2016). Why this disparity is also present in 
HPV-positive disease is less clear, however several hypotheses have been suggested. It could 
partially be explained by the higher prevalence of oral high risk HPV infection in men. In the 
USA in the 2009-2010 period, the oral prevalence was 3.6% in women vs 10.1% in men. This 
included two peaks: 7.3% and 11.4% in men aged 30-34 and 60-64 respectively (Gillison et al. 
2012). However, this finding is not consistent across the literature as some studies report very 
little variation in oral HPV prevalence between men and women (Kreimer et al. 2010). Sexual 
behaviour, including the number of lifetime sexual partners may also play a role. In the USA, 
men have been reported to have on average a higher number of partners than women 
(D’Souza et al. 2014). Different rates of seroconversion between men and women following 
HPV infection could also be relevant. Following natural genital infection with HPV, some 
people develop detectable antibodies against the virus while others do not. The higher the 
antibody titre, the higher the protection to subsequent infection compared to seronegative 
individuals (Safaeian et al. 2010). Several studies have shown a higher level of seroconversion 
in women compared to men. In one study in England, seroconversion for HPV6, 11, 16, and 18 
was 16.4%, 5.7%, 14.7%, and 6.3%, respectively, among females, compared to 7.6%, 2.2%, 
5.0%, and 2.0%, respectively, among males (i.e. seroconversion for all types was significantly 
higher in females than males: P < 0.001) (Desai et al. 2011). 
Tonsil tissue is an immunologically active site, and may therefore be an unexpected site 
for HPV infection. However, the specialised epithelium lining the tonsillar crypt may actually 
facilitate HPV infection. In the reticulated epithelium, the epithelial cells junctions are not as 
strong as they involve a mix of infiltrating lymphocyte and epithelial cells. This structure 
facilitates the virus access to epithelial stem cells (Egawa et al. 2015). The unsuitability of the 
tonsil to accommodate the full viral life cycle has also been suggested as a reason why HPV 
infection might more often result in tumour development in the tonsils (Powell et al. 2015). 
The capacity to produce virions has recently been shown in vitro using raft cultures, but it 
remains to be observed in tonsils (Israr et al. 2016). Similarly to genital HPV infections, 
persistent oral cavity HPV infections are at risk of developing into oral or oropharyngeal SCC, 
and the latency period for OPSCC development has been estimated to be 10-30 years (Gillison 
et al. 2015). 
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1.2.5 Clinical and pathological features of HPV-positive vs HPV-negative tumours 
HPV-positive and negative tumours differ in their histological appearance. HPV-positive 
tumours have a tendency to present with several features traditionally associated with poor 
clinical outcomes. They tend to be less differentiated, not present signs of keratinisation and 
have a basaloid appearance (Ang and Sturgis 2012). By contrast, HPV-positive tumours are 
generally smaller macroscopically at the time of diagnosis which is reflected by an average 
lower T grade in the Tumour Node Metastasis (TNM) grading (Gillison et al. 2012). The nodal 
stage also tends to differ, with a higher proportion of HPV-positive patients presenting with 
nodal metastasis at the time of diagnosis (Goldenberg et al. 2008). Immunological differences 
also occur, HPV positive tumours have a higher density of CD8+ lymphocytes infiltration 
compared to HPV negative lesions (Näsman et al. 2012). 
The demographic characteristics of OPSCC patients also show some association with 
tumour HPV status. People presenting with a HPV-positive tumour tend to: be younger, have 
never smoked (or smoked very little), be predominantly of white race, have better overall 
health performance status, and show absence of anaemia, relative to patients whose tumour 
is negative for the presence of HPV (Ang and Sturgis 2012).  
Various genetic differences between HPV-positive and negative tumours have been 
reported. The increasing use of next generation sequencing has enabled the characterisation 
of large sample cohorts and the description of distinct mutational profiles. An analysis of 
whole-exome sequencing data from 74 HNSCC tumour-normal pairs showed that the mutation 
rate of HPV-positive tumours was approximately half that found in HPV-negative HNSCC (mean 
number of mutations per megabase = 2.28 vs 4.83 mutations; P = 0.004) (Stransky et al. 2011). 
The most common mutational differences are associated with the gene coding for the protein 
p53. Mutations in p53 are important in the malignant transformation of many cancers but are 
rarely present in HPV-positive tumours. This is presumably because p53 mutation would be 
redundant against a background of p53 protein loss caused by the viral protein E6.  
The Cancer Genome Atlas study included several head and neck sites, and identified 
different expression profiles for HPV-positive and negative tumours. Some genetic alterations 
were commonly found in both HPV-positive and negative HNSCC (e.g. region 3q26/28 which 
involves TP63, SOX2 and PIK3CA). The gene encoding the cell cycle transcription factor E2F1 
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was amplified in some HPV-positive tumours, while the CDKN2A gene, encoding p16 protein, 
was generally intact (but was often mutated in HPV-negative). Regarding the oropharynx in 
particular, several genes were up-regulated in HPV-positive OPSCC, including CDKN2A/C, RPA2, 
MCM2/3/5, and TAF7L. The type of genetic alterations seen in HPV-negative OPSCC was similar 
to the pattern observed in other smoking related tumours.  
HPV-positive OPSCC also show patterns of mutations characteristic of up-regulation of 
APOBEC (Apolipoprotein B mRNA Editing catalytic polypeptide) activity (Stransky et al. 2011; 
Alexandrov et al. 2013; Lawrence et al. 2015). APOBECs are a family of 11 cytidine deaminase 
proteins capable of binding to RNA and single-stranded DNA. These enzymes, through the 
conversion of cytosine to uracil, have a variety of important biological functions (Salter et al. 
2016). Activation-induced deoxycytidine deaminase is expressed in B cells and implicated in 
antibody diversity through its role in somatic hypermutation and class switch recombination 
(Muramatsu et al. 2000). APOBEC1 is mostly known for its ability to bind and regulate the 
stability of RNA. APOBEC2 and 4 are not well characterised, but APOBEC2 may be involved in 
embryonic development (Liao et al. 1999; Anant and Davidson 2000). The APOBEC3 subfamily 
(APOBEC3 A, B, C, D, F, G, H) have been characterised in more detail, and are involved in the 
innate immune response to viruses and retroviruses in particular by interfering with viral 
replications and clearing foreign DNA (Chiu and Greene 2008; Stenglein et al. 2010). APOBEC 
have been studied in relation to cancer as they could potentially lead to the acquisition of 
somatic mutations involved in tumour development. Mutagenic processes tend to cause a 
specific type of mutation which can be identified, called mutational signatures. APOBEC 
catalysed cytosine deamination is one mutational signatures already identified in several types 
of tumours (Roberts et al. 2013). Tumours in which APOBEC associated mutations have been 
identified include other HPV-associated tumours such as cervical cancer (Burk et al. 2017). In 
relation to HNSCC, HPV-positive tumours have been linked with an enriched signature of 
APOBEC mutations compared to HPV-negative cases (Faden et al. 2017). 
1.2.5.1 HPV and prognosis 
In recent decades, several clinical trials have shown that the response to therapy was 
better in patients with HPV-positive tumours compared to HPV-negative OPSCC. This was 
associated with increased survival and reduced disease progression. The better prognosis of 
HPV-positive patients in general has been observed with a range of treatments, including 
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surgery, chemotherapy and radiotherapy, or combinations thereof. In South Wales, a 
retrospective study demonstrated a clear association between HPV-positivity and favourable 
prognosis, with 3 and 5-year overall survival rates of 82.6% and 75.4% respectively in HPV-
positive patients, compared to 32.2% and 25.3% in HPV-negative patients, equating to a 78% 
reduction in death rate associated with HPV-positivity (HR 0.220, 95% Confidence Interval (CI); 
0.132-0.366, p < 0.001) (Evans et al. 2013). A recent meta-analysis, including clinical trial data 
for 1130 OPSCC patients, indicated a hazard ratio for improved overall survival of 0.49 (95% CI 
0.35-0.69) associated with HPV-positive tumours (Masterson et al. 2014). 
It has also been noted that survival has increased in the HPV-positive patients but has 
remained the same in HPV-negative patients (Chaturvedi et al., 2011). It is however notable 
that even within the HPV-positive tumours survival varies widely, and other factors associated 
with HPV-positive tumours such as young age, disease status, smoking and lower alcohol 
consumption could account together for up to 9% of the response of HPV-positive tumours 
(Ang et al. 2010). Smoking and HPV status are not exclusive, and tobacco consumption also 
affects the outcome of HPV-positive patients. Independently of p16 status, smoking 
significantly increased the risk of death and of disease progression (Gillison et al. 2012). 
Accordingly, Ang et al. proposed that patients could be divided into 3 groups: Low risk, 
comprising “typical” HPV-positive patients; High risk comprising HPV-negative patients; and an 
intermediate risk groups including HPV-positive smoker with high nodal stage and HPV-
negative non-smokers with T2 and T3 stage (Ang et al. 2010). 
The implications of, and the mechanisms behind, the difference in prognosis have been 
studied using retrospective FFPE samples and patients derived cell lines. However, few HPV-
positive HNSCC cell lines have been described in the literature. As of 2012, five lines had been 
published and only one originated from the oropharynx (Steenbergen et al. 1995; Balló et al. 
1999; Lansford et al. 1999; Ferris et al. 2005; Tang et al. 2012). In contrast to the current trend 
in HPV-positive patients, all of these lines were derived from heavy or ex-smokers. The 
available cell lines may therefore not provide the best possible representation of typical HPV-
positive non-smoking patients with OPSCC. The development of new cell lines, from typical 
HPV-positive patients, is needed to increase our understanding of treatment response in HPV-
positive smokers and non-smokers. 
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1.2.5.2 Tumour microenvironment 
The tonsils are highly infiltrated by immune cells due to the communication with the 
underlying lymphoid tissue through the crypts reticulated epithelia. As a result, the oropharynx 
has a crucial role in the detection of, and protection against, pathogens entering the organism 
through the aero-digestive system. In a variety of cancers, the tumour microenvironment and 
the local, as well as systemic immune responses have been shown to play an important role in 
the control and growth of tumours (Vesely et al. 2011). In the context of HPV-positive OPSCC, 
this is of particular interest as the presence of viral antigens can elicit an immune response.   
An HPV-specific immune response can be detected in some HPV-positive HNSCC patients 
mainly with oropharyngeal tumours. Detection of circulating T cells specific to HPV16 E7 
epitopes occurs more frequently in HPV-positive than HPV-negative patients (Hoffmann et al. 
2006). Locally, HPV16 infection can, in some patients, result in a local HPV16 specific T cell 
response comprising of both CD4+ and CD8+ T cells, which is absent in HPV-negative patients 
(Heusinkveld et al. 2012). 
The number of cytotoxic T lymphocytes (CD8+) Tumour Infiltrating Lymphocytes (TIL) 
has been associated with clinical outcome independently of HPV status following radiotherapy. 
Patients with higher amounts of CD8+ TIL had better clinical outcomes than those with fewer 
TIL. The same tendency has been observed once patients were stratified according to HPV 
status (Näsman et al. 2012). Similarly, the amount of CD8+ TIL has been associated with 
favourable outcome in patients treated with chemotherapy. However, no significant influence 
of the infiltration levels of other T lymphocytes such as T helper (CD4+) and T reg (FOXP3+) has 
been recorded (Balermpas et al. 2014; Balermpas et al. 2016). While CD8+ TIL seems to have a 
positive influence on the outcome irrespective of HPV-status, the total amount of infiltrated 
cells is higher in HPV-positive patients. This indicates that those tumours might be more 
immunogenic and hence could contribute to the overall better outcome observed in these 
patients (Balermpas et al. 2016). 
Downregulation of the PD1-PDL1 immune checkpoint, which impairs the function of TIL, 
has been linked with immune evasion in various tumours (Topalian et al. 2016). This is also of 
interest in the oropharynx as PDL1 is expressed in the tonsil crypts where many HPV-positive 
tumours originate. In HNSCC, PDL1 is expressed in most tumours and PD1 by TIL (Lyford-Pike et 
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al. 2013). Similar to CD8, PD1 and PDL1 expression is overall higher in HPV-positive patients 
compared to HPV-negative patients (Balermpas et al. 2017). The activation of the PD1-PDL1 
checkpoint suggests a mechanism of tumour immune evasion in HPV-positive HNSCC. The use 
of novel therapies targeting the PD1-PDL1 checkpoint is currently being investigated for HNSCC 
with promising results for some patients (Seiwert 2016). 
PDL1 expression has been investigated as a biomarker for overall outcome. Its influence 
varies greatly between studies with positive and no association with outcome reported (Kim et 
al. 2016; Balermpas et al. 2017). The combination of high CD8 TIL and high PDL1 expression 
has however been identified as a predictive marker of favourable outcome in several cohorts. 
While this is the case in both HPV-positive and negative status, they are more common in HPV-
positive cases (Cancer Genome Atlas Network 2015; Balermpas et al. 2017).  
1.2.6 Diagnosis of OPSCC and HPV testing 
Patients can present with a variety of symptoms, but often have painless lumps in the 
neck. When the tumour originates in the tonsil crypts, it can grow undetected for a prolonged 
period. Diagnosis of oropharyngeal cancer is based on imaging techniques as well histological 
examination of biopsies obtained during panendoscopy. As it is the case for other tumours, the 
stage of the disease can be established according to the TNM classification where T1-T4 
describes the size of the tumour, N0-N3 refers to nodal stage, and M0-M1 indicates if 
metastases are present (Patel and Shah 2005). 
HPV-positivity in OPSCC can be an indicator of better prognosis and treatment response 
in some patients, hence p16 Immuno Histochemistry (IHC), as a surrogate marker of HPV 
infection, is now generally performed for OPSCC patients. In a research or clinical trial setting, 
the presence of HPV in a tumour can be shown by the presence of high risk HPV DNA, RNA or 
proteins or the up-regulation of human proteins (p16). Various techniques can be used, in 
isolation or in combination, for this purpose. The main goal of HPV detection is to identify 
infections in which HPV is likely to be driving the disease. The gold standard method is to 
establish the presence of transcriptionally active HPV by amplifying E6 or E7 transcripts as the 
combined actions of these two proteins is essential in carcinogenic transformation (Wiest et al. 
2002; Schache et al. 2011).  
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When detecting HPV RNA, the best results are obtained from fresh or fresh frozen tissue 
and reverse transcription quantitative Polymerase Chain Reaction (PCR). However this can be 
logistically challenging as OPSCC biopsies are routinely processed and stored as Formalin Fixed 
Paraffin Embedded (FFPE) tissue blocks, and RNA obtained from FFPE samples can be 
unsuitable for RNA based testing (von Ahlfen et al. 2007; Robinson et al. 2012). p16 IHC on 
FFPE slides is therefore commonly used. p16 is widely recognised as a surrogate biomarker of 
HPV infection as it is strongly up-regulated following the action of the E7 protein (Doorbar 
2005). However while p16 detection has a high sensitivity, it can lack specificity (Prigge et al. 
2017), and some OPSCC have also been described as p16 positive but HPV-negative, 
highlighting that factors other than HPV can up-regulate p16 in tumours (Perrone et al. 2011). 
Hence p16 IHC is often used in combination with detection of HPV DNA in FFPE samples. 
 HPV DNA can be detected by in situ hybridisation (ISH) or PCR. Several DNA based tests 
can detect the presence of groups of high risk HPV types, while others detect HPV16 in 
isolation. These tend to be PCR and Enzyme Linked Immunosorbent Assay (ELISA) based 
techniques. Most HPV genotyping PCRs target the L1 region of the HPV genome, the amplicons 
are then hybridised with a cocktail of probes for the various HPV types (Robinson et al. 2012). 
The use of p16 and DNA based testing as standalone tests do not reach the sensitivity and 
specificity of mRNA detection. Combinations of those tests on the other hand provide reliable 
methods of HPV detection. The combination of p16 and HPV DNA by ISH has emerged as a 
diagnostic standard of HPV-positive OPSCC (Smeets et al. 2007; Schache et al. 2011; Prigge et 
al. 2017). 
1.2.7 Treatment of OPSCC 
Historically, OPSCC patients were often treated with open surgery such as 
mandibulotomy followed by extensive reconstruction. This approach led to a high number of 
severe and/or fatal complications. However, the locoregional control and 5-year disease 
specific survival was similar to that observed with radiotherapy alone or a combination of 
surgery and radiotherapy. This led to the reduction of extensive open surgery (Parsons et al. 
2002). Contemporary treatment of OPSCC, independently of HPV status, utilises laser and 
robotic surgery, radiotherapy (intensity modulated) and chemotherapy (induction and/or 
concurrent) often combined as chemoradiotherapy (Evans and Jones 2016). Radiotherapy, 
even intensity modulated, can cause significant toxicity to adjacent tissues affecting the 
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salivary glands, swallowing function and teeth. The patient’s quality of life can be substantially 
reduced in the long term, especially when the swallowing function is impaired (Denis et al. 
2003; Eisbruch et al. 2011). There is therefore mounting interest in development of less toxic, 
targeted treatments for OPSCC. 
1.3 DNA damage and repair 
DNA damage occurs continuously in cells as a consequence of exogenous and 
endogenous factors. Exogenous causes include ultraviolet radiations, ionising radiations, and 
chemical compounds (e.g. metabolites of alcohol, tobacco and some foods). Endogenous 
sources include replication errors, free radicals and spontaneous loss or alteration of purine or 
pyrimidine bases (e.g. due to breakage of glycosidic bonds between the pentose sugar and 
base, or alteration such as methylation) (Lindahl 1993). While a very low mutation rate is an 
evolutionary necessity, the maintenance of genomic integrity is essential to allow the cells, and 
ultimately the organism, to function properly (Kolodner et al. 2002). Numerous mechanisms 
exist to ensure detection and repair of damaged DNA. These include BER, Nucleotide Excision 
Repair (NER), Mismatch Repair (MMR), Homologous Recombination (HR) and Non-
Homologous End Joining (NHEJ). These pathways can be broadly divided in those that deal 
with, or involve, DNA Single Strand Breaks (SSB) and those that address Double Strand Breaks 
(DSB) (Sancar et al. 2004). 
BER is the predominant pathway for repair of DNA lesions caused by endogenous 
sources such as reactive oxygen species and depurination events (David et al. 2007). BER 
involves the removal of the damaged base by a glycosylase, followed by the excision of the 
sugar phosphate by the AP endonuclease APE1, which leaves a gap in the sequence (Krokan et 
al. 1997). The damaged termini are repaired by a complex including APE1, DNA polymerase β, 
polynucleotide kinase 3’-posphatase (PNKP) and aprataxin (APTX) (Sobol et al. 1996; Mol et al. 
2000; Rass et al. 2007). The X-ray repair cross-complementation protein 1 (XRCC1) scaffolding 
protein, acts by stabilising and stimulating the components of the complex (Kubota et al. 
1996). New nucleotides are added by DNA polymerase β and the remaining gap sealed by DNA 
ligase (Cotner-Gohara et al. 2008).  
Direct SSB, for example arising as the result of the disintegration of deoxyribose sugar, 
are detected by poly (ADP-ribose) polymerase (PARP) 1. PARP1 migrates to sites of SSB and 
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causes rapid conversion of NAD+ to ADP-ribose polymers (PAR), promoting the recruitment 
and/or activation of further proteins involved in SSB repair (Masson et al. 1998). Similarly to 
BER, damaged ends are repaired by a protein complex including XRCC1, polymerase β, and 
ligase 3 (El-Khamisy et al. 2003). During replication, unrepaired SSB can cause a collapse of the 
replication fork or stalled transcription which results in the formation of DSB (Branzei and 
Foiani 2010).  
DSB repair is primarily achieved through the HR and NHEJ pathways. Both pathways 
include damage recognition and repair mechanisms which function together to achieve repair. 
Three proteins are central to the recognition stage: Ataxia Telangiectasia Mutated (ATM), 
Ataxia Telangiectasia and RAD3 related (ATR) and DNA-dependent Protein Kinase (DNA-PK) 
(Branzei and Foiani 2010). DNA-PK signalling is involved in NHEJ, ATM signalling in HR, whilst 
ATR is implicated in DSB arising due to stalled replication forks (Jackson 2002).  
Homologous recombination is the more complex DSB repair mechanism but also the 
most accurate, as it utilises the sister chromatid as a template to repair the lesion. However, it 
only occurs in stages of the cell cycle during which a sister chromatid is present i.e. when the 
DNA has been replicated but before cell division, in S and G2-phases (Saleh-Gohari and 
Helleday 2004). The process begins with resection by an exonuclease of one of the two DNA 
strands at each DNA end. The resulting single stranded DNA then invade the DNA of the 
undamaged sister chromatid, and base pair with their complementary sequences. The intact 
strand is used as a template for DNA synthesis, and a DNA polymerase extends the single 
stranded DNA in a 5’-3’ direction. In the final steps, the Holliday junctions are resolved and the 
DNA nicks are ligated (Weinberg 2013).  
NHEJ occurs mostly in the G1-phase of the cell cycle, when sister chromatids are not 
present (Rothkamm et al. 2003). Hence, by comparison with HR repair, NHEJ is inevitably a 
relatively error-prone process. This is because the alignment between the DNA ends being 
joined is not informed by an undamaged template. NHEJ also begins with resection of one 
strand of each broken DNA end, but the two ends are then joined without reference to a 
template. This tends to result in deletion of short sections of DNA and also has the potential 
result in genomic rearrangements (Lieber 2010). Variations of NHEJ have been described, only 
the general process is described here. Ku proteins bind to DNA ends, enabling the recruitment 
of nucleases and polymerases at the break site (Ma et al. 2004). Ligation requires the presence 
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of two blunt ends, the ends are processed to achieve this. Proteins involved in end processing 
include DNA-PK and Artemis (Ma et al. 2002). The gaps are ligated by a DNA ligase 4 complex 
(DNA ligase 4-XRCC4) (Gu et al. 2007). 
1.3.1 HPV and DNA damage  
Several lines of evidence show significant interactions between HPV and DNA repair 
proteins. The production of new virus particles is dependent upon activation of both the ATM 
and ATR DNA repair pathways (Moody and Laimins 2009; Reinson et al. 2013; Hong et al. 2015; 
Kanginakudru et al. 2015). Activation of the ATM pathway ordinarily occurs in response to the 
presence of DNA DSB, while activation of ATR results from replication stress and the presence 
of single-stranded DNA at stalled replication forks (Eyfjord and Bodvarsdottir 2005; Sulli et al. 
2012). High risk HPV have been shown to regulate components of these DNA repair pathways 
to promote viral replication (Wallace and Galloway 2014). This is mediated mainly by the E1 
and E7 proteins which recruit repair proteins for viral replication (Moody and Laimins 2009; 
Fradet-Turcotte et al. 2011). 
Interaction between the ATM and ATR DNA repair pathways is mediated by the 
ATM/ATR interacting Fanconi Anemia (FA) protein FANCD2, which is recruited to viral genomes 
and is required for maintenance of viral genomes in undifferentiated cells (Spriggs and Laimins 
2017) The FA pathway is responsible for repair of DNA inter-strand crosslinks and includes 
multiple DNA repair proteins including BRCA1 and -H2AX. HPV also recruits additional DSB 
repair proteins to the HPV DNA foci, including 53BP1, RAD51 and BRCA1. -H2AX is also found 
at these foci (Gillespie et al. 2012). The E7 protein also targets clapsin for proteolytic 
degradation which in turn inhibits the DNA damage checkpoint response (Spardy et al. 2009). 
Most previous studies have addressed the relationships between HPV and DNA repair in 
the context of productive infections, in which the HPV genome is episomal. However, in 
cancers, HPV is rarely found in its episomal form, but instead is more commonly (c. 70% cases) 
integrated into the host genome (Parfenov et al. 2014). In this situation the predominant 
effects of HPV on DNA repair appears to be to cause a specific defect in repair of DNA DSB 
(Duensing and Münger 2004) and induce activation of APOBEC activity (Henderson et al. 2014; 
Vieira et al. 2014). This is consistent with the genomic instability observed during the 
Chapter 1  Introduction 
 
25 
 
carcinogenesis process, in tumour cells, and with the presence of APOBEC signature mutations 
in HPV-positive OPSCC (Henderson et al. 2014). 
Studies comparing the radio-sensitivity of a limited number of HPV-positive and negative 
cell lines have demonstrated that HPV-positive lines are usually less able to repair DSB. Two 
studies have investigated reduced repair of DSB in HPV-positive cell lines and both suggest that 
persistence of DSB, assessed by immunofluorescence for -H2AX, correlated with the radio-
sensitivity of the lines (Kimple et al. 2013; Rieckmann et al. 2013). Both also agree that in HPV-
positive lines, accumulation of DSB results in failure to traverse the G2/M checkpoint, causing 
accumulation of cells in G2. The events following G2 arrest are less well defined. Kimple et al. 
suggested that following irradiation, HPV-positive cells showed increased p53 and phospho-
p53, and this was associated with significant increases in apoptosis. In contrast, Rieckmann et 
al. assessed apoptosis by caspase 3 activation and PARP cleavage in irradiated cells and found 
no increase in apoptosis in either HPV-positive or negative lines. Taken together, these studies 
suggest exploiting deficiencies in DNA damage repair in HPV-positive OPSCC could have 
potential as a therapeutic strategy. 
1.3.2 Synthetic lethal therapy and PARP inhibition 
The concept of synthetic lethality was originally used to describe a genetic interaction in 
which the combination of two gene knockouts is lethal. More recently, this concept has been 
extended to include interactions between proteins and pathways that are normally non 
essential but that are critical for survival in cancer cells. This principle is highly relevant in 
cancer therapy because many tumours harbour genetic mutations that are not present in the 
other cells of the body (Kaelin 2005). Such treatments could be highly beneficial due to the 
potential to selectively kill cancer cells while sparing normal cells (Helleday 2011). The 
archetypical therapeutic example of synthetic lethality is the use of PARP inhibitors (PARPi) as 
monotherapy for treatment of tumours with defects in repair of DSB by HR (Bryant et al. 2005; 
Committee for Medicinal Products for Human Use 2014).  
In OPSCC some studies have indicated a possible common defect in HR. Therefore 
targeting SSB repair could lead to synthetic lethality in OPSCC cells. The mode of action of a 
PARPi in OPSCC is illustrated in Figure 1.6. 
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Figure 1.6: PARP inhibition leading to synthetic lethality in OPSCC 
Normal cells are able to repair DNA damage via SSB and DSB repair. In HPV-positive cancer 
cells DSB repair is defective but SSB repair is intact. Normal cells treated with a PARPi would be 
able to repair the DSB resulting from collapsed replication fork due to the unrepaired SSB. 
However in HPV-positive cells treatment with PARPi will cause an unrepairable level of DNA 
damage leading to cell death. 
 
1.3.3 PARP proteins involvement in DNA repair 
PARP comprise a family of 17 proteins with a wide range of functions in biological 
pathways and processes including DNA repair, DNA transcription, genomic stability and cell 
cycle control (Krishnakumar and Kraus 2010). PARP catalyse the parylation reaction, a 
reversible post-transcriptional modification which entails covalent attachment of ADP ribose 
units to the carboxyl groups of glutamate, aspartate and lysine residues of the target proteins 
or itself using NAD+ as a substrate (D’Amours et al. 1999; Altmeyer et al. 2009). Most members 
of the PARP family catalyse the addition of a single ADP unit whilst others such as PARP1, 
PARP2 and PARP5 synthesise linear or multi-branched ADP polymers. The majority of PARP are 
located in the cytoplasm. Their expression is ubiquitous in human cells but expression profiles 
are not cell type specific. However, within a cell, localisation varies throughout the cell cycle 
(Vyas et al. 2014).  
The best known and most abundantly expressed of the PARP family is PARP1. This 113 
kDa protein is composed of a DNA binding domain which contains N-terminal zinc finger 
motives in tandem repeat, a caspase 3 cleavage site and nuclear localisation signal, an auto-
Chapter 1  Introduction 
 
27 
 
modification domain involved in protein-protein interactions and a catalytic domain binding 
for NAD+. The catalytic domain is characteristic of PARP proteins (Kameshita et al. 1984).  
PARP1 is important in DNA repair, most notably in SSB repair, but also in DSB repair. 
PARP1 acts as a sensor for SSB and quickly binds to the break site. The zinc finger motives are 
essential in the recognition and binding of PARP1 to the site of DNA breaks. Zinc finger motives 
from two separate PARP1 molecules are able to interact with each other forming a complex of 
two PARP1 molecules and DNA. This allows for the recognition of a variety of DNA lesions 
including DSB, SSB and gaps (Ali et al. 2012). Multiple inter-domain interactions occur 
following PARP1 binding to DNA. As a result, the low basal level activity of the catalytic domain 
is increased through changes in its thermal stability. The conformational changes also 
enhances the catalytic domain to the protein substrates (Langelier et al. 2012).Through its 
parylation activity, the protein itself is modified as well as interacting with several other 
proteins such as DNA repair and chromatin remodelling factors to recruit them to the break 
site. Recruited proteins include XRCC1, DNA polymerase β and PCNA (Masson et al. 1998). 
PARP1’s role in DSB repair is less well characterised, but includes interactions with various 
proteins involved specifically in NHEJ and HR such as MRE11, KU80 and NBS1, and also with 
proteins involved in DNA damage sensing such as ATM (Galande and Kohwi-Shigematsu 1999; 
Haince et al. 2007; Haince et al. 2008). PARP1 does not remain at the site of DNA damage, its 
removal is necessary for adequate repair (Amé et al. 2009). The auto-parylation on PARP1 as 
well as the parylation of downstream targets is transient due to the activity of glycohydrolases. 
The poly-ADP-ribose-glycohydrolase cleaves the ribose-ribose bonds leaving one ADP ribose 
unit on the protein. This residue is later removed by a mono-ADP-ribose glycohydrolase (Slade 
et al. 2011; Rosenthal et al. 2013). 
Within the PARP family, PARP2 is the most similar to PARP1. This 66 kDa protein has 
similar localisation within the cells and also contains a nuclear localisation signal and DNA 
binding domain (Amé et al. 1999). Similarly to PARP1, PARP2 is involved in BER via its 
interaction with XRCC1, DNA polymerase β and DNA ligase 3 (Schreiber et al. 2002). 
1.3.4 Olaparib 
Olaparib (also known as KU-0059436 and AZD2281) was developed by KuDOS 
Pharmaceuticals, which has been bought by AstraZeneca. It is marketed for clinical use under 
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the brand name Lynparza. Olaparib displays inhibitory activity concentrated towards PARP1 
and 2. However, its cellular effect is mediated mainly via PARP1 inhibition as it constitutes the 
majority of the total PARP proteins. Knock down of PARP2 was showed to have minimal effect 
on Olaparib cytotoxicity (Murai et al. 2012)  
Olaparib molecular formula and chemical name are shown in Figure 1.7. It is based 
around a phthalazizone structure and was developed to obtain an orally bioavailable 
compound. It includes an amine group which replicates the interaction between NAD and 
PARP thus preventing the binding of the nicotinamide structure of NAD with the active site on 
PARP1. This involves the formation of bonds between the inhibitor and Ser904 and Gly863 on 
the PARP protein which are similar to the ones formed between NAD and PARP during the 
normal enzymatic activity (Jagtap and Szabó 2005; Menear et al. 2008). The effect of Olaparib 
is not mediated solely by its catalytic inhibition, another mode of action referred to as PARP 
trapping has been described. The use of a PARP inhibitor also inhibits the auto-
phosphorylation of PARP itself, a process required for PARP dissociation form the DNA 
(Mortusewicz et al. 2007). As a result, Olaparib treatment causes the binding of both PARP1 
and PARP2 to the chromatin forming complexes of PARP and single stand DNA intermediate. 
These complexes do not dissociate, during replication they are converted into more toxic 
lesions inducing further cytotoxicity. This process does not correlate with the catalytic 
inhibition capacity of PARP inhibitors (Murai et al. 2012) 
In early in vitro studies, Olaparib was found to have the same potency against PARP1 
and PARP2. The PARP inhibitory activity of Olaparib was tested in SW60, a human 
adenocarcinoma cell line, via the measurement of PAR (the downstream product of PARP 
activation). Following consideration alongside other candidates with a similar chemical 
structure, Olaparib was selected for clinical development (Menear et al. 2008). Another in vitro 
study using a panel of 95 cell lines, including some HNSCC lines, showed wide variation in IC50, 
ranging from 0.018 µM to over 10 µM. Higher sensitivity (IC50 <1 µM) correlated with BRCA1 
and 2 mutation and low HR pathway gene expression. Low expression of PARP1 was also 
associated with reduced sensitivity (study number KTS00101, October 2007 unpublished, 
described in the FDA pharmacological report). Another study with a panel including 11 HNSCC 
lines found a correlation between sensitivity to platinum based agent carboplatin and cisplatin 
and Olaparib sensitivity (study number KTS0049, September 2008 unpublished). 
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In humans, the drug is metabolised via CYP3A4 and 3A5. The main metabolic processes 
are hydrolysis and oxidation with some products undergoing multiple metabolic 
transformations. Excreted products are found in faeces and urine. Olaparib was quickly 
absorbed with the peak plasma concentration reached after 1-3 h, and was mostly excreted 
within 48 h. No significant off-target activity was observed at clinically relevant doses 
(observed in rat, dog and human studies KMX032 and KKR007). 
In 2014, a marketing authorization for Lynparza was granted by the European medicine 
agency. The 50 mg hard capsules are indicated as monotherapy for the maintenance 
treatment of adult patients with platinum-sensitive relapsed BRCA mutated (germline and/or 
somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who 
are in response (complete response or partial response) to platinum-based chemotherapy. 
Olaparib is now being evaluated as monotherapy, and in combination with chemo and 
radiotherapy, in numerous trials around the globe. Tumour sites being investigated include 
breast, ovarian, lung, oesophagus, pancreas and prostate (clinicaltrials.gov). In the context of 
HNSCC, the US Clinical Trial database (clinicaltrials.gov) lists numerous trials evaluating 
Olaparib treatment in diverse HNSCC subsites (summarized in Table 1.1). However, in many 
cases, these clinical studies are supported by limited in vitro data. 
 
 
Figure 1.7: Chemical structure of Olaparib 
4-(3-(1-(cyclopropanecarbonyl)piperazine-4-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one, 
with the molecular formula C24H23FN4O3 was first described as KU-0059436, then AZD2281, 
then Olaparib, before being marketed under the name Lynparza. 
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Table 1.1: Clinical trials of Olaparib in HNSCC 
Study title Country Treatment 
Phase I Study of Olaparib Combined with Cisplatin-
based chemoradiotherapy to treat locally advanced 
head and neck cancer (ORCA-2) 
UK 
Olaparib 
Cisplatin 
Radiation therapy 
Preoperative administration of Olaparib with or 
without Cisplatin in patients who are candidates for 
surgery of carcinoma of head and neck (OPHELIA) 
Greece 
Olaparib 
Cisplatin 
Study of Olaparib with radiation therapy and 
Cetuximab in advanced head and neck cancer with 
heavy smoking history 
USA 
Olaparib 
Cetuximab 
Radiation therapy 
Pharmacodynamic study to assess the anti-
proliferative activity of the PARPi Olaparib in patients 
With HPV positive and HPV negative HNSCC 
USA Olaparib 
Phase I study of Olaparib with Cisplatin based 
chemoradiotherapy in squamous cell carcinoma of the 
head and neck (ORCA) 
UK 
Olaparib; cisplatin; 
Radiation therapy 
A study to investigate biomarker effects of pre-
surgical treatment with DNA Damage Repair (DDR) 
agents in patients With Head and Neck Squamous Cell 
Carcinoma (HNSCC) 
USA, France, 
UK 
AZD6738 
Olaparib 
Olaparib and radiotherapy in head and neck Cancer Netherlands 
Olaparib 
Radiation therapy 
Selumetinib and Olaparib in solid tumours USA 
Selumetinib 
Olaparib 
Radiotherapy and Olaparib in Combination for 
carcinoma of the oesophagus (ROCOCO) 
UK 
Olaparib  
Radiation therapy 
Ascending doses of AZD6738 in combination With 
chemotherapy and/or novel anti-cancer agents 
AstraZeneca - 
multinational 
AZD6738 in 
combination with 
carboplatin; 
AZD673; 
AZD6738 in 
combination with 
Olaparib; 
AZD6738 in 
combination with 
MEDI4736 
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1.4 Study hypotheses and aims 
1. Low-level high-risk HPV infection occurs and can be detected in non-malignant 
tonsils. 
a. Obtain a large number of tonsil samples from a population likely to 
harbour high-risk HPV infection. 
b. Detect HPV presence in the samples and type the virus using several tests. 
2. HPV-positive and negative OPSCC lines have distinct patterns of gene expression 
(including pathways relating to DNA repair). 
a. Develop new HPV-positive oropharyngeal cell lines from low or non-
smoker patients and validate them as models for OPSCC. 
b. Establish and characterise a panel of HPV-positive and negative cell lines 
representing the wide variations seen in OPSCC tumours (p53 status, 
treatment, smoking status). 
c. Investigate individual transcripts expression as well as processes and 
pathways differentially expressed within the panel. 
3. A synthetic lethal approach using Olaparib would be suitable to target HPV-
positive OPSCC lines. 
a. Determine the colony formation capacity of each cell line of the panel 
following treatment with a range of doses of Olaparib. 
b. Investigate the difference in response between lines regarding 
accumulation of unrepaired DSB and cell cycle distribution following 
treatment. 
c. Investigate the level of PARP1 and p53 expression following treatment. 
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Chapter 2 - Material and methods 
2.1 Cell culture 
This section contains a description of the cell lines, cell culture reagents and culture 
conditions used. 
2.1.1 Established cell lines 
2.1.1.1 3T3 mouse fibroblasts 
The mouse embryo fibroblast cell line J2 3T3 was established in 1963 (Todaro and Green 
1963). During this project, they were used to supplement the culture of the Primary Culture of 
Oropharyngeal Cells (PCOC) cultures and the low-density culture of other cell lines during 
Olaparib dosing assays. Stocks of J2 3T3 stocks (passage 10-15) cells were obtained from Dr 
Sally Roberts (University of Birmingham). 
2.1.1.2 CaSki 
The CaSki cell line was derived from a cervical carcinoma metastasised to the small 
bowel in a 40 year-old Caucasian female (Pattillo et al. 1977). This cell line is infected with 
HPV16 and contains around 600 copies of the HPV genome integrated in tandem. CaSki cells 
were obtained from the European Collection of Authenticated Cell Cultures (catalogue number 
87020501). 
2.1.1.3 SiHa 
The SiHa cell line was derived from a cervical SCC in a 55 year-old woman. SiHa cells 
contain 1 to 2 integrated copies of HPV16. Viral integration caused the disruption of E2 and E4 
open reading frames (Baker et al. 1987). This cell line was sourced from the American Type 
Culture Collection (catalogue number HTB-35). 
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2.1.1.4 HeLa 
HeLa cells were derived from a cervical adenocarcinoma in a 31 year-old African 
American woman. Cells contain integrated HPV18 (Scherer et al. 1953). This line was obtained 
from the American Type Culture Collection (catalogue number CCL-2). 
2.1.1.5 UPCISCC90 
UPCISCC90 is an oropharyngeal squamous cell carcinoma cell line derived from a base of 
tongue SCC in a 44 year-old male smoker (Ferris et al. 2005). This cell line contains between 
100-150 integrated copies of HPV16 at various sites in tandem. It was obtained from the 
Deutsche Sammlung von Mikroorganismen und Zellkulturen, (catalogue number ACC 670). 
2.1.1.6 UMSCC4, 6, 19, 47, 74a 
UMSCC4 is an HPV-negative cell line derived from a tonsil SCC in a 47 year-old woman. 
UMSCC6 and UMSCC19 are HPV-negative lines derived from oropharyngeal SCC in a 37 year-
old man and a 67 year-old man respectively. UMSCC74a is an HPV-negative cell line derived 
from a base of tongue SCC in a 50-year-old-man. UMSCC47 was derived from the oral cavity of 
a 53 year-old man and contains integrated copies of HPV16. All of these cell lines were 
obtained from Professor Thomas Carey (University of Michigan). 
2.1.2 Human epidermal keratinocytes 
Human Epidermal Keratinocytes isolated from neonatal foreskin (HEKn) were purchased 
from Thermo Fischer Scientific (catalogue number C0015C) (Thermo Fisher Scientific, 
Waltham, USA). These cells are derived from normal tissue and are not infected by HPV. HEKn 
were used as controls for the Olaparib dosing experiments. With the culture conditions used, 
they can sustain approximately 30 population doublings. 
2.1.2.1 PCOC2 and PCOC3 
PCOC2 and PCOC3 HPV16-positive lines were derived during this project as described in 
Section 2.1.5 . PCOC2 was derived from a tonsil SCC in a 52 year-old male non-smoker and 
PCOC3 from a tonsil SCC in a 44 year- old male ex-smoker. 
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2.1.3 Cell culture material 
2.1.3.1 Cell culture vessels 
All tissue culture flasks (T25, T80 and T175), multiwell plates (6 wells) and single plates 
(6 and 10 cm diameter) were obtained from Thermo Fisher or VWR (Thermo Fisher Scientific; 
VWR, Lutterworth, UK). 
2.1.3.2 Media 
Cell culture media were supplemented, these reagents and their suppliers are listed in 
Table 2.1. The formulations of media used are outlined in Table 2.2 and Table 2.3. All 
components were thawed or warmed in a 37 °C water bath before use. Glasgow Minimal 
Essential Medium (GMEM) was used for the culture of the PCOC lines; this media was 
formulated with and without Epidermal Growth Factor (EGF). Dulbecco’s Modified Eagle’s 
Medium (DMEM) (Sigma-Aldrich, Gillingham, UK) was used for the J2 3T3 cells, CaSki, SiHa and 
other established cell lines. EpiLife (Thermo Fisher Scientific) media supplemented with 1% 
Human Keratinocyte Growth Supplement (HGKS) was used for the culture of HEKn. 
 
Table 2.1: Reagents used in media formulation and their sources 
Reagents Sources 
Fetal Bovine Serum (FBS) 
Sigma-Aldrich  
Newborn Calf Serum (NCS) 
Penicillin/Streptomycin (Pen Strep) 
Hydrocortisone 
Cholera toxin 
L-glutamine 
Non Essential Amino Acids (NEAA) 
EGF 
HKGS Thermo Fisher Scientific 
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Table 2.2: GMEM media composition 
Components Concentration 
FBS 10% 
Penicillin 100 U/ml 
Streptomycin 100 ng/ml 
Hydrocortisone 1.5 nM 
Cholera toxin 0.1 nM 
L-glutamine 2 mM 
EGF 10 ng/ml 
-  
Table 2.3: DMEM media composition 
Components Concentration 
NCS 10% 
Penicillin 100 U/ml 
Streptomycin 100 ng/ml 
L-glutamine 2 mM 
NEAA 0.2% 
 
2.1.3.3 Cell culture solutions 
The isotonic solution Phosphate Buffer Saline (PBS) was used to wash cell layers, to 
resuspend cells before antibody staining and to dilute solutions. A 1× solution containing 10 
mM phosphate buffer, 138 mM sodium chloride and 2.7 mM potassium chloride was obtained 
by diluting the content of one pouch (9.07-10 g) in 1 l of deionised water (Sigma-Aldrich). The 
pH was adjusted to 7.4 and the solution autoclaved.  
Trypsin 0.05%/ethylenediaminetetraacetic acid (EDTA) 0.02% (TE) was obtained by 
diluting 100 ml of 10× stock solution in 900 ml PBS, aliquoted and stored at -20 °C (Sigma-
Aldrich). 
2.1.4 General cell culture 
2.1.4.1 General culture conditions 
All cell lines were cultured in a humidified incubator at 37 °C, with 5% carbon dioxide. 
Copper sulphate was used to prevent bacterial growth in the water tray. Cell culture was 
performed in a class II safety cabinet using aseptic technique. Surfaces were cleaned using a 
70% ethanol solution. Before use, cell culture reagents were warmed to 37 °C. Liquid waste 
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was inactivated in a sodium dichloroisocyanurate (Presept) solution, diluted according to the 
manufacturer’s instructions, prior to being discarded.  
2.1.4.2 Cell counting and viable cell counts 
Cell numbers (total and viable cells) were assessed using a haemocytometer (Camlab, 
Cambridge, UK) and a 0.4% w/v trypan blue solution for viability (Thermo Fisher Scientific). 
A single cell suspension of the cell line to be counted was prepared and 10 µl loaded on 
each side of a haemocytometer. Cells present within the grid were counted using a light 
microscope with 100X magnification. Viability counts were obtained by diluting the cell 
suspension 1 in 2 with trypan blue solution prior to loading the haemocytometer. Non-viable 
cells, stained in blue, were excluded from the count.  
The number of cells contained in 1 ml was obtained by multiplying the average number 
of cells in the 25 squares of 1 grid (obtained from the average of 2 grids minimum) by 10000 
and by the dilution factor 2 in case of viability counts. 
Formula: Average number of cells per 25 squares×10000×dilution factor = number of cells/ml 
2.1.4.3 Freezing and storage 
Cells were counted, pelleted by centrifugation (5 min at 160×g) and resuspended in 
freezing media at a density of 2×106 cells/ml. The composition of freezing media is outlined in 
Table 2.4. A volume of 1 ml was dispensed in each cryovial and placed in a Nalgene Mr Frosty 
freezing device at -80 °C for at least 12 h (Thermo Fisher Scientific). Cryovials were then 
transferred to a liquid nitrogen unit for long term storage.  
 
Table 2.4: Freezing media composition 
Cell line Freezing media composition 
PCOC FBS, 10% Dimethyl Sulfoxide (DMSO) 
Keratinocytes DMEM, 10% FBS, 10% DMSO 
HEKn EpiLife, 10% DMSO 
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2.1.4.4 Thawing of cryopreserved cells 
Cryovials were briefly placed into a 37 °C water bath until the culture was mostly 
melted. The content of the vial was then transferred into a 15 ml falcon tube containing 9 ml 
of the appropriate media and mixed gently by hand. Cells were pelleted by centrifugation (5 
min at 160×g) and resuspended in the appropriate media. A viable cell count was performed, 
before transferring cells to a culture vessel. PCOC cells were seeded into 10 cm plates with 
2×106 irradiated J2 3T3 cells in 10 ml GMEM EGF- media. Already established keratinocytes 
were seeded into T25 flasks in 5 ml DMEM media. HEKn cells were seeded at a density of 
2.5×103 cells/cm2 into T175 flasks.  
2.1.4.5 Subculture 
Subculture was performed once 80% confluence was reached. The media was removed 
and the adherent cell layer was rinsed with PBS. Cells were incubated with TE solution until 
80% detached from the culture vessel (the times necessary to achieve this for each line are 
described in Table 2.5). The culture vessels were lightly tapped to mechanically dislodge the 
remaining cells. TE was inactivated with an equal volume of the appropriate media and the cell 
suspension collected in a sterile universal container. Cells were pelleted by centrifugation (5 
min at 160×g) and resuspended in the appropriate media. Cells were frozen for liquid nitrogen 
storage when required.  
Already established keratinocytes lines were routinely split according to the ratios 
described in Table 2.5. The cell suspension in DMEM media was distributed in T80 or T175 
flasks with a total volume of 15 or 25 ml respectively. Due to their high cell-cell adhesion, 
UPCISCC90 were first incubated 20 min with 2 mM PBS/EDTA then 5 min with TE. 
The main modification in the PCOC subculture was related to the presence of irradiated 
J2 3T3 cells. Following the PBS rinse, a 2 min incubation with TE was used to remove the 
remaining J2 3T3 cells prior to adding the TE. PCOC cells were counted and seeded at a density 
of 0.8 to 1×106 cells per 10 cm plate with 2×106 irradiated J2 3T3 cells in a total of 10 ml GMEM 
EGF- media. Thereafter media was replaced every two days with GMEM EGF+ media and 
irradiated J2 3T3 cells when cover was sparse (usually twice a week). 
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HEKn cells were counted and seeded in T175 flasks at a density of 2.5×103 cells/cm2 in a 
total of 25 ml of EpiLife media. Media was renewed every two days until 50% confluence was 
reached and every day thereafter.  
Table 2.5: Trypsin/EDTA incubation time and split ratio of cell lines 
Cell line TE incubation time (min) Split ratio 
PCOC2 15 - 
PCOC3 15 - 
HEKn 5 - 
UMSCC4 10  1/3 
UMSCC6 5 1/2 
UMSCC19 10 1/2 
UMSCC47 10 1/3 
UMSCC74a 7 1/2 
UPCISCC90 5 1/2 
 
2.1.5 Primary Culture of Oropharyngeal Cells  
2.1.5.1 Sample collection and processing 
Ethics and NHS RD approval (reference 13/WA/0002) were obtained for the PCOC 
study and it was adopted into the NISCHR portfolio. Patients were recruited into the study 
during head and neck clinics and were consented by the clinical team (Dr Evans, Mr Owens and 
Mr Al-Husseini). Some patients were recruited at the time of diagnosis and others at the 
beginning of their treatments. Two routes of biopsy collection were used depending on the 
surgical procedure involved. In most cases an extra biopsy was taken during panendoscopy 
and placed directly in transport media. In some cases, when the whole tumour was resected, it 
was first assessed by a pathologist and any spare material used for research. The samples were 
placed in transport media, at room temperature until processed (for more details see the 
Study Protocol included in Appendix 1). The collection and processing steps for cell culture are 
illustrated in Figure 2.1. The samples were cut into two, half was used for nucleic acid 
extraction and the other half for cell culture. The tissue for cell culture was washed 3 times 
with PBS/Pen Strep 1×/amphotericin B 5.6 mg/l and incubated in the last wash for 15 min 
(Sigma-Aldrich). Tissue culture plates were coated with a thin layer of FBS. The biopsy was 
placed on the plate and curved scissors were used to it cut into pieces of 2 mm or less. During 
this process extra FBS was added if needed to avoid the biopsy drying out. The fragments of 
sample were then spread evenly between several 10 cm culture plates and incubated at 37 °C, 
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with 5% carbon dioxide, for 2 h in an inverted position. GMEM EGF- culture media (10 ml) 
containing 2×106 irradiated J2 3T3 cells was then added and the plates returned to the 
incubator.  
 
Figure 2.1: PCOC biopsy processing 
PCOC biopsies were placed in transport media until processed. Half of each biopsy was lysed 
and homogenised than stored for nucleic acid extration. The other part of the biopsy was 
washed in PBS/Pen Strep/Amphotericin B, than cut into small fragments and placed into 
culture plates coated with FBS. Plates were incubated 2 h before EGF- GMEM and irradiated 
3T3 feeder cells were added.  
 
2.1.5.2 PCOC2 and PCOC3 samples 
PCOC2 was derived from a fit 52 year-old man with no smoking history or any previous 
tumours. A primary tumour staged T4N2bM0 was found in the left tonsil involving the tongue 
base and posterior pharyngeal wall. The patient underwent a course of chemoradiotherapy 
which was completed in June 2013. As of April 2016, follow-up showed a positive outcome 
without any recurrence. 
PCOC3 was derived from a 44 year-old man. He was a fit ex-smoker with a history of less 
than 10 pack/year and without any known previous tumours. The cut off between a light and 
heavy smoker is often regarded as 10 pack/year (Ang et al. 2010). A primary tumour in the 
right tonsil was staged T1N2aM0. The patient was treated by trans-oral laser resection and 
oropharynx and neck dissection. This was followed by post-operative radiotherapy, completed 
in June 2013. The treatment response was complete and no recurrence was observed as of 
2016. 
2.1.5.3 Early cell culture 
The media was changed to GMEM EGF+ after two days and thereafter renewed every 
two days. Irradiated J2 3T3 cells were replaced when the coverage of the flask area became 
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sparse, usually twice a week. Photographs were taken using a Zeiss Axiovert 35M inverted 
bright field microscope and camera every 2-3 days in the early stages of culture to record the 
development of cell outgrowth (Zeiss, Cambridge, UK). Once some colonies were visible 
macroscopically, with a size of over 3 mm in diameter, cells were passaged for the first time. 
Cell passaging was performed largely as previously described. The main difference was the use 
of a short TE incubation of 5 to 10 min as the length of TE incubation needed to detach all cells 
was unknown. TE containing detached cells was removed and inactivated every 5 to 10 min 
and fresh TE added until cells growing out of the explants detached. The cell suspension was 
then centrifuged and the pellet resuspended in GMEM EGF- media. The cells were then placed 
in a new culture plate labelled passage 1 with 2×106 irradiated J2 3T3 cells. New GMEM EGF- 
media was added to the plates containing biopsy pieces still attached, this process was 
repeated over time until all the biopsy pieces detached or stopped producing cell outgrowth.  
Early stage primary cultures were passaged once colonies were 50-70% confluent, from 
passage 2 onwards, cells were frozen down if enough cells were available, otherwise cells were 
cultured until consistent growth was obtained.  
2.1.6 Culture of J2 3T3 cells 
2.1.6.1 Thawing and seeding 
J2 3T3 cells were thawed as described previously and plated into a T25 flask containing 5 
ml of DMEM media. Once the cells reached 80% confluence they were transferred into a T80 
flask containing 15 ml media then into several T175 flasks at a 0.5 to 1×106 cells density, using 
the method previously described.  
2.1.6.2 Subculture 
When 80% confluence was reached in T75 flasks, cells were collected for irradiation and 
re-seeded for further use. Cells were used until passage 25 than discarded and replaced by a 
new batch. Cells were harvested (using a 5 min TE incubation) and counted. Several T175 flasks 
were seeded at a density of 0.8 to 1×106 cells in a total of 25 ml DMEM media. The remaining 
cell suspension was placed in a new sterile universal container and stored at 4 °C until 
irradiation.  
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2.1.6.3 Irradiation  
The J2 3T3 cells were irradiated using a caesium-137 source until a dose of 60 Gy was 
achieved (Best Theratronics, Ottawa, Canada). Irradiation rendered 3T3 cells post-mitotic i.e. 
unable to divide but capable of secretion of extra cellular matrix proteins. In further sections, 
irradiated J2 3T3 cells are referred to as 3T3 feeder cells or 3T3’s when used to support other 
cells culture. 
2.1.7 Growth curves 
Cells were grown until 80% confluent, harvested and counted. The cells were plated in 
five 6-well plates with and without 3T3 feeder cells. The densities of PCOC and 3T3 feeder cells 
were adapted from 0.8×106 PCOC cells and 2×106 3T3 feeder cells cultured in a 10 cm plate. 
Every 24 h, cells contained in 3 wells were trypsinised. The cell suspension for each well was 
counted 3 times. One count corresponded to one grid of a haemocytometer. The average 
number of cells per well and per ml was calculated. 
2.1.8 Chamber slide growth 
Cells were harvested and counted before plating them at double the density used in 
normal condition in 3 ml media to ensure enough cells attached to the glass slides. Cells were 
fixed once they reached 50% confluent or over. An equivalent volume of 4% formaldehyde was 
added to the media to pre-fix cells for 2 min. The solution was then discarded and 4% 
formaldehyde added for 20 min. The solution was discarded and the slides washed with PBS. 
The chambers were removed and slides stored in PBS.  
2.1.9 Mycoplasma detection 
2.1.9.1 Reagents preparation and storage 
A PCR based assay was used to screen cell lines for mycoplasma contamination. The 
primer set used in Venor GeM mycoplasma detection kit is specific to the highly conserved 16s 
rRNA coding region which allows for the detection of a range of mycoplasma species (Minerva 
Biolabs, Berlin, Germany). The reagents were rehydrated with PCR grade water according to 
the manufacturer’s instructions and stored at -20 °C. 
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2.1.9.2 Sample collection and storage 
Cultures were grown to at least 90% confluence and 500 µl of supernatant transferred 
to a microfuge tube. The samples were incubated at 95 °C for 10 min then cellular debris were 
pelleted by centrifugation (5 s at 8000×g), the supernatant was used in the PCR reaction mix. 
The reaction mix was assembled in a designated PCR hood in sterile conditions 
according to Table 2.6. A volume of 23 µl was dispensed in each tube, 2 µl of negative control, 
positive control or sample were added to the designated tubes. DNA polymerase (5 U/µl) was 
not included in the kit and purchased separately (Minerva Biolabs). The amplification was 
performed as described in Table 2.7 using a Nexus GSX1 thermocycler (Eppendorf, Stevenage, 
UK).  
 
Table 2.6: Composition of mycoplasma PCR reaction 
Reagent Volume n=1 (µl) 
PCR grade water 15.3 
10× reaction buffer 2.5 
Primer/nucleotide mix 2.5 
Internal control 2.5 
Polymerase 0.2 
Total volume 23 
 
Table 2.7: Mycoplasma thermocycler conditions 
Phase Temperature (°C) Time Cycles 
Initial denaturation 94 2 min 1 
Denaturation 94 30 s 
39 Primer annealing 55 30 s 
Extension 
 
 
 
72 30 s 
Final extension 72 30 s 1 
 
2.1.9.3 Gel electrophoresis and result interpretation 
A 1.5% agarose gel was made and the samples loaded in the wells as described in 
section 2.2.5.2 . The electrophoresis was run at 100 V for 20 min. The gel was observed under 
UV light. The presence of a 191 bp internal control in all sample lanes indicated the success of 
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the reaction. Mycoplasma DNA was indicated by the presence of an extra band of around 265-
278 bp. 
2.2 Nucleic acid extraction 
This section describes the various samples, their processing and the different methods 
of DNA and RNA extractions used. 
2.2.1 DNA extraction from tonsil homogenate 
2.2.1.1 Samples 
Tonsil homogenates in a sucrose solution (n=524) were obtained from the National 
Anonymous Tonsil Archive. Samples were stored at -80 °C and thawed at room temperature 
before DNA extraction. 
2.2.1.2 Phenol Chloroform DNA extraction 
Microfuge tubes (2 ml volume) were filled with 150 µl of pre-warmed Tris/EDTA lysis 
buffer (composition outlined in Table 2.8), 500 µl tonsil homogenate and 100 µl of 20 mg/ml 
Proteinase K (Roche, Burgess Hill, UK). A blank extraction control was included every 23 
samples. Samples were incubated overnight at 56 °C with gentle rotation (180 RPM). 
Table 2.8: Composition of 5x 250 mM Tris/5 mM EDTA lysis buffer 
Component Final Concentration (M or %) 
Tris 0.5 M 
HCl 32% 
NaCl 2 M 
EDTA 0.2 M 
SDS 10% 
De-ionised water 300 ml, pH adjusted to 8, fill to 500 ml 
 
The phenol chloroform extraction was performed in a safety cabinet with external 
venting. Following the addition of 750 µl of Phenol chloroform isoamyl alcohol pH 8 (Sigma-
Aldrich), the tubes were vortexed, rotated for 5 min at room temperature (RT) then 
centrifuged 5 min at 8000×g. The aqueous phase was transferred to newly labelled tubes and 
the same process repeated following the addition of 750 µl chloroform isoamyl alcohol. The 
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volume of each sample was estimated and 1/10 of the volume of sodium acetate 3 M and an 
equal volume of isopropanol were added (Sigma-Aldrich). The samples were vortexed briefly 
and incubated at room temperature for 1 h then centrifuged at 8000×g for 10 min. A 70% 
ethanol solution was added to each tube (500 µl). The samples were vortexed, rotated gently 
for 10 min and centrifuged 5 min at 8000×g before discarding the supernatant. A further 
centrifugation of 10 s at 8000×g was used to remove any residual supernatant and the pellets 
allowed to dry at 37 °C for 10 min. Pellets were resuspended in 500 µl of Tris 10 mM/EDTA 1 
mM pH 8 and incubated at 56 °C for 1h with gentle rotation at 160 RPM. Samples were stored 
at -20 °C. After 24 h a 3 µl aliquot was taken from each sample to quantify the DNA.  
2.2.2 DNA and RNA extraction from cell culture 
DNA and RNA were purified separately using QIAamp DNA Mini and RNeasy Fibrous 
Tissue kits (QIAGEN, Hilden, Germany). The extractions were performed according to the 
manufacturer’s recommendation; the general processes are summarised below. 
2.2.2.1 Harvesting cells for DNA/RNA extraction 
Cells were harvested and counted once 80% confluence was reached. A maximum of 
5x106 cells were placed in a 2 ml tube and centrifuged for 5 min at 300×g. The supernatant was 
discarded and the pellet lysed and resuspended according to the manufacturer’s 
recommendation. 
2.2.2.2 DNA extraction using QIAamp DNA Mini kit 
The pellet was resuspended in 200 µl PBS, mixed with 200 µl of AL buffer and 20 µl of 
Proteinase K. The mixture was incubated 10 min at 56 °C. Next, 200 µl of 100% ethanol were 
mixed with the sample, prior to loading on a QIAamp DNA mini spin column. The sample was 
centrifuged through the column for 1 min at 6000×g which bound the DNA to the membrane. 
Washes were performed with 500 µl of AW1 buffer followed by a 1 min centrifugation at 
6000×g then with 500 µl AW2 buffer followed by a 3 min centrifugation at 20000×g. The flow-
through was discarded after each centrifugation. The column was transferred to a new 2 ml 
collection tube and centrifuged at 20000×g for 1 min to eliminate any risk of buffer AW2 carry 
over. DNA was eluted with twice 50 µl of elution buffer followed by a 1 min centrifugation at 
6000×g and store at -20 °C.  
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2.2.2.3 Total RNA extraction using RNeasy fibrous tissue mini kit 
The columns and reagent contained in this kit were the same as the RNeasy mini kit. The 
protocol used was the recommended protocol for total RNA extraction from cell lines 
contained in the RNeasy mini kit. The working area and the equipment used were cleaned with 
RNaseZap (Sigma-Aldrich) to eliminate RNase which could degrade the RNA. The cell pellet was 
lysed with 600 µl of RLT buffer, containing 6 µl of 14.3 M β-mercaptoethanol (Sigma-Aldrich). 
All steps of the extraction were performed at RT, the RNA was kept on ice after the elution 
prior to long term storage. 
The lysate was homogenised by passing at least 5 times through a sterile 20-gauge 
needle. The lysate was mixed with 70% ethanol and centrifuged through the provided RNeasy 
mini column 700 µl at a time 15 s at 8000×g, this bound the RNA to the silica membrane. The 
column was washed with 350 µl of RW1 buffer, centrifuged for 15 s at 8000×g and the flow-
through discarded.  
The samples were treated with DNase to eliminate DNA contamination in downstream 
applications. Prior to use, the DNase stock powder was dissolved in 550 µl of RNase-free water 
according to the manufacturer’s instruction, aliquoted and stored at -20 °C. The working 
DNase solution was made by mixing 10 µl of DNase I with 70 µl of RDD buffer. The 80 µl of 
DNase I incubation mix were added directly on the column membrane and incubated at RT for 
15 min. This was followed by another wash with 350 µl RW1 buffer and two washes with 500 
µl RPE buffer, a longer centrifugation time of 2 min was used to dry the membrane for the last 
wash. A 2 min centrifugation step (8000×g) in a new collection tube was used to eliminate RPE 
carry over. The RNA was eluted using twice 30 µl RNase free water (centrifuged 1 min at 
8000×g) and stored at -80°C.  
2.2.3 Genomic DNA and total RNA extraction from oropharyngeal cancer biopsies 
A method of simultaneous DNA and RNA extraction combining RNeasy fibrous tissue 
mini kit and QIAamp DNA Mini kit based on a protocol obtained from the Wales Cancer Bank 
was used. This section describes the variation from the protocols used for of each kit 
individually. 
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Half of each biopsy was homogenised using a TissueRuptor (QIAGEN) for 20 s in 600 µl 
RLT buffer containing 6 µl of 14.3 M β-mercaptoethanol (Sigma-Aldrich) and reagent DX 
(QIAGEN) to a final concentration of 0.5% v/v to prevent foaming.  
Each sample was divided into two 300 µl volumes which were processed in parallel. The 
sample was mixed with 20 µl of Proteinase K and 708 µl of RNase free water then incubated 
for 10 min at 56 °C. The digestion solution was centrifuged 3 min at 8000×g and 650 µl of 
supernatant were removed to be processed for RNA extraction. The pellet was resuspended in 
the remaining volume and placed at 55 °C for later DNA purification.  
The tube containing the clear lysate was processed for RNA purification by mixing in half 
a volume of 100% ethanol. The sample was then processed as previously described in the 
RNeasy protocol. 
Following the RNA purification, the tube containing the homogenised biopsy kept at 55 
°C was processed for DNA purification. The sample was mixed with 350 µl of buffer AL and 
incubated at 70 °C for 10 min before mixing in 350 µl 100% ethanol. This sample was loaded 
onto the membrane of a QIAamp DNA mini spin column 600 µl at a time and centrifuged 1 min 
at 8000×g before discarding the flow-through. This step was repeated until the whole sample 
passed through the column. The following washes and elution were performed as described 
previously in the QIAamp protocol.  
2.2.4 Nucleic acid quantification  
The concentration and purity of the nucleic acids were evaluated using a NanoDrop 
1000 Spectrophotometer (Thermo Fisher Scientific) according to the manufacturer’s 
instructions. A blank measure was established by loading 3 µl of the elution solution. The 
absorbance at 230 nm and 260 nm wavelengths of 2 µl of each samples was recorded. The 
absorbance measures provided the concentration in ng/µl and the ratio between 230/260 nm. 
High purity was indicated by ratios between 1.8 and 2.2. 
2.2.5 DNA integrity 
PCR amplification of a 209 bp or 1020 bp fragment of the housekeeping gene β-globin 
was used to assess the integrity of extracted DNA and its suitability for PCR base techniques. 
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Primers, shown in Table 2.9, were purchased from Sigma-Aldrich (Saiki et al. 1988; de Roda 
Husman et al. 1995). This section describes the overall PCR technique and gel electrophoresis 
used in all further PCR based assays.  
Table 2.9: β-globin primers sequences 
Primers  Forward primer Reverse primer 
Amplicon 
(bp) 
PCO3/PCO5 ACACAACTGTGTTCACTAGC GAAACCCAAGAGTCTTCTCCT 209 
1kF/1kR ATCCAAATAAGGAGAAGATATGC AAACATCAAGCGTCCCATAG 1020 
 
2.2.5.1 General reaction set up 
PCR reactions were set up in a designated PCR hood. A master mix was made, which 
included PCR grade water, primers, buffers and Taq polymerase (QIAGEN and Sigma-Aldrich). 
This was distributed as 20 µl per labelled PCR tubes. Five microliters of diluted DNA, water for 
the negative control or 5 µl of HPV-positive sample for positive control was then added to the 
corresponding tubes. The reagents and volumes used are shown in Table 2.10. The sealed 
tubes were placed in a Nexus GSX1 thermocycler (Eppendorf) and the amplification reaction 
performed according to conditions in Table 2.11. The samples were then stored at 4 °C for 
short term usage or at -20°C for long term storage.  
Table 2.10: Composition of β-globin PCR reaction 
Reagent Concentration Volume n=1 (µl) 
Primers (each) 5 µM 2.5 
Deoxynucleotide (dNTP) 2 mM 2.5 
10X reaction buffer 1× 2.5 
Hotstar Taq polymerase 5U/µl 0.1 
PCR grade water - 9.9 
DNA 1/10 5 
Total volume - 25 
 
Table 2.11: β-globin thermocycler conditions 
Phase Temperature (°C) Time Cycles 
Initial denaturation 94 15 min 1 
Denaturation 94 30 s 
40 Primer annealing 55 30 s 
Extension 
 
 
 
72 60 s 
Final extension 72 4 min 1 
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2.2.5.2 Agarose gel electrophoresis 
A 2% w/v agarose gel was prepared using 1x Tris/Borate/EDTA (TBE), agarose and 1 µl 
10 mg/ml ethidium bromide per 100 ml of gel (Sigma-Aldrich). Samples were mixed with 5 µl 
of orange G loading dye (Sigma-Aldrich). The first well from each row of the gel was loaded 
with 10 µl of FullRanger DNA ladder for amplicons up to 5000 bp or PCR Ranger ladder for 
fragments up to 1000 bp (Norgen Biotek, Thorold, Canada). The other wells were loaded with 
10 µl of the combined sample/orange G. The gel was run 1 h at 100 V in an electrophoresis 
tank containing 1×TBE to allow separation of the products. The bands were visualised and 
photographed under UV light using a GelDoc-It imaging system (UVP, Upland, USA). A product 
size of 209 bp or 1020 bp β-globin indicated the presence of intact DNA fragments and the 
suitability of the sample for further PCR analysis. 
2.2.6 RNA integrity 
RNA samples were analysed for integrity with an Agilent RNA 6000 Nano kit combined 
with Agilent 2100 Bioanalyser (Agilent Technologies, Santa Clara, USA) by Central 
Biotechnology Services (Cardiff University). During this chip electrophoresis assay, the RNA 
molecules were separated by size in the chip’s micro-channels and detected by laser induced 
fluorescence. The molecular weight was determined by comparison with a ladder of known 
fragment sizes; the amount of fluorescence measured correlated with the amount of RNA. The 
results were represented either as gel like images or electropherograms. The RNA integrity 
was assessed by the ratio of the 18s and 28s ribosomal fractions. An RNA Integrity Number 
(RIN) was automatically calculated using an algorithm developed by the manufacturer. A RIN of 
10 corresponded to un-degraded RNA whereas 0 showed the presence of only degraded RNA. 
RIN of 8 or over are generally accepted as good quality for sequencing analysis.  
With the chip placed in the priming station, 9 µl of premade gel-dye mix equilibrated at 
room temperature was loaded at the bottom of a marked well. The plunger was set to 1 ml 
and the priming station closed. The plunger was pressed down, held for 30 s and released, to 
distribute the gel-dye mix. The chip was removed from the priming station and 9 µl of gel-dye 
mix loaded to other designated wells. The remaining wells were used for sample and the 
ladder (previously thawed, denatured 2 min at 70 °C and stored on ice), 5 µl of RNA 6000 nano 
marker were loaded in each well with 1 µl of sample or 1 µl of ladder. The chip was vortexed 
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for 60 s then inserted into the Agilent Bioanalyser and analysed according to manufacturer’s 
instructions.  
2.3 Short Tandem Repeat typing 
This assay was used to compare the Short Tandem Repeat (STR) profiles (DNA 
fingerprints) of the newly developed oropharyngeal cancer cell lines and the biopsies they 
were derived from. It is an STR multiplex assay which amplifies 15 tetranucleotide loci. It was 
performed with assistance from Dr Sian Meyrick and Dr Steve Austin (Cardiff University 
Haematology Department) using an AmpFlSTR Identifiler PCR amplification kit according to the 
manufacturer’s instructions (Thermo Fisher Scientific). 
A single multiplex PCR was used to amplify all 15 loci. The locus designation and their 
chromosome location are described in Table 2.12. PCR primers bind to flanking regions of the 
STR sites resulting in different product sizes depending on the number of repeats present. One 
primer of each pair has a fluorescent label resulting in fluorescently labelled products. The PCR 
master mix was assembled by combining for each sample 10.5 µl of AmpFlSTR PCR reaction 
mix, 0.5 µl of AmpliTaq Gold DNA polymerase and 5.5 µl of AmpFlSTR identifiler primer set. 
Fifteen microliters of the master mix were dispensed to each tube and 10 µl of sample DNA, 
diluted to a concentration of 005-0125 ng/µl, was added. The amplification was done using a 
GeneAmp PCR system 9700 according to the cycle described in Table 2.13 (Thermo Fisher 
Scientific). 
The PCR products were separated by electrophoresis in a capillary filled with 
performance optimised polymer 4 and detected on an ABI Prism 310 Genetic Analyser 
(Thermo Fisher Scientific). A system of 5 fluorescent dyes was used for detection. Following 
excitation, the dyes were distinguished using virtual filters and CCD imaging and the light 
intensities collected by the ABI Prism 310 data collection software. Following analysis an 
electopherogram was generated and the peaks used to compare similarities between samples 
at the different loci.  
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Table 2.12: Designation of Loci used in STR typing and their chromosome location 
Locus Designation Chromosome Location 
D8S1179 8 
D21S11 21q11.2-q21 
D7S820 7q11.21-22 
CSF1PO 5q33.3-34 
D3S1358 3p 
TH01 11p15.5 
D13S317 13q22-31 
D16S539 16q24-qter 
D2S1338 2q35-37.1 
D19S433 19q12-13.1 
vWA 12p12-pter 
TPOX 2p23-2per 
D18S51 18q21.3 
Amelogenin X: p22.1-22.3 Y:p11.2 
D5S818 5q21-31 
FGA 4q28 
 
 
Table 2.13: STR typing thermocycler conditions 
Phase Temperature (°C) Time (min) Cycles 
Initial denaturation 95 11  1 
Denaturation 94 1  
28 Primer annealing 59 1  
Extension 
 
 
72 1  
Final extension 60 1  1 
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2.4 Amplification of HPV16 genes E1, E2 and E6 
The amplification of a 161 bp fragment of the HPV16 E6 gene was used confirm the 
presence of HPV16. The HPV16 E1 and E2 genes are often disrupted when the virus integrates 
within the human genome, their disruption was used as a surrogate marker for HPV 
integration. Tiling PCRs amplifying 2 overlapping fragments of HPV16 E1 and 5 overlapping 
fragments of HPV16 E2 were used. Details of the primers are illustrated in Table 2.14 and 
amplification conditions in Table 2.15. The reaction composition was the same as the β-globin 
PCR, described in section 2.2.5.1 . 
Table 2.14: E1, E2 and E6 primers sequence and amplicon size 
Primer
s name 
Forward primer Reverse Primer Amplicon (bp) 
E1 CTAGGAATTGTGTGCCCATCTG ACGTTGGCAAAGAGTCTCCATC 1954 
E1.1 CTAGGAATTGTGTGCCCATCTG CTTTCTATCCATTCTGGCGTGTCT 1069 
E1.2 GATAGAGCCTCCAAAATTGCGT ACGTTGGCAAAGAGTCTCCATC 995 
E2 TTAAGTTTGCACGAGGACGA CGCCAGTAATGTTGTGGATG 1167 
E2.1 AGGACGTGGTCCAGATTAAG TCAAACTGCACTTCCACTGT 414 
E2.2 TAACTGCACCAACAGGATGT GCCAAGTGCTGCCTAATAAT 340 
E2.3 ATCTGTGTTTAGCAGCAACG TAAATGCAGTGAGGATTGGA 224 
E2.4 ACAGTGCTCCAATCCTCACT TCACGTTGCCATTCACTATC 244 
E2.5 GGCATTGGACAGGACATAAT CAAAAGCACACAAAGCAAAG 207 
E6 GAACAGCAATACAACAAACC GATCTGCAACAAGACATACA 161 
 
Table 2.15: E1, E2 and E6 PCR thermocycler conditions 
Assay Phase Temperature (°C) Time Cycles 
E1 
Initial denaturation 95 15 min 1 
Denaturation 94 30 s 
30 Primer annealing 59 30 s 
Extension 72 3 min 
Final extension 72 7 min 1 
E2 
Initial denaturation 95 15 min 1 
Denaturation 94 30 s 
40 Primer annealing 58 30 s 
Extension 72 30 s 
Final extension 72 5 min 1 
E6 
Initial denaturation 94 15 min 1 
Denaturation 94 30 s 
40 Primer annealing 55 30 s 
Extension 72 60 s 
Final extension 72 4 min 1 
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2.5 HPV typing 
2.5.1 GP5+/GP6+ 
GP5+/GP6+ PCR-EIA is a PCR based assay which uses solid phase enzyme immunoassay 
(EIA) to detect several types of HPV (Jacobs et al. 1997). This technique can detect 14 high risk 
types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 and 6 low risk types: 6, 11, 40, 42, 43, 
44. A fragment of the HPV L1 open reading frame is amplified using consensus primers 
targeting well conserved sequences. The forward primer is termed GP5+ and the biotinylated 
reverse primer GP6+ (Table 2.16). The biotinylated PCR products are captured on streptavidin 
coated wells. After denaturation, the amplicons are hybridised with digoxigenin labelled HPV 
oligonucleotides probes which are specific for individual HPV types.  
Table 2.16: GP5+/GP6+ primers sequence 
Primer Sequence Amplicon (bp) 
GP5+ TTTGTTACTGTGGTAGATACTAC 
142 
GP6+ GAAAAATAAACTGTAAATCATATTC 5’Biotinylated 
 
2.5.1.1 GP5+/GP6+ PCR EIA 
DNA was extracted from tonsil homogenates samples (as described in section 2.2.1 and 
diluted 1/10. The reaction components were assembled according to Table 2.17and the PCR 
conditions are shown in Table 2.18. 
Two EIA were performed, the first used a cocktail of probes for the 14 high risk HPV 
types and the second used a cocktail of probes for the 6 low risk types. The PCR products were 
bound to a 96 Streptawell plate (Roche), 5 µl of amplicon were added per well with 50 µl of 
wash buffer. The plates were incubated 1h at 37 °C then washed 3 times with 1× wash buffer. 
The wash buffer was made as a 5× stock, comprising of 43.8 g of NaCl, 22 g of sodium citrate 
and 25 ml of tween 20 in 1 l of sterile water. DNA bound to the plates was denatured using 100 
µl of 0.2 M NaOH per well, followed by 3 washes.  
The digoxigenin labelled probe cocktail (Roche) was added, 50 µl of 10 µM probe 
solution per well and left to hybridize with the amplicons for 1 h at 37 °C. The plates were 
washed 3 times to remove unbound probes and 50 µl anti-Digoxigenin conjugate (Roche) were 
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added per well. This was followed by 1 h incubation at 37 °C and 5 washes. The substrate 
solution was added, 100 µl per well and the plates were incubated 1 h at 37°C in the dark.  
The absorbance at 415 and 630 nm was recorded after 1, 2 and 24 h using a Bio-Rad 550 
microplate reader (Bio-Rad, Watford, UK). A sample was considered positive when its 
absorbance values were at least 3 times higher than the negative control or background value.  
Table 2.17: Composition of GP5+/GP6+ PCR reaction 
Reagent Concentration Volume n=1 (µl) 
Primers (each) 5 µM 2.5 
dNTP 2 mM 2.5 
10X reaction buffer 1× 2.5 
MgCl2 50 mM 1.75 
Hotstar Taq polymerase 5U/µl 0.1 
PCR grade water - 11.15 
DNA 1/10 2 
Total volume - 25 
 
Table 2.18: GP5+/GP6+ PCR thermocycler conditions 
Phase Temperature (°C) Time Cycles 
Initial denaturation 94 4 min 1 
Denaturation 94 30 s 
40 Primer annealing 40 90 s 
Extension 72 1 min 
Final extension 72 4 min 1 
 
2.5.2 HPV detection using Inno DNA EIA SPF10 kit 
This is an in vitro PCR DNA EIA (DEIA) which can detect 40 types of HPV with a high 
sensitivity (Innogenetics, Gent, Belgium). Due to the small size of the fragments amplified this 
assay is suitable for use with degraded or archival material (Tjalma et al. 2013). The HPV types 
detected are: HPV 3-8, 11, 13, 16, 18, 26, 27, 30-35, 37, 39, 40, 42, 43, 44, 45, 51-56, 58-62, 64-
71 and 74. The protocol recommended by the manufacturer was used without modifications. 
A PCR step amplified a 65 bp fragments in the L1 region, one of the primers is biotinylated 
resulting in the labelling of one strand of the product. The amplicons were captured on the 
wells of a streptavidin coated plate. An incubation with a denaturating solutions and a washing 
step were used to remove the non-biotinylated strand. The amplicons were incubated with a 
cocktail of digoxygenin-labelled HPV-specific probes. The label was then detected using an 
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anti-digoxygenin enzyme conjugate which was visualised by a chromogenic substrate. The 
absorbance of each well was measured and the presence of HPV DNA determined by 
comparing the optical density of the PCR product to that of a cut-off value. To avoid 
contaminations two rooms were used: one for the PCR set up and the second for the ELISA. 
2.5.3 Data analysis 
The validation criteria of the assays were as follows: 
1. The optical density of the HPV-positive sample preparation control was over 4 times 
the level of optical density of the HPV borderline DEIA control. 
2. The optical density of the HPV-negative sample preparation control was over 4 lower 
than the level of optical density of the HPV borderline DEIA control. 
3. The optical density of the HPV-positive control was over 4 times the optical density of 
the HPV borderline DEIA control.  
4. The optical density of the HPV-negative control was over lower than the optical 
density of the HPV borderline DEIA control.  
5. The optical density of the HPV-positive DEIA control was over or equal to 3 times the 
optical density of the HPV borderline DEIA control. 
6. The optical density of the HPV borderline DEIA control was over or equal to 0.1 times 
the optical density of the HPV borderline DEIA control. 
7. The optical density of the HPV-negative DEIA control was lower or equal to 0.6 times 
the optical density of the HPV borderline DEIA control. 
If all of those criteria were met, the results were analysed. Samples were considered 
HPV-positive if their optical density was greater than the optical density of the HPV borderline 
DEIA control. Samples were considered HPV-negative if their optical density was equal or less 
then the optical density of the HPV borderline DEIA control. Samples with an optical density 
between 0.75 or 1 times of the optical density of the HPV borderline DEIA control were re-
tested.  
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2.6 Detection of TP53 mutation by direct sequencing 
PCOC2 and PCOC3 were analysed for TP53 mutation using the IARC protocol, 2010 
update (http://p53.iarc.fr/Download/TP53_DirectSequencing_IARC.pdf). This technique was 
based on the amplification of 13 fragments of the TP53 gene within exons 2-11 followed by 
direct sequencing, the resulted sequences were analysed to detect any mutations.  
2.6.1 Sample preparation 
Cells were harvested, processed for DNA extraction and the DNA analysed with a 
NanoDrop 1000 Spectrophotometer to assess the concentration and purity. The samples were 
diluted to 50 ng/µl using PCR grade water (Sigma-Aldrich). 
2.6.2 PCR reaction 
The 13 primer sets were obtained from Sigma Aldrich, their sequences and amplicons 
sizes are described in Table 2.19. The reactions components were assembled in a PCR hood in 
sterile conditions as described in Table 2.20, the mix was transferred to labelled tubes. 
Depending on the primer sets, 4 different amplifications cycles were used as detailed in Table 
2.21 and runned on a Techne TC-512 thermocycler (Bibby Scientific, Stone, UK). 
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Table 2.19: TP53 PCR primers and corresponding programs 
Primers/direction Sequence 
Region 
Amplified 
Amplicon 
(bp) 
PCR 
Program 
P-559 (F) 
P-E3Ri (R) 
tctcatgctggatccccact 
agtcagaggaccaggtcctc 
Exons 2-3 344 B 
P-329 (F) 
P-330 (R) 
tgctcttttcacccatctac 
atacggccaggcattgaagt 
Exon 4 353 B 
P-326 (F) 
P-327 (R) 
tgaggacctggtcctctgac 
agaggaatcccaaagttcca 
Exon 4 413 B 
P-312 (F) 
P-271 (R) 
ttcaactctgtctccttcct 
cagccctgtcgtctctccag 
Exon 5 248 B 
P-239 (F) 
P-240 (R) 
gcctctgattcctcactgat 
ttaacccctcctcccagaga 
Exon 6 181 B 
P-236 (F) 
P-240 (R) 
tgttcacttgtgccctgact 
ttaacccctcctcccagaga 
Exons 5-6 467 B 
P-333 (F) 
P-313 (R) 
cttgccacaggtctccccaa 
aggggtcagaggcaagcaga 
Exon 7 237 C 
P-237 (F) 
P-238 (R) 
aggcgcactggcctcatctt 
tgtgcagggtggcaagtggc 
Exon 7 177 B 
P-316 (F) 
P-319 (R) 
ttccttactgcctcttgctt 
aggcataactgcacccttgg 
Exon 8 231 B 
P-314 (F) 
P-315 (R) 
ttgggagtagatggagcct 
agtgttagactggaaacttt 
Exons 8-9 445 B 
9F (F) 
9R (R) 
gacaagaagcggtggag 
cggcattttgagtgttagac 
Exon 9 215 E 
P-E10Li (F) 
P-562 (R) 
caattgtaacttgaaccatc 
ggatgagaatggaatcctat 
Exon 10 260 D 
P-E11L2 (F) 
P-E11Re (R) 
agaccctctcactcatgtga 
tgacgcacacctattgcaag 
Exon 11 245 B 
 
 
Table 2.20: Composition of TP53 PCR reaction 
Reagent Concentration Volume n=1 (µl) 
Primers (each) 10 µM 0.8 
dNTP 5 mM 0.8 
10 reaction buffer 1× 2 
Hotstar Taq polymerase 5U/µl 0.1 
PCR grade water - 14.5 
DNA 50 ng/µl 1 
Total volume - 20 
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Table 2.21: TP53 thermocycler conditions 
Name Phase Temperature (°C) Time Cycles 
B 
Initial denaturation 94 2 min 1 
Denaturation 94 30 s 20 
-0.3 °C every 3 
cycles 
Primer annealing 63 45 s 
Extension 
 
 
72 1 min  
Denaturation 94 30 s 
30 Primer annealing 60 45 
Extension 
 
 
 
72 1 min 
Final extension 72 10 min 1 
C 
Initial denaturation 95 15 min 1 
Denaturation 94 30 s 
50 Primer annealing 60 30 s 
Extension 
 
 
 
72 30 s 
Final extension 72 10 min 1 
D 
Initial denaturation 94 2 min 1 
Denaturation 94 30 s 20 
-0.5 °C every 3 
cycles 
Primer annealing 58.5 45 s 
Extension 
 
 
 
72 1 min  
Denaturation 94 30 s 
30 Primer annealing 55 45 s 
Extension 
 
 
 
72 1 min 
Final extension 72 10 min 1 
E 
Initial denaturation 94 2 min 1 
Denaturation 94 30 s 
50 Primer annealing 57 30 s 
Extension 
 
 
 
72 30 s 
Final extension 72 10 min 1 
 
2.6.3 DNA purification 
Following the PCR reactions a gel electrophoresis using 5 µl of product was used to 
verify the size of the products and the remainder of the samples were stored at -20 °C until 
further use. The Illustra GFX PCR DNA and Gel Band Purification Kit (GE Healthcare, Amersham, 
UK) was used to purify and concentrate DNA according to the manufacturer’s protocol. Once 
defrosted, a gel electrophoresis was run with each sample. Each band was viewed under low 
setting UV light and cut out using a clean scalpel. Gel bands were placed in labelled tube of 
known weight and the weight of each gel slice calculated.  
For each 10 mg of gel band, 10 µl of capture buffer 3 were added in each tube. The 
agarose was melted with a 60 °C incubation, mixing the tubes by inversion until the agarose 
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was fully melted. The pH of the samples was checked using their colour and adjusted with the 
addition of 3M NaOH pH5 until the required colour (yellow/pale orange) was achieved.  
The samples were centrifuged briefly then transferred onto a GFX microspin column 
placed in a collection tube800 µl at a time. Following 1 min incubation at room temperature 
the columns and collection tubes were centrifuged 30 s at 16000×g and the flow-through 
discarded. This step was repeated if the sample volume exceeded 800 µl.  
The membrane was washed by adding 500 µl of wash buffer type 1 to each sample, 
centrifuged 30 s at 16000×g and the flow-through was discarded. This step was repeated 
followed by a further 30 s centrifugation at 16000xg to ensure there was no carryover of the 
capture buffer.  
The columns were transferred to new labelled DNase free tubes. The DNA was eluted by 
the addition of 10 to 50 µl of elution buffer 6, incubated at room temperature for 1 min then 
centrifuged 1 min at 16000×g. The samples were either processed immediately or stored at –
20  C until further use. Prior to freezing a 5 µl aliquot was taken from each sample to verify the 
purification process and estimate the DNA concentration. 
Gel electrophoresis was performed as previously described and a picture taken. For each 
sample the presence of a single band was checked. The concentration of each PCR product to 
be sequenced was estimated by comparing the brightness of each band to the ladder of known 
concentration. The samples were then diluted using PCR grade water to obtain a concentration 
of 1 µg/ml in a 20 µl volume. The PCR primers were also diluted to a concentration of 3.2 
pmol/µl in 20 µl. Both the diluted samples and primers were shipped for Sanger sequencing 
(Source BioScience, Nottingham, UK). 
2.6.4 Data analysis 
The chromatograms of the Sanger sequencing reactions were analysed manually using 
BioEdit software (Ibis Biosciences, Carlsbad, USA) to check that each base corresponded to the 
peak in the chromatogram before the generation of fasta files for each sequence. Using the 
fasta format files, parts of the sequence of poor quality were removed, usually at either end of 
the sequence. The remaining test sequence was aligned with the genomic sequence 
NC_000017.10 (Homo sapiens chromosome 17, which includes the TP53 gene). In cases where 
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the alignment between the test and reference sequence was less than 100%, mismatches were 
compared with the chromatograms to check whether this came from an error or a true 
mismatch. The fasta format sequence was adjusted accordingly. The portions of the adjusted 
fasta format sequence containing mismatches were aligned to the IARC TP53 sequence and 
the position of the mismatches recorded. The positions of mismatches were then entered in 
the NCBI SNP database (https://www.ncbi.nlm.nih.gov/snp) to check whether they 
corresponded to known variations.  
2.7 Olaparib dosing assay 
2.7.1 Drug preparation 
Olaparib (AZD2281) was purchased as 10 mg powder (Selleckchem, Munich, Germany). 
Due to low water solubility, DMSO was used in the first dilution step. A 10 mM stock solution 
was made by adding 2.3017 ml of DMSO and mixing until all powder was dissolved. A second 
stock solution of 1000 µM was made following a 1/10 dilution of stock 1 in cell culture media 
(DMEM, GMEM or EpiLife). Both stock solutions 1 and 2 were aliquoted into single use doses 
and stored at -80 °C for a maximum of 1 year.  
2.7.2 Crystal violet staining 
The media was pipetted out of each plate. The remaining media and 3T3 feeder cells 
were removed with a PBS wash. The plates were incubated for 2 min with 5 ml of 50% v/v 
PBS/methanol. This solution was discarded and replaced with 5 ml of 100% methanol per 
plate. Following a 10 min incubation at RT, the methanol was discarded and the plates left to 
dry. Crystal violet, 5 ml per plate, was added and the plates were incubated for a maximum of 
10 min (Thermo Fisher Scientific). The crystal violet was removed and filtered to be reused, the 
plates were rinsed with water and left to dry at RT. 
2.7.3 Plating density assay 
Cells were harvested once 80% confluence was reached and counted. The cell 
suspension was diluted to obtain solutions of various cell densities and plated in 6 cm plates. 
For each condition triplicates were used both in the presence of and without 3T3 feeder cells 
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at a density of 1×106 per plate. The plates were then placed in the incubator and the media 
replaced after 7 days. After 10-15 days, the plates were stained with crystal violet. 
2.7.4 Olaparib dosing experiment 
These experiments investigated the effect of a single dose of Olaparib on the colony 
forming capacity of a cell line panel. The concentrations of Olaparib used were: untreated, 
vehicle only (containing 0.1% DMSO), 0.1 µM, 0.5 µM, 1 µM, 5 µM and 10 µM. The DMSO 
concentration was adjusted to 0.1% in all conditions, this corresponded to the amount of 
DMSO contained in the 10 µM condition. For each condition triplicates were used. 
Cells were harvested and counted and the resulting cell suspension diluted if necessary. 
Stock solutions were made in 3 x 50 ml tubes each containing enough cells for eight 6 cm 
plates, in a total of 40 ml media and containing 8x106 3T3 feeder cells if necessary. The cell 
densities used for each cell line were determined as described in the previous section. The cell 
suspension was pipetted into 21 culture plates which were incubated for 24 h to allow cells to 
attach before treatment with the drug Olaparib. 
A 10 µM solution of Olaparib was made following a 1/100 dilution of the 1000 µM stock 
2 solution (350 µl of stock 2 into 34.65 ml media). A serial dilution in 20 ml universal tubes was 
used to obtain the other Olaparib solutions. The required amount of DMSO was added to each 
tube to adjust the concentration to 0.1% before vortexing and transferring solution to the next 
tube. The vehicle solution was obtained by adding 20 µl DMSO to 20 ml of media.  
After the 24 h incubation, the plates were checked under the microscope to ensure cells 
adhered to the plates and if present that the 3T3 feeder cells covered to whole plate. The 
media was pipette out and discarded. The plates were labelled in triplicates with each 
condition and 5 ml of treated solutions were added to the corresponding plates. The plates 
were returned to the incubator and left undisturbed for 7 days. At day 8, the plates were 
observed and the media was pipetted out and replaced (without Olaparib). The plates were 
incubated until the end of the experiment, as determined by the density tests. Pictures were 
taken using a bright field microscope and attached camera at several magnifications and the 
plates were stained with crystal violet as described previously. 
Chapter 2  Material and methods 
 
61 
 
2.7.5 Colony counting and data analysis 
Picture of the plates were taken using a Canon EOS Rebel T3 camera coupled with a 
Colony Doc-It imaging station (UVP). For each plate, 3 pictures were taken. The plate was 
rotated 90 ° between each image acquisition. Colonies were counted using Colony Doc-It 
software (UVP). For each experiment a template was created by selecting a panel of pixel 
colours. The template was designed to recognise colonies and minimise the background. The 
template was then used to count colonies on 3 pictures per plate, for each plate within the 
triplicate of each condition. The average number of colonies was calculated for each plate and 
for each condition. Using this number, the plating efficiency and the surviving fraction were 
calculated. 
2.8 DNA DSB and cell cycle analysis 
This section describes the final protocol used for the serine 139 phosphorylates histone 
H2AX (-H2AX) and 4′, 6-Diamidine-2′-phenylindole (DAPI) staining of nuclei and flow 
cytometry analysis. Several variations of the treatment conditions, timing and reagents were 
used in method development experiments. These will be described in the result section. 
2.8.1 Cell seeding and treatment 
Cells were harvested once 80% confluence was reached and counted. The required 
amount of cells was seeded in fourteen 6 cm or wells of 6 well plates in 5 ml of media 
according to Table 2.22. Six well plates were used for PCOC2 and PCOC3 to scale down the 
amount of cells needed and these were grown with the support of 3T3 feeder cells. Plates 
were treated once at least 40% confluence was reached (Table 2.22). In each experiment, 4 
plates were left untreated with the media renewed. The other conditions were each applied to 
2 plates: vehicle (0.1% DMSO), 0.1 1 and 10 µM Olaparib, 25 µM Etoposide (Sigma-Aldrich). As 
was described in previous experiments using Olaparib, the DMSO level was adjusted to 0.1% in 
each condition.  
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Table 2.22: Cells seeding densities and days until Olaparib treatment for DSB and cell cycle 
analysis 
Cell line Seeding density Days until treatment 
PCOC2 95 000 + 250 000 3T3 feeder cells (6 well plates) 5 
PCOC3 95 000 + 250 000 3T3 feeder cells (6 well plates) 7 
UMSCC47 175 000 2 
UPCISCC90 100 000 3 
UMSCC4 100 000 2 
UMSCC19 150 000 3 
UMSCC74a 800 000 2 
HEKn 55 000 7 
 
2.8.2 Cell collection 
After 24 h and 48 h cells from two untreated plates and one of each treated conditions 
were photographed then harvested. A viability count was performed for each condition and 
200 000 cells transferred to labelled 1.5 ml tubes to be used for nuclei isolation and staining 
(Table 2.23). 
Table 2.23: Content of tubes analysed by flow cytometry 
Conditions Tube name 
untreated PBS 
untreated -H2AX single stain 
untreated DAPI single stain 
untreated Untreated double stain 
vehicle Vehicle double stain 
0.1 µM Olaparib 0.1 µM Olaparib double stain 
1 µM Olaparib 1 µM Olaparib double stain 
10 µM Olaparib 10 µM Olaparib double stain 
25 µM Etoposide 25 µM Etoposide double stain  
 
2.8.3 Nuclei preparation and staining 
The 1.5 ml tubes were centrifuged 5 min at 160×g at RT to pellet the cells. The 
supernatant was discarded and the cells resuspended in 1 ml of cold lysis buffer (Table 2.24). 
Following the lysis buffer addition, the tubes were directly centrifuged 5 min at 3.3 RPM and 4 
°C. The supernatant containing cellular debris was discarded and the nuclei gently 
resuspended in PBS or staining solution before being transferred to round bottom tube (BD 
biosciences, Oxford, UK). The nuclei preparations were incubated for 20 min before flow 
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cytometry analysis. Tubes were kept on ice protected from light the whole time. DAPI was 
purchased as a powder solution and diluted in double distilled water to obtain a main stock 
solution of 1 mg/ml (Sigma-Aldrich). The Anti--H2AX antibody clone JBW301 fluorescein 
isothiocyanate (FITC) conjugate was raised in mice (Merck-Millipore, Watford, UK; catalogue 
16-202A). 
Table 2.24: Composition of 1× cell lysis buffer 
Components Concentration Source 
Sucrose 320 mM 
Sigma-Aldrich 
Tris-HCl pH8 10 mM 
MgCl2 2.5 mM 
Triton X-100 0.5% 
 
2.8.4 Flow cytometry analysis 
Nuclei were analysed using a BD FACSCanto II flow cytometer (BD biosciences). DAPI was 
excited with the 405 nm violet laser and the FITC fluorochrome with the 488 nm blue laser. 
One drop of BD CompBeads Negative Control was added to the single stain tubes to facilitate 
compensation (BD biosciences). UPCISCC90 and PCOC3 cells had a tendency to clump resulting 
in the presence of aggregates in the nuclei preparation. To avoid cytometer blockage, the 
nuclei preparation was passed through 20 µm CellTrics filters (Sysmex, Milton Keynes, UK). The 
data analysis was performed using FlowJo (FlowJo LLC, Ashland, USA). The cell cycle pattern of 
single nuclei was analysed using the Watson pragmatic algorithm. 
2.9 Western blotting 
2.9.1 Materials 
All materials used for the protein extraction, western blotting and their sources are 
outlined in Table 2.25 and Table 2.26. Chemicals used to make any additional solutions were 
purchased from Sigma-Aldrich. 
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Table 2.25: Material used in the protein extraction and their source 
Material Source 
cOmplete mini EDTA-free protease inhibitor cocktail 
Sigma-Aldrich 
Protein standard 2 mg protein/ml 
Sodium orthovanadate (200 mM) 
DNase 1mg/ml 
 
Table 2.26: Western blot material and their sources 
Material Sources 
Mini gel tank 
Thermo Fisher 
Scientific 
PowerEase 90W power supply 
Novex Bolt transfer buffer 20× 
Bolt 4-12% Bis-Tris plus gels 15 wells 
Novex Bolt Mops SDS running buffer 20× 
Novex MagicMark XP Western protein Standard (ladder) 
Novex Nitrocellulose Pre-Cut Blotting Membranes 
Novex Bolt LDS sample buffer 4× 
Novex Bolt Antioxidant 
Novex Bolt sample reducing agent 10× 
p53 antibody (rabbit) cat: 9282 
Cell Signaling, 
Danvers, USA 
Phospho-p53 (Ser15) antibody (rabbit) cat:9284 
PARP1 antibody (rabbit) cat:9542 
β-Actin (13E5) antibody (rabbit) cat: 4970 
Goat polyclonal Secondary Antibody to Rabbit IgG adsorbed cat: ab97080 Abcam, 
Cambridge, UK Amersham ECL prime blocking reagent 
GE Healthcare 
Amersham ECL prime detection reagent 
De-ionised water Pharmacy 
pharmacy  
2.9.2 Sample preparation 
Cells were seeded and treated as described for the flow cytometry experiments (section 
2.8.1). The only variation was the replacement of the Etoposide condition by a 10 Gy irradiated 
sample. Cells were collected 24 h and 48 h after treatment. Cells from each condition were 
harvested and counted. Afterwards, cells were washed by centrifugation in 1 ml of cold TBS. 
The TBS was discarded and the pellet was snap frozen in liquid nitrogen before storage at -80 
°C for at least 24h before protein extraction. TBS solution contained 50 mM TrisHCl and 150 
mM NaCl made up to 1 l in water. 
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2.9.3 Protein extraction 
Samples, reagents and newly labelled tubes were kept on ice throughout the extraction. 
Pellets were thawed on ice in the presence of DNase (1 µl of 1 µg/ml solution per 1×106 cells). 
Homogenisation buffer (50 µl per 1×106 cells) was added to each tube and mixed by vortexing. 
Tubes were incubated on ice for 30 min, vortexing them every 10 min. The samples were 
centrifuged 5 min at 8000×g and 4 °C. The supernatant was transferred to new tubes and the 
volume recorded. Samples were stored at -80 °C. 
2.9.4 Bradford assay 
Samples were thawed on ice. In a 96 wells plate, a stock solution was made for each 
sample using a 1/20 dilution in water. Samples were pipetted in duplicates, 10 µl each, before 
the addition of 190 µl Bradford reagent (diluted 1/2). The plate was incubated 25 min at RT 
protected from light and the absorbance at 595 nm was recorded. Using a standard curve, the 
protein concentration of each sample was calculated. 
2.9.5 Protein sample preparation 
Protein samples for all cells lines were prepared to give a final loading concentration of 
1000 µg/ml. LDS loading buffer and reducing agent were added to the sample to obtain a 1× 
final concentration. Water was then added up to the desired volume. Samples were mixed by 
vortexing before a 10 min incubation at 70 °C. A brief centrifugation was used to remove 
condensation from the caps and the samples kept on ice until the electrophoresis. 
2.9.6 Electrophoresis 
The gel tank was rinsed with tap water than assembled according to the manufacturer’s 
instructions and filled half way with 1× running buffer (made by diluting 50 ml of Mops SDS 
running buffer 20× in 950 ml of water). A pre-cast gel cassette was removed from its packaging 
and rinsed with de-ionised water. The tape covering the slot at the back was peeled off and 
the comb gently removed. The wells and the cassette were rinsed twice with 1× running 
buffer. The cassette was inserted into the electrophoresis tank and clamped into place leaving 
the wells out of the buffer. Twenty microliters of sample were loaded per well whilst one well 
on either side of the samples was used for the ladder (5 µl). The gel was lowered into the 
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buffer and the tank filled up with 1× running buffer. The electrophoresis was run for 35 min at 
200 V (constant) and 100 mA. 
2.9.7 Transfer 
During the electrophoresis, the transfer pads and nitrocellulose membrane were soaked 
in transfer buffer. The transfer buffer composition is detailed in Table 2.27. The filter paper 
was soaked briefly just before use. The anode and cathode were rinsed with transfer buffer 
then 5 ml of transfer buffer placed in each. At the end of the electrophoresis, the plastic 
cassette was separated using a gel knife. One side was removed so that the gel was left 
adhering on the other side and the wells were cut out. One piece of filter paper was placed on 
the gel before it was detached from the remaining cassette side and transferred filter paper 
down onto blotting pads in the cathode. The rest of the transfer sandwich was assembled 
according to Figure 2.2, the membrane was placed on the gel followed by another sheet of 
filter paper and blotting pads. The Anode was place on top to close the module before placing 
it in the electrophoresis tank. The centre of the module was filled with transfer buffer as well 
as the tank just below the electrodes. A 10 V constant voltage and 160 mA were applied for 1 
h. 
 
Table 2.27: Composition of 1× transfer buffer 
Component Volume (ml) 
Bolt transfer buffer (20×) 50 
Bolt antioxidant 1 
Methanol 100 
Water 849 
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Figure 2.2: Western blotting transfer sandwich 
Assembly of transfer pads, filter paper, gel and transfer membrane in the blotting module for 
protein transfer. 
2.9.8 Blocking 
A 5% blocking solution was prepared by dissolving 0.5 g ECL blocking solution in 10 ml 
TBST per membrane. TBST was formulated like TBS, adding 1 ml of Tween20. The membrane 
was washed twice for 5 min in 20 ml water in a shaker set at 1 revolution per second. The 
blocking solution was applied and the membrane incubated 1 h in a shaker at the same speed.  
During the blocking, the primary antibody solutions were prepared in 10 ml of 5% 
blocking solution. Primary antibodies were all used at 1/1000 dilution. After the blocking, the 
membrane was rinsed twice with TBST then washed in TBST on the shaker 15 min followed by 
3 times 5 min. The membrane was incubated overnight in the primary antibody solution in a 
cold room on a shaker. If the primary antibody used was targeting a phosphorylated protein, a 
1/1000 dilution of phosphatase was added.  
The next day the membrane was rinsed twice with TBST and washed on a shaker at 
room temperature 15 min then 3 times 5 min in TBST. The secondary antibody solution was 
prepared using a 1/5000 dilution in 10 ml of 2% blocking solution per membrane. The 
membrane was incubated 1 h in the secondary antibody on the shaker. It was then rinsed 
twice with TBST and washed 15 min then 3 times 5 min in TBST on the shaker. 
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2.9.9 Chemiluminescence 
The ECL Prime chemiluminescence substrate solution was prepared by mixing 2 ml of 
solution A and B equilibrated at RT and keeping the solution in the dark. The membrane was 
drained from excess liquid and placed on a clean plastic sheet. The chemiluminescence 
substrate was spread evenly on the membrane and incubated in the dark for 5 min. The 
solution was drained and another plastic sheet placed on top of the membrane. Image capture 
was performed using a LAS-3000 imager (Fujifilm) using an initial 30 s exposure than 2 min 
increments. The analysis and quantification was performed using Image Studio Lite (LI-COR 
Biotechnology, Cambridge, UK). 
2.9.10 Reprobing 
Following image capture, the membrane was rinsed with TBST then washed twice with 
TBST for 5 min in the shaker. The membranes were left to dry overnight in the dark then 
stored at 4 °c wrapped in plastic film. The steps described above were then followed starting 
after the blocking. 
2.10 RNA sequencing 
RNA sequencing enables the accurate profiling of the entire transcriptome of a cell or 
tissue (Wang et al. 2009). RNA was extracted, quantified and quality tested as described in 
sections 2.2.2, 2.2.4 and 2.2.6. A sequencing library was then prepared using the TruSeq mRNA 
library preparation kit (Illumina, San Diego, USA). The library was sequenced using the Illumina 
2000 sequencing technology. Both the library preparation and the sequencing were carried out 
as a commercial service provided by the Beijing Genomics Institute. Sequencing data was 
returned via an FTP server and was analysed with support from Drs Kevin Ashelford and Peter 
Giles of the Wales Gene Park. Data analysis included quality assessment, analysis of viral gene 
expression and integration, differential gene expression and Gene Ontology (GO) analysis. 
Comparison of expression levels of individual genes were also performed. 
2.10.1 Library preparation and cluster amplification 
A short insert sequencing library was prepared using the TruSeq Stranded mRNA library 
preparation kit (Illumina). This enabled capture of the coding transcriptome with precise 
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strand identification (achieved using oligo-dT bead-based capture of poly-A tailed mRNA). 
Library generation was performed by the Beijing Genomics Institute in accordance with the 
manufacturer’s instructions. mRNA was first captured, then fragmented by the use of high 
temperature and divalent cations. The fragments were reverse transcribed into cDNA and 
adapters ligated to both ends. The library was amplified by PCR using a primer cocktail which 
annealed to the adapters. 
Cluster amplification was performed on glass flow cells coated with two types of 
oligonucleotides, each complimentary to one of the adapters. Following the binding of a cDNA 
strand to an oligonucleotide on the flow cell, a complementary strand was synthesized by a 
polymerase. The double stranded molecules were denatured and the original template washed 
away. The DNA strand then folded over to bind to the other oligonucleotide complimentary to 
its 3’ end. The complimentary strand was synthesized by the polymerase and the double 
strands denatured. This process resulted in two complimentary strands each bound to an 
oligonucleotide. This process was repeated and resulted in the clonal amplification of the 
cDNA strands. This occurred at different places or clusters on the chip for all fragments present 
in the library. 
2.10.2 Sequencing reactions 
Sequencing was performed using a 101 bp paired-end strategy. This approach facilitated 
sequencing of both ends of each fragment to generate high-quality alignable sequence. Paired-
end RNA sequencing enables discovery applications such as detection of gene fusions in cancer 
and characterisation of novel splice isoforms. Sequencing was performed at the Beijing 
Genomics Institute using a HiSeq 2000 (Illumina). Sequencing primers were bound to the end 
of the template and nucleotides, each labelled with a different fluorescent dye, were added. 
Only the nucleotide corresponding to the sequence was incorporated. Following each 
nucleotide addition, the fluorochromes were excited by a light source and the signal recorded. 
Sequencing data were recorded in pairs, each fragment was sequenced both ways. Following 
this, FastQ files were generated and were the basis of subsequent analysis. 
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2.10.3 Sequence data analysis 
2.10.3.1 Quality control 
For each sample, standard indicators of sequence quality were assessed using a 
combination of FastQC and a variety of custom codes. Metrics assessed included (but were not 
limited to) total number of reads, median insert size, per base quality assessment and 
sequence length distribution. 
2.10.3.2 Sequence mapping 
Reads were mapped against human reference sequence hg19 (genome build 19) and 
HPV16 reference sequence NC_001526 using Tophat2 (Center for Computational Biology, 
USA). The number and proportion of mapped reads were determined. 
2.10.3.3 Gene expression 
Raw read counts were calculated for each feature in the UCSC hg19 and HPV16 gene 
model (returning NCBI RefSeq IDs). A read was counted if it had the same orientation 
(strandedness) and at least 20 bases of a read were mapped to the exon. The output 
generated is a text file containing the raw read count for each transcript and transcript feature. 
2.10.3.4 Differential gene expression 
The gene expression text files were read in to R and a matrix created of transcript read 
counts for all samples. Differentially expressed genes were identified using an edgeR analysis 
on normalised count data (Robinson et al. 2010). The edgeR analysis comprises three distinct 
stages. A normalisation, estimate of common dispersion, followed by a test for a difference in 
means between two groups of data. The resulting p-values were corrected for multiple testing 
and false discovery issues using the False Discovery Rate (FDR) method (Benjamini and 
Hochberg 1995). The results of this analysis were represented using heatmaps. Data was log2 
transformed and median centred before hierarchical clustering (using average linkage and 
Pearson's correlation as the similarity metric) to group similar data together and reveal any 
patterns within the dataset. The resulting values were then converted into colours, where 
green is under expressed (compared to median), black is around the median expression and 
red is over expressed. 
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2.10.3.5 Gene ontology over-representation analysis 
Over-representation analysis against GO classifications was applied to investigate 
biological themes within the resultant lists of differentially expressed genes. Analysis was 
performed in R using the Goseq library against GO categories of biological process, molecular 
function and cellular components (Young et al. 2010). The results were sorted by the p-value 
of a hypergeometric based test yielding categories where more genes have been classified 
with that category than would be expected by chance. The resultant data was corrected for 
multiple testing and false discovery using the FDR method.  
2.10.3.6 Human-viral fusion transcript plots (Circos plots) 
Circos plots were used to visually represent the location and abundance of human-viral 
mRNA fusion transcripts. Circos is a software package for visualizing genomic data in a circular 
layout (Krzywinski et al. 2009). A circos links track was generated from the BAM file for each 
sample by filtering the reads in a stepwise fashion. First duplicate reads were removed (using 
picard tools), the reads were filtered to remove good pairs (reads on the same region of the 
same chromosome) using samstools and finally filtering to only include reads where one read 
pair mapped to NC_001526. The generated tracks file was plotted onto a combined hg19 and 
HPV16 ideogram. 
2.10.3.7 Integrative genomics viewer 
Levels of viral gene expression, mismatches with the reference sequence and splicing 
patterns were visualised using the Integrative Genomics Viewer (IGV), available from the Broad 
Institute (Robinson et al. 2011).  
2.10.3.8 Genview 
Histograms showing expression levels for individual genes were produced using the 
“Genview” software designed by Dr Peter Giles of the Wales Gene Park. 
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Chapter 3 - HPV prevalence in non-malignant tonsils 
3.1 Introduction 
The incidence of oropharyngeal cancers has sharply increased over recent years 
(Schache et al. 2016; Mourad et al. 2017). This has been associated with a higher proportion of 
HPV-related diseases originating in the tonsils and base of tongue. However, the natural 
history and pathobiology of HPV infection in the oropharynx is still very poorly described. The 
Cardiff HPV Research Group therefore undertook a study to investigate the biology of HPV in 
non-malignant tonsils. The primary objective was to determine the prevalence of HPV infection 
in non-malignant tonsil tissue in both sexes across all age groups. The secondary objectives 
were to determine the contribution of different routes of transmission, confirm the site of HPV 
infection within the tonsil, establish whether productive infections (i.e. resulting in the 
generation of infectious virus particles) are present in the tonsils, and explore whether HPV 
infection in the tonsil is associated with neoplasia. 
The results were intended to inform cost-benefit analyses of the potential of HPV 
vaccination against specific HPV types and support decisions regarding the appropriate age at 
which to vaccinate. They were also envisaged as having potential to provide baseline data 
against which the effects of HPV vaccination on tonsillar HPV infection could be measured. 
3.1.1 Background 
In a study of oral rinse samples from 5579 people in the USA, HPV DNA was identified in 
10.1% of men and 3.6% of women (Gillison et al. 2012). However, it was important to 
investigate HPV infection in actual tonsil tissue, as the assessment of HPV prevalence in the 
tonsils using oral rinse or exfoliated cell samples is unreliable. Oral rinse samples are very 
poorly representative of tonsillar tissue, as shown by the weak correlation between HPV 
positivity in OPSCC tumour tissue and oral rinse samples taken from the same patients prior to 
surgery (Schwartz et al. 1998; D’Souza et al. 2007). This is likely due to the site of 
infection/neoplasia being located within the reticulated crypts, rather than on the surface 
epithelium of the palatine tonsils (Begum et al. 2005). This emphasises that HPV infection in 
the tonsils can only be adequately assessed using biopsy material including both surface and 
crypt epithelia.  
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Unlike the stratified epithelium in the cervix, the reticulated tonsil crypt epithelium 
might not allow a complete HPV life cycle, associated with the production of virions and the 
slow development of pre-malignant lesions. Few studies have investigated HPV prevalence in 
non-malignant tonsils and whether pre-malignant lesions occur and can be detected is 
currently unknown.  
3.1.2 Study design and samples 
Tonsil tissue was obtained from the National Anonymous Tonsil Archive. This archive 
was originally established to investigate the prevalence of disease-related prion proteins in the 
British population (Clewley et al. 2009). Paired palatine tonsils were obtained, with consent, 
from children and adults of all ages undergoing elective tonsillectomies. During the 2004-2008 
period, over 100000 tonsils pairs were collected from 138 hospitals throughout England and 
Scotland. One tonsil from each pair was stored in formalin then embedded in paraffin. The 
other was stored as fresh tissue at -4 °C then homogenised and kept at -80 °C. Cases were 
selected from the archive, stratified for age, sex and geographical distribution. A total of 4095 
FFPE samples were equally distributed in age groups ranging from 0 to over 50 years old. 
In the initial phase of the study, completed before the start of this PhD, 3377 FFPE non-
malignant tonsil samples had been analysed for the presence of HPV DNA using two PCR-based 
techniques: HPV16 E6 PCR and GP5+/6+ EIA. No HPV was detected in any of those samples. 
This result was unexpected and raised concerns regarding the adequacy of the sampling 
method, and the sensitivity of the assays used. The DNA for the HPV detection assays was 
extracted from thin sections, cut using a microtome, from the centre of the resected tonsils. It 
was possible that this method may have missed small foci of infection. The main assay used in 
the initial phase was the GP5+/6+ EIA, the sensitivity of which has been aligned with clinically 
significant infection in cervical cytology samples (i.e. containing a relatively high viral load). It 
was possible that this was insufficient to detect very low levels of clinically insignificant 
infection. These concerns were addressed in the second phase of the project, which was 
conducted as part of this PhD. 
In Phase 2, a second panel of samples was selected from whole homogenised tonsils, 
and HPV tested for both high and low risk HPV types using 3 different techniques, including the 
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most sensitive commercially available assay. The results of this second part of the study are 
presented in this chapter and discussed in the context of the overall study.  
3.1.3 Aim and hypothesis 
The aim was to determine the prevalence of HPV infection in non-malignant tonsil tissue 
from men likely to harbour infection. The hypothesis tested was that low-level high risk HPV 
infection occurs and can be detected in non-malignant tonsils. 
3.2 Materials and methods 
3.2.1 Clinical samples 
The purpose of the second part of the study was to ensure that the presence of small 
foci of HPV infection was not missed in FFPE samples. To account for this possibility, the 
analysis was centred on a subset of 524 tonsil homogenates selected from the original 4095 
cases (fixed and homogenised tonsils were available for most patients within the tonsil 
archive). Two age groups were chosen to represent patients most likely to harbour HPV 
infection: men aged 25-34 years (n=335) and 44 years (n=189). Based on oral rinse samples, 
HPV prevalence is higher in these groups (Gillison et al. 2012).  
3.2.2 HPV testing 
DNA was extracted from the homogenised tonsil samples using a phenol-chloroform 
based method. The suitability of the extracted DNA for PCR-based analysis was assessed by 
amplification of a 209 bp fragment of the human β-globin gene (this was longer than the 
amplicons generated by the HPV tests). The presence of HPV DNA was assessed using three 
different HPV assays, each with distinct performance characteristics (listed below). Two of the 
assays (HPV16 E6 PCR and GP5+/6+ PCR-EIA) had previously been used on the original set of 
samples.  
HPV16 E6 PCR: This assay amplified the E6 region which is maintained in both 
productive and oncogenic infections. Only HPV16, the most common HPV type causing 
squamous cell carcinoma in the tonsil was targeted. HPV16 E6 PCR was rapid, cost effective 
and enabled a first evaluation of the prevalence of the most common HPV type in OPSCC. The 
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other two assays depend on amplification of the HPV L1 region, which can potentially be lost 
as a result of viral integration, resulting in false negative data. HPV16 E6 PCR was used as an 
end-point assay. A result was called positive if a 161 bp band was observed on the gel as well 
as in the CasKi positive control, in conjunction with the absence of a band in the negative 
control. 
GP5+/6+ EIA: A widely applied “in-house” method depending on amplification of the 
HPV L1 region and two separate EIA using a cocktail of probes detecting 14 high risk types and 
6 low risk types. This allowed comparison of the data with previously generated data, and 
could potentially show whether positive results were due to changes to the sampling regime or 
greater assay sensitivity. 
SPF10-DEIA: A commercially available assay that amplifies a small region (65 bp) of the 
HPV L1 gene. It is regarded as the most sensitive assay available and has been used in several 
large epidemiological studies (Tjalma et al. 2013). It also enabled the detection and typing of a 
wider range of HPV types (40 types).  
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3.3 Results 
3.3.1 HPV typing 
DNA extraction was performed on 524 cases. The β-globin fragment was successfully 
amplified in 511/524 cases (97.5%). Positivity was determined by the visual presence of a 209 
bp amplicon following gel electrophoresis (Figure 3.1). Only β-globin positive samples were 
taken into account in further assays. HPV DNA was not identified in any samples using any of 
the assays (Table 3.1). All positive and negative controls gave the expected results. Positivity of 
samples was assessed by gel electrophoresis for HPV16 E6 PCR (Figure 3.2) and absorbance 
readings for GP5+/6+ and SPF10-DEIA as illustrated for SPF10-DEIA in Figure 3.3. 
 
Table 3.1: Sample adequacy (β-globin) and HPV testing stratified by age 
Age Group 
(years) 
 
(yrs) 
Samples 
(n) 
β-globin 
HPV detection Assay 
HPV16 E6 GP5+/6+ SPF10-DEIA 
24-29 167 162 0 0 0 
30-34 168 162 0 0 0 
45-49 114 113 0 0 0 
50+ 75 74 0 0 0 
Total 524 511 0 0 0 
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Figure 3.1: Example of β-globin PCR gel image 
DNA extracted from all tonsil homogenates samples and blanks was assessed for suitability of 
PCR-based assays with a β-globin PCR. Extraction blanks (Extr blk) were included every 24 
samples. PCR positive (CasKi) and negative (master mix only) controls were included in each 
PCR round. These confirmed the lack of technical issues and contamination during the PCR 
process. Samples for which a band of 209 bp was visible by gel electrophoresis were taken into 
account for HPV typing. 
 
 
 
Figure 3.2: Example of E6 PCR gel image 
A previously amplified fragment of the HPV16-positive CasKi cell line was used as a size marker 
(161 bp) next to the DNA ladder. In each PCR rounds internal PCR positive (CasKi) and negative 
(master mix only) controls confirmed the absence of technical issues and contamination. No 
band of 161 bp was visible in any of the samples. All the samples were HPV16 negative. 
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Figure 3.3: Example of SPF10-DEIA data: absorbance at 450 nm 
Results from each plate were validated by the controls according to the manufacturer's 
protocol and only interpreted if all validation steps were passed. HPV-positive samples were 
highlighted in green and HPV-negative in red. 
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3.4 Discussion 
No high risk or low risk HPV DNA was detected in any of the 511 non-malignant tonsil 
homogenates samples from men in the age groups most likely to harbour HPV infection. 
Amplification of the housekeeping gene β-globin in 97.5% of samples and inclusion of PCR 
controls showed that negative results were not due to inhibition during the PCR or low-quality 
DNA. This data appeared to validate and support the results of phase one of the study. 
Together, these findings suggested that HPV infection in non-malignant tonsil is a very rare 
event. The greatest possible population prevalence for HPV, consistent with the absence of 
HPV in the 3377 English and Scottish males and females included in the study, is 0.089% (95% 
CI 0–0.089%).  
During the first part of the study, no HPV DNA was detected in 3377 FFPE samples. The 
material from which DNA was extracted comprised two 10 µM cuts through the middle of the 
tonsil (this method was chosen as it potentially would allow subsequent histopathological 
investigations in positive samples). A possible explanation for the absence of HPV was that 
small foci of infection in the tonsil could have been missed. The tonsil homogenates were used 
to address this issue as they contained the whole tonsil. The sample panel was modified to 
concentrate on groups with the highest susceptibility to HPV infection: men aged 25-34 and 
over 44 years old. These groups were designed based on published HPV prevalence data. A 
study using oral rinse samples reported an overall higher prevalence in men and a bimodal 
distribution with regard to age. The prevalence peaked in the 30-34 and 60-64 age groups 
(Gillison et al. 2012). In England in 2010 (year of study design), tonsil SCC were most common 
in men aged 45-75 years old (Office for National Statistics 2015). 
The possible lack of detection sensitivity was also addressed. The sensitive nature of 
GP5+/6+ EIA and HPV16 E6 PCR had previously been assessed in the laboratory through the 
2011 LabNet WHO study (Eklund et al. 2012). Its sensitivity was determined to be the 
equivalent of 500 HPV genome copies per PCR. The detection sensitivity of the HPV16 E6 PCR 
was assessed using dilutions of CasKi cells known to contain around 600 copies of HPV 
genome. It was estimated to be 500 genome copies per PCR. These two tests provided a 
robust detection of HPV16, most commonly associated with tonsil SCC, and detection of 
another 13 high risk and 6 low risk types. To increase the detection sensitivity, a third test was 
selected to use on the tonsil homogenates samples. SPF10-DEIA enabled the detection of 2 
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HPV genome copies per PCR and a wider range of HPV types. The combination of whole 
tonsils, high sensitivity assays and samples from men most likely to harbour HPV16 infection 
strengthened the results.  
Variable HPV prevalence rates have previously been reported in tonsils. Several small 
studies focused on paediatric populations in which tonsil samples are more readily available. A 
study conducted in Finland on 106 samples from children aged 2-14 years old with tonsillar or 
adenoid hyperplasia found a prevalence of 8.5% not correlated with sex. HPV16 accounted for 
66.7% of these (Mammas et al. 2006). Other studies in Brazil (n=100) and the USA (n=50) did 
not report any cases of high risk HPV infection, the only positive case identified was an HPV11 
infection in the USA study (Moreira et al. 2006; Sisk et al. 2006). Small sample size and 
variation in detection methods, as well as geographical differences, could explain the range of 
prevalence detected. The origin of HPV infection in children may differ from adults, vertical 
and horizontal HPV transmission between mother and child have been described but might not 
be the single mode of HPV acquisition in children (Castellsagué et al. 2009). The consequences 
of HPV infection in paediatric populations in relation to the rise of tonsil SCC or the HPV 
prevalence in adults are currently unknown.  
Only a small number of studies have reported HPV prevalence from adult tonsil samples. 
A 6.3% HPV16 prevalence was observed across 206 samples from people ranging from 1.5-72 
years old in Finland. The highest incidence occurred in the 1.5-6 and 17-25 year-old groups 
(Chen et al. 2005). However, others reported findings similar of those presented in this 
chapter, i.e. very rare occurrence of HPV infection in non-malignant tonsils. No HPV16 or 18 
were detected in a retrospective study of 212 FFPE samples from patients aged 21 years or 
older in the USA (Ernster et al. 2009). More recently, the results of the SPLIT study were 
published. In this study, samples were obtained from 200 patients aged 18 or over undergoing 
tonsillectomies for benign disease. Cells were collected from deep brushing of the tonsil and 
used for DNA extraction and liquid based cytology for each sample. Two women were HPV16-
positive, one had no cytological lesion and the other could not be interpreted. Both of these 
studies are in concordance with the results presented in this chapter, indicating that HPV 
infections are a rare occurrence in non-malignant tonsils in the adult population (Franceschi et 
al. 2015).  
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HPV prevalence at genital sites varies between countries (De Vuyst et al. 2009; Hariri et 
al. 2011). Similar variations could occur in the tonsils, therefore, results from one population 
might not be relatable to another. The estimated fraction of OPSCC attributed to HPV varies 
across the world and within Europe (Castellsagué et al. 2016). Samples used in this study were 
collected between 2004 and 2008 in England and Scotland. During this period the age-
standardised rate of tonsillar squamous cell carcinoma per 100000 people in England 
increased from 2.6 to 3.4 according to the Cancer registration statistics (Office for National 
Statistics 2015). The results are likely to be a good representation of the British population but 
might not apply to other geographical areas.  
As opposed to the low prevalence reported in tonsils, HPV is more frequently detected 
in the oral cavity of cancer-free subjects through oral rinse or gargle samples (Kreimer et al. 
2010; Gillison et al. 2012). Epithelial cells contained in these samples originate from the oral 
cavity. Oral HPV infection is common at diagnosis in patients with OPSCC but not always 
present (Rettig et al. 2015). 
3.4.1 Strengths and Weaknesses 
The power of this study lies in the high number of samples tested: 3377 in phase one, 
and the additional 511 presented in this chapter. So far, this is the largest sample cohort 
published (Palmer et al. 2014), in Appendix 3. The results are also strengthened by the use of 
multiple assays targeting several regions of the HPV genome, and by the high sensitivity of the 
SPF10 PCR DEIA. The use of whole tonsils presented some limitations even though it ensured 
that any potentially HPV-infected cells in the tonsil were taken into account. The high amount 
of lymphoid cells mixed with the squamous epithelial cells could render the detection of small 
foci of HPV infection harder.  
3.4.2 Conclusion 
The findings described in this chapter highlight the differences between the natural 
history of HPV-driven cervical and tonsillar SCC. In the cervix, high risk HPV infections are 
common and easily detectable, with a small proportion resulting in SCC. Furthermore, virus-
induced neoplasias are well described and can be observed for years before leading to 
neoplasia in some cases. In the tonsils, HPV infection appears to be a very rare event despite 
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the possible exposure from virus present in the oral cavity. This suggests that when HPV does 
infect tonsil tissue, this could often result in tumour development.  
These data have important implications for the prevention of OPSCC. Screening for and 
treatment of HPV-associated pre-cancers has been highly effective in reducing the incidence of 
cervical SCC. Screening for OPSCC or its precursors has been considered (Gillison et al. 2013) 
However, testing requires the identification of a treatable HPV-associated premalignant 
neoplasia, and this was not observed in the current study. Therefore, it appears that 
prophylactic vaccination, potentially including males, may be the most promising option for 
prevention of OPSCC. 
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Chapter 4 - Primary culture of oropharyngeal cells 
4.1 Introduction 
The study of head and neck cancer biology, and of HPV-positive disease in particular, is 
hampered by the lack of in vitro models. Relatively few HPV-positive head and neck cancer cell 
lines have been derived and described in the published literature. Five were described in 
publications in 2012, however only one of these originated from the oropharynx (Steenbergen 
et al. 1995; Balló et al. 1999; Lansford et al. 1999; Ferris et al. 2005; Tang et al. 2012). These 
lines have characteristics commonly found in HPV-positive tumours, such as wild-type p53 
gene and p16 positivity, indicating that the disease could be HPV-driven (although one line, 
93VU147T, differs from the others with described genetic alterations and mutated p53) 
(Steenbergen 1995). All 5 lines originate from patients who were current or ex-smokers at the 
time of diagnosis. Smoking has been identified as an adverse prognostic factor in both HPV-
positive and HPV-negative tumours (Maxwell et al. 2010). The increased sensitivity to 
treatment and survival often observed in HPV-positive patients tends to be seen in non-
smokers, whereas survival of HPV-positive smokers is reduced. Another group which 
encompasses HPV-positive smokers with positive lymph nodes and HPV-negative non-smokers 
with low disease stage has been described (Ang et al. 2010). It shows intermediate survival 
between “pure” HPV-positive and negative cases. Hence, the available cell lines may not 
provide the best possible representation of typical HPV-positive non-smoking patients with 
OPSCC. New cell lines, from typical HPV-positive patients, are needed to increase the 
understanding of treatment response of both HPV-positive smokers and non-smokers. 
The aims of the work described in this chapter were to derive novel cell lines from 
oropharyngeal tumour biopsies, and to validate and characterise the successfully grown lines 
as models for HPV-positive oropharyngeal cancer. Lines were phenotypically described, 
including their morphology and growth characteristics. The cell lines were validated by 
confirming the type of cell cultured and by comparing the STR profiles of cell lines with the 
original biopsies. 
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4.2 Terminology 
Biopsies were processed using an explant method. Each biopsy was cut into small tissue 
pieces and placed in culture. The term explant was only applied to biopsy pieces producing 
new cell growth. Throughout this chapter, the term primary culture designates developed cells 
up until the first passage. Once they have been passaged multiple times, they are called short-
term cultures. Once cells sustained growth to a higher passage, and more importantly a 
greater number of population doublings than what would be expected from “normal” tonsil 
epithelium cells, a cell line can be deemed immortal. Such cells are likely to have overcome 
telomere mediated senescence and programmed cell death. This suggests that they are likely 
to derive from cancer cells present in the biopsy.  
Because the study was named Primary Culture of Oropharyngeal Cells (PCOC), biopsies 
collected, and any cell line derived from a biopsy, were called PCOC#, with # corresponding to 
the chronological order of biopsy collection.  
4.3 Protocol development and sample collection 
4.3.1 Protocol development 
The explant protocol had previously been used by other members of the group for the 
culture of gynaecological biopsies. It was first followed without modifications (Stanley 2002). 
However, in initial experiments, culture plates containing pieces of the biopsy were found to 
contain yeast on day 2 and discarded. Yeast infections (e.g. Candida albicans), can be common 
in the oral cavity and oropharynx. To address this, an antifungal agent (amphotericin B), was 
added to the initial washing step. Amphotericin B was also added in the media of the PCOC2 
early cultures. However, the antifungal had an adverse effect on the 3T3 feeder cells. The 
length of time they remained attached to the plates was shortened. Hence, amphotericin B 
treatment was stopped after 6 days. Thereafter amphotericin B was only used in the washing 
step and as a short treatment if yeast contamination occurred.  
4.3.2 Study samples 
The PCOC study was sponsored by Cardiff University and approved by the Cardiff and 
Vale University Health Board R&D Office. Ethical approval was obtained from the Research 
Chapter 4  Primary culture of oropharyngeal cells 
 
85 
 
Ethics Committee for Wales and the study was adopted into the NISCHR portfolio. Patients 
with a suspected oropharyngeal primary tumour were potentially eligible for inclusion (see 
study protocol in Appendix 1 for full inclusion criteria). Patients undergoing treatment at the 
Cardiff and Vale NHS Trust were identified by their head and neck surgical consultants or 
consultant oncologists in the course of their clinical practice. Biopsies could be obtained at two 
points in the patient pathway. This was important as patients are treated differently according 
to the size and stage of the tumour. Biopsies could be collected during panendoscopy (a biopsy 
taken under general anaesthetic for histopathological analysis) or after surgical resection 
(surplus material was collected from the pathologist). In both cases, biopsies were stored in 
transport media to minimise tissue degradation. Twelve patients were consented between 27 
Feb 2013 and 12 May 2014, and a total of 13 biopsies were collected (for the 4th patient 
recruited into the study, PCOC4, samples were received on two occasions: at the time of the 
diagnostic biopsy and during tumour resection, both were recorded as PCOC4). PCOC9 was 
obtained from a 73-year-old man who was later diagnosed with a lymphoma. As a result, 
PCOC9 was not included in further descriptions of study samples. 
Approximately one-third of the patients were women, and the mean age was 52.66 
years. Biopsies were taken from the tongue base (4) or the tonsil (6) prior to treatment. 
Characteristics of each biopsy regarding sex, age, smoking status, previous tumour history, site 
of biopsy, TNM stage, p16 status, treatment and outcome are described in Table 4.1. 
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Table 4.1: Description of the PCOC study sample 
Study 
number 
Sex 
(M/F) 
Age 
(years) 
Smoking 
status* 
Site TNM Stage p16 IHC Treatment** Recurrence 
PCOC1 M 63 
Current, 
30 pack/yrs 
Tongue 
base 
T4aN2bM0 
Not 
available 
Right neck dissection + definitive 
chemoRT to tongue base 
None 
2016 
PCOC2 M 52 Never smoker Left tonsil T4aN2bM0 Positive ChemoRT 
None 
2016 
PCOC3 M 44 
Ex-smoker, 
<10pack/yr 
Right tonsil T1N2aM0 Positive 
Transoral laser resection, 
oropharynx and neck dissection, 
post-op RT, 
None 
2106 
PCOC4 M 50 Never smoker Left tonsil T2N2bM0 Positive Left neck dissection+post-op RT 
None 
2016 
PCOC5 F 62 Not available 
Tongue 
base 
T2N2bM0 Positive 
Neck dissection +definitive 
chemoRT 
None 
2016 
PCOC6 F 59 
Ex-smoker, 
15pack/yr 
Right tonsil T2N2bM0 Positive 
Neck dissection + definitive 
chemoRT 
None 
2016 
PCOC7 F 56 
Ex-smoker, 
<10pack/yr 
Tongue 
base 
T2N2bM0 Positive 
Neck dissection + definitive 
chemoRT 
None 
2016 
PCOC8 M 71 Never smoker Right tonsil T2N2bM0 Positive ChemoRT 
None 
2016 
PCOC10 M 41 
Ex-smoker, 
20pack/yr 
Tongue 
base 
T2N2bM0 Positive ChemoRT 
None 
2016 
PCOC11 M 50 Never smoker Right tonsil T3N2bM0 Positive 
Neck dissection + definitive 
chemoRT 
None 
2016 
PCOC12 F 53 
Current 
<10pack/yr 
Right tonsil T4aN2bM0 Positive ChemoRT 
None 
2016 
* Pack-years refers to the number of cigarette packs smoked per day multiplied by the number of years the person has smoked. 
** Radiotherapy (RT), post-operative (post-op). 
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The biopsies varied in size and were composed of both tumour and parts of the 
surrounding tissue. This resulted in the growth of a variety of cells, this was apparent following 
48 h of culture when the media was replaced. During the first 2-4 days, some unidentified non-
adherent cells and red blood cells were observed in vascularised biopsies. Both were 
subsequently discarded with media changes. Explants were visible after 2-7 days of culture. 
Biopsy pieces that did not produce outgrowths 7 days after plating were regarded as 
unsuccessful. Some tissue fragments did not attach to the plates, additionally low adhesion of 
some explants resulted in loss/detachment following the first media change at day 2. 
Afterwards, all explants remained attached. Of the 13 patient biopsies, 8 produced visible new 
cell growth after 7 or fewer days (Table 4.2). Two of these, PCOC2 and PCOC3, were 
successfully grown over multiple passages. 
Extended cell growth from explants of the other biopsies was unsuccessful for several 
reasons. PCOC1 cultures were discarded after two days due to fungal contamination. A yeast 
infection in PCOC6 developed amphotericin B resistance after 3 passages, resulting in the loss 
of cultures. A widespread bacterial contamination occurred when several biopsies (PCOC7-11) 
were in early stages of culture. The contamination spread to all biopsies and cell lines present 
in the incubator. The bacterial spread seemed independent of the operator and reagents used. 
After initial antibiotic treatment with gentamicin failed, the bacteria was typed to tailor the 
treatment to its sensitivity. It was identified as a Stenotrophomonas using MALDI-TOF. 
Stenotrophomonas are ubiquitous environmental bacteria that are naturally resistant to many 
broad-spectrum antibiotics, but which are often sensitive to co-trimoxazole. Remaining 
cultures were treated with co-trimoxazole. The concentration required to kill the bacteria was 
toxic for the cells and the cultures of PCOC7 passage (p) 1, PCOC8 p5, PCOC9 p1, PCOC10 p1 
and PCOC11 p1 were lost. The origin of the contamination was not identified and resulted in 
the closure of cell culture for a month. Explants from the PCOC12 biopsy produced cell 
outgrowths which were successfully passaged twice. Cell growth slowed down after the 
second passage, and a change of morphology was observed (cells became bigger and 
heterogeneous in shape). Cultures were passaged a third time, but this was followed by 
senescence in all cells (Table 4.2). 
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Table 4.2: Growth status of PCOC biopsies 
Study number Explant growth Outcome 
PCOC1 Yes 
Discarded  
Yeast contamination 
PCOC2 Yes Established line 
PCOC3 Yes Established line 
PCOC4 No No explants growth 
PCOC5 No No explants growth 
PCOC6 Yes 
Discarded  
Resistant yeast contamination 
PCOC7 Yes 
Discarded  
Stenotrophomonas contamination 
PCOC8 Yes 
Discarded (passage 5)  
Stenotrophomonas contamination 
PCOC9 Yes 
Discarded (passage 1)  
Stenotrophomonas contamination 
PCOC10 Yes 
Discarded (no passage) 
Stenotrophomonas contamination 
PCOC11 Yes 
Discarded (no passage) 
Stenotrophomonas contamination 
PCOC12 Yes Senescence (passage 3) 
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4.4 Growth and characterisation of the PCOC2 and PCOC3 cell lines 
4.4.1 Histology 
Sections of the original tumours from which the PCOC2 and PCOC3 cell lines were 
derived, were obtained to assess cellular morphology, and the presence of specific 
proliferation, cell cycle and differentiation markers. These were then stained with 
Haematoxylin and Eosin (HE) to observe general histology, Ki67 as a proliferation marker and 
p16 as a marker of HPV infection. Staining was performed by UCL-Advanced Diagnostics and 
University Hospital of Wales pathology department, the pathological description was kindly 
provided by Dr Adam Christian (UHW pathologist). 
The PCOC2 tumour was initially described as a moderately differentiated squamous cell 
carcinoma. A mix of severe and lower grade dysplasia was observed (Figure 4.1 A and B). The 
severely dysplastic epithelia was characterised by the presence of mitotic figures in all layers, 
in addition to pleomorphic cells and a loss of maturation (Figure 4.1 C). Consistent with the 
features observed with HE staining, Ki67 staining was present in all layers of the severely 
dysplastic epithelia. p16 staining was strong and diffuse confirming likely HPV infection in the 
affected area (Figure 4.1 D and E). 
PCOC3 was described as a moderately differentiated squamous cell carcinoma with a 
complex papillary architecture. A section through the resected tonsil showed a complex 
papillary architecture with evident severe dysplasia. This was illustrated by the presence of 
pleomorphic nuclei (i.e. nuclei showed diverse size and shapes) and mitotic figures in all layers 
of the epithelia as well as a loss of maturation in the top layers (Figure 4.2 A and C). A pocket 
of cells was visible invading into lymphoid tissue (Figure 4.2 B). The presence of neoplasia and 
disordered architecture was confirmed by the presence of strong Ki67 staining in all layers of 
the epithelia both in the dysplastic and invasive tissue (Figure 4.2 D). Strong and diffuse p16 
staining showed that both the dysplastic and tumoral area were likely to be infected with HPV 
(Figure 4.2 E). 
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Figure 4.1: PCOC2 HE, Ki67 and p16 IHC staining 
A: Low magnification view of a PCOC2 FFPE block stained with HE. 
B: Higher magnification image of the zone circled in black in figure A: the epithelia shows signs 
of severe dysplasia. 
C: Higher magnification image of severely dysplasic epithelia: mitotic figures in all layers, no 
maturation , disorganised tissue. 
D: Ki67 staining of dysplasic epithelia showing proliferation throughout the epithelia. 
E: p16 staining: Cells strongly stained for p16.  
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Figure 4.2: PCOC3 HE, Ki67 and p16 IHC staining 
A: Low magnification view of a PCOC3 FFPE block stained with HE. 
B: Higher magnification image of the zone circled in black in figure A: signs of invasion of 
epithelial cells in the underlying lymphocytes. 
C: Higher magnification of dysplasic epithelia: mitotic figures in all layers, no maturation, 
disorganised tissue. 
D: Ki67 staining: proliferation throughout the epithelia. 
E: p16 staining: Cells strongly stained for p16. 
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4.4.2 Early stages of culture 
Cells grown from PCOC2 and PCOC3 explants were successfully cultured for around 20 
passages (24 and 19 respectively). Growth pattern, cell and colony morphology were assessed 
in early passages of cultures. The phenotypic characterisation provided informations related to 
the cell types present and the health of cells derived from explants. Cells were also checked for 
signs of apoptosis and senescence (e.g. blebbing or enlargement).  
Tissue from the tumours of both patients was subjected to the explant culture 
procedure. In both cases, non-adherent cells were present at day 2 but were easily removed 
with a washing step prior to the media change. Cell outgrowths were visible from explanted 
tissue at day 4 and 6 respectively. Cells grew around the explanted tissue resulting in a “fried 
egg” colony shape, with no space visible between the cells (Figure 4.3). Colonies expanded as a 
result of the division of the peripheral cells, displacing the lowly adherent 3T3 feeder cells 
layer (Figure 4.4). The growth rate differed between PCOC2 and 3, with PCOC2 cells growing 
faster from the beginning. As a result, PCOC3 cultures developed over a longer period.   
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Figure 4.3: Morphology of PCOC2 and PCOC3 explants 
A: PCOC2 explant growth. Explants (blue arrow) grew in a roughly circular pattern around the 
parental biopsy piece (circled in orange) (100X magnification). 
B: PCOC2 cells of polygonal shape ressembling keratinocytes growing tightly (200X 
magnification). 
C: PCOC3 cells, growing from the parental biopsy piece as polygonal cells forming tight 
colonies (100X magnification). 
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After 7 days, the cell outgrowths from PCOC2 had reached sufficient size to be passaged. 
Cells were trypsinised and plated as single cells, this provided growth space to the cells 
previously located in the centre closest to the tissue pieces (and hence avoiding cell cycle exit 
into G0). As the optimum length of trypsinisation was unknown, 5 minutes increments were 
used, removing the trypsin and collecting cells each time. New cells were polygonal, similar to 
keratinocytes, and grew as tight round colonies. Thereafter cells were split when 80% 
confluence was reached. In early stages of culture, PCOC2 plates were contaminated with 
fibroblasts colonies. Fibroblasts originated from the connective tissue surrounding the tonsil 
and were easily distinguished from the keratinocytes by their elongated shape. The fibroblast 
growth was reduced by maintaining a high density of 3T3 feeder cells. Differential 
trypsinisation was also used to remove the fibroblasts. Due to their low adhesion to the plate, 
fibroblasts detached sooner than keratinocytes following a short trypsinisation 1-2 min (Figure 
4.5). 
A yeast contamination was detected in PCOC3 plates within the first week. Cultures 
were treated with amphotericin B and the contamination cleared after 2 weeks. During the 15 
days of treatment with amphotericin B, cells outgrowth slowly developed from the biopsy 
pieces. Amphotericin b reduced the time 3T3 feeder cells remained attached, and they were 
replaced every 2 days to maintain the cover. Cells were first passaged and re-plated as single 
cells after 13 days as part of a washing step to eliminate the contamination. PCOC3 cells were 
noticeably bigger than PCOC2 cells while also having polygonal shapes and growing tightly 
(Figure 4.4).  
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Figure 4.4: Morphology of PCOC2 and PCOC3 cells in culture and 3T3 feeder cells 
displacement 
A: Small PCOC2 colony, formed of around 9 dividing cells. Polygonal cells grow without gaps 
between them hence forming tight colonies roughly circular in shape (200 x magnification).  
B: PCOC3 colony, formed of two parts. The outer cells are polygonal and growing as a tight 
monolayer, the centre is composed of a multilayer of cells. Cells are rounding up at the top and 
detaching from the colony (200x magnification). 
C: 3T3 feeder cells covering the plates being displaced by the growing colonies. As a result, 3T3 
feeder cells are compacted between the growing PCOC colonies (blue arrows) (50x 
magnification).  
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Figure 4.5: Human fibroblast contamination on PCOC2 p1 culture 
A: 3T3 feeder cells which cover the plate (pointed by blue arrows) did not have a characteristic 
fibroblast morphology and did not divide in culture due to the 60 Gy radiation they received. A 
human fibroblast colony (pointed by a green arrow) is composed of dividing cells with a 
characteristic elongated shape.  
B: Difference in adhesion to the dish between keratinocytes and fibroblasts was used to 
remove both 3T3 feeder cells and human fibroblasts with a short TE treatment. The image was 
taken immediately after a short TE treatment. 
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4.4.3 Heterogeneous colony morphology 
Two types of colonies were observed in both PCOC2 and PCOC3. Some cells, deemed 
colony type 1, grew as a flat monolayer. These colonies had a tendency to be faster growing 
and cover larger surfaces. In the second type of colony (type 2), cells grew upwards, forming 
multi-layers. This resembled the growth pattern of a stratified epithelium, with cells detaching 
once they reached the top layer. These colonies were slower growing and occupied smaller 
surfaces. The proportion of the two types of colonies differed in PCOC2 and PCOC3 and varied 
over time. 
At p1, the PCOC2 culture was composed equally of flat growing type 1 colonies and 
differentiating type 2. The proportion of type 1 colonies increased over time in PCOC2 cultures, 
and by p6 only flat growing colonies were present (Figure 4.6 A and B). PCOC3 cells grew as 
differentiating type 2 colonies only at p1. This resulted in slow colony development not 
reaching 80% confluence. Consequently, the cell line could not be frozen at early passages 
(due to a lack of cells). The colony morphology changed over time. By p3 all colonies were still 
differentiating but grew larger. These colonies were intermediate between type 1 and 2, 
composed of cells growing upward in the centre and laterally at the edges. By p7 most colonies 
grew flat and at p14 differentiating colonies were no longer present (Figure 4.6 C, D and E). 
The differences in colony morphology and growth speed greatly influenced the time needed to 
develop the lines: PCOC2 reached p7 after 2 ½ months, while PCOC3 took 5 months.
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Figure 4.6: Variations in PCOC2 and PCOC3 colony morphology 
A: PCOC2 p1. Two colony morphologies are present: 50% of flat colonies (circled in orange) and 50% of 
colonies growing as a multilayer (circled in green) (50x magnification).  
B: PCOC2 p7. The amount of multilayered colonies decreased over time, by p7 only flat colonies were 
present (100x magnification).  
C: PCOC3 p1. Only colonies growing as multilayers, similar to cells differentiating, were present at p1 
(50x magnification).  
D: PCOC3 p5. Over time, PCOC3 colony morphology changed as more cells grew as a monolayer 
resulting in colonies with a mix of cells growing laterally on the edges and upwards in the centre (an 
example is circled in blue) (50x magnification).  
E: PCOC3 p7. Colonies composed of monolayers were faster growing than differentiating cells, by p7 all 
cells grew as monolayers, forming tight colonies.  
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4.4.4 Established cultures and amplification 
To judge whether PCOC2 and PCOC3 were likely to be immortal lines, population 
doublings (PD) were estimated and compared with the number of PD expected from non-
immortal cells. Untransformed neonatal foreskin keratinocytes (HEKn) cells, available from Life 
Technologies, can be grown in culture for approximately 30 PD before senescing. Commercially 
available human tonsil epithelial cells (HTEpiC) can be cultured for approximately 15 PD 
(ScienCell, Carslbad, USA; ref: www.sciencellonline.com/human-tonsil-epithelial-cells.html).  
Based on culture records, PCOC2 plating efficiency was estimated to be 10.7%, and 30 
PD were achieved by p9. Due to the growth pattern of PCOC3 accurate cell counts were not 
available for the first few passages and the number of PD can only be roughly estimated. With 
this caveat, and based on the calculated plating efficiency of 12.5%, 3 population doublings per 
passage were estimated. Counting from p3, 30 population doublings were reached by p13.  
Stocks of PCOC2 and PCOC3 cell lines were expanded using the earliest available frozen 
aliquots to obtain a large number of cryopreserved samples of the same passage. At least 50 
aliquots of PCOC2 p7 and PCOC3 p14 were frozen. The stored PCOC2 and PCOC3 cultures were 
likely to contain a heterogeneous population as they were expanded from early passage 
samples. In order to minimise the risk of experimental artefacts caused by selection of sub-
populations in long term culture, these heterogeneous populations of p7 and 14 were used in 
all further experiments. An alternative approach would have been to use single cell cloning to 
isolate different clonal populations. However, heterogeneous cell populations were judged to 
be more representative of the original tumours. This was a dominant concern as the intended 
use of these cell lines was to study treatment response.  
4.5 Model validation 
It was important that the newly derived cell lines should be validated as appropriate 
models of HPV-positive OPSCC. This included confirmation of their genetic origin from the 
parent biopsy and that the cells were keratinocytes. The absence of mycoplasma 
contamination was also confirmed. 
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4.5.1 The PCOC cell lines were derived from the original tumour biopsies 
STR profiling is based on the amplification of a series of polymorphic STR loci. The numbers of 
repeats of each allele at each site creates a unique profile for each individual (Nakamura et al. 
1987). To allow future identification of the PCOC cell lines, and to confirm that they were 
derived from the original tumour biopsies, the STR profiles of the original biopsies were 
compared with those of the derived cells lines (Figure 4.7 and Figure 4.8). This confirmed that 
PCOC2 and PCOC3 cells were derived from the associated biopsy. It also demonstrated that 
PCOC2 and 3 cell lines differed from each other, and from established HPV-positive cell lines 
used in the laboratory (e.g. Hela, Siha, and Caski cells). Small variations were observed 
between the profiles obtained from the main biopsy and the cell lines. For example, the PCOC2 
cell line profile appeared to have lost the 4 repeat alleles of THO1. These variations are 
consistent with loss of heterozygosity (such variations are common in immortal cell lines). 
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Figure 4.7: STR profile of PCOC2 biopsy and derived cell line 
Short tandem repeats were amplified at 16 loci. Alleles are indicated in the grey bars 
immediately above the traces, and the number of repeats by the grey vertical lines. The biopsy 
profile is shown in the upper panel of each pair of images, and is outlined in blue. The cell line 
profile is shown in the lower panel of each pair.  
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Figure 4.8: STR profile of PCOC3 biopsy and derived cell line 
Short tandem repeats were amplified at 16 loci. Alleles are indicated in the grey bars 
immediately above the traces, and the number of repeats by the grey vertical lines. The biopsy 
profile is shown in the upper panel of each pair of images, and is outlined in blue. The cell line 
profile is shown in the lower panel of each pair.   
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4.5.2 PCOC cells are keratinocytes 
Initial cell type characterisation was solely based on morphology. Cytokeratin (CK) 
expression is often used to define epithelial cells. Various cytokeratins, (e.g. 7, 8 and 19) are 
expressed in the tonsil (Clark et al. 2000). Their expression in PCOC2 and 3 cells and the 
original tumours was used to confirm the cell type on a molecular level. PCOC2 and PCOC3 
cells stained strongly for all 3 cytokeratins. Cells in the original tumours were also stained by all 
3 cytokeratins. The only difference was a weaker expression of CK8 in the PCOC2 tumour. 
Abnormal cytokeratin expression can occur in dysplastic and tumour cells. The CK pattern 
displayed by PCOC2 and PCOC3 was consistent with an epithelial origin. Overall, this confirmed 
a similar cytokeratin pattern in the tumours and derived cell lines, and strongly suggests that 
the cells are derived from tonsil epithelia and are keratinocytes (Figure 4.9).  
4.5.3 Mycoplasma detection 
Mycoplasma, due to their small size (± 100nm), are not detectable by light microscopy. 
Mycoplasma contamination in cell cultures causes biochemical and metabolic changes 
affecting a wide range of pathways which could alter experiment results (Miller et al. 2003). 
PCOC2 and PCOC3 cultures were tested for mycoplasma contamination by PCR. Both cell lines 
were confirmed to be free of mycoplasma after amplification and storage (data not shown). 
  
Chapter 4  Primary culture of oropharyngeal cells 
 
104 
 
 
Figure 4.9: IHC staining for cytokeratins 7, 8 and 19 of PCOC2 and PCOC3 cells and original 
tumours 
A: PCOC2 cells stained strongly for all 3 cytokeratins (CK) while cells in the tumours were 
strongly stained for CK 7 and 19. The tumour showed weak diffuse staining for CK8.  
B: PCOC3 cultured cells and the original tumour cells were stained strongly for all 3 
cytokeratins.  
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4.6 Assessment of HPV status 
DNA was extracted from each biopsy and assessed using PCR targeting a 161 bp region 
of the HPV16 E6 gene. The adequacy of each sample for PCR-based analysis was confirmed by 
the amplification of a 209 bp fragment of the human β-globin gene. In accordance with the 
p16 IHC data obtained from the pathology department at the University Hospital of Wales, all 
oropharyngeal biopsies except PCOC9 were confirmed HPV16 positive (Table 4.1 and Figure 
4.10). PCOC9 was shown to be HPV-negative, which is consistent with the patient being 
diagnosed with lymphoma. Explant cells from this biopsy were probably normal oropharyngeal 
cells, which were unlikely to lead to an established cell line. 
In cervical SCC, HPV16 E1 and E2 genes are often disrupted as a result of integration of 
HPV DNA into the host genome (Pett and Coleman 2007). Tiling PCR assays amplifying 
overlapping fragments that span the E1 and E2 regions were used to detect HPV gene 
disruption (Figure 4.11). Disruption of the E1 and E2 regions was used as a surrogate marker 
for the presence of HPV integration. In several cases (PCOC1-5) the shorter fragments of E1 
(1069 and 995 bp) were amplified, but the full length fragment (1954 bp) was not. This could 
indicate that DNA fragmentation during extraction or processing for PCR rendered the 
amplification of the larger fragment difficult. All E1 and E2 gene fragments were present in 
PCOC1-PCOC6 and PCOC10-PCOC12. Full length E1 and E2 genes were present in these 
biopsies, indicating presence of either episomal or mixed (episomal and integrated) infections. 
The second fragment of E2 and all E1 fragments were detected in PCOC7. This might indicate a 
disruption of E1 due to an integration event. Only the first fragment of E1 was detected in 
PCOC8. This was a sign of an integration event disrupting the second part of E1 and causing the 
loss of E2. No E1 or E2 fragments were detected in PCOC9 further confirming the absence of 
HPV16 infection (Figure 4.12).  
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Figure 4.10: PCR amplification of β-globin and HPV16 E6 fragments in PCOC biopsy DNA 
Three PCRs were performed for each samples: HPV16 E6 (E6 161 bp), β-globin (BG, 209 bp) 
and an E6 PCR blank as a negative control (E6 blk).  
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Figure 4.11: Schematic representation of HPV16 E1 and E2 gene tiling PCR assay 
Whole genes and overlapping fragments of E1 and E2 genes were amplified by PCR. The 
absence of some fragments or of the whole gene indicates a disruption likely caused by an 
integration event (N.B: These are surrogate markers of integration as they do not enable to 
differentiate between fully integrated cases or a mix of episomes and integrated virus). 
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E1 E2 
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PCOC9          
PCOC10          
PCOC11          
PCOC12          
Figure 4.12: PCR amplification of E1 and E2 HPV16 genes in PCOC biopsy DNA 
Successfully amplified fragments or full genes are indicated in green and unsuccessful in red. 
E1 and E2 genes were present in PCOC1-PCOC6 and PCOC10-PCOC12, likely indicating either 
an episomal or mixed infection. HPV appeared to be integrated into the host genome in PCOC8 
resulting in the loss of the second part of E1 and the whole E2. PCOC7 could not be interpreted 
due to an inconclusive E1 result. The HPV-negative status of PCOC9 was confirmed. 
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4.7 PCOC cell lines require post-mitotic 3T3 feeder cells to support 
optimal growth 
The PCOC lines were derived with the support of post-mitotic 3T3 feeder cells. The use 
of 3T3 feeder cells was stipulated in the protocol originally used for gynaecological biopsies. 
3T3 feeder cells support, combined with media additives, are a well described technique to 
enhance keratinocytes growth (Rheinwald and Green 1975). However for convenience, it 
would be simpler to culture them without 3T3 feeder cells. The effects of growth with and 
without 3T3 feeder cells were therefore investigated by generating growth curves. The 
optimum seeding densities were previously determined in 10 cm plates so that cells did not 
reach more than 80% confluence after one week (0.8 million cells and 2 millions 3T3 feeder 
cells). Seeding densities were scaled down to suit the culture area of 6 wells plates. Over a 9 
days period, cell counts were performed each day by manual counting with a 
haemocytometer, following trypan blue staining. All experiments were performed in 
triplicates. As in standard culture conditions, media (EGF+) was replaced every other day, and 
3T3 feeder cells were replaced as needed. 
The resulting growth curves are shown in Figure 4.13. PCOC2 and PCOC3 cells were not 
able to grow efficiently without the support of 3T3 feeder cells. PCOC2 cells attached to the 
plate but failed to divide, apparently remaining in lag phase. Their number remained constant 
throughout the experiment. PCOC3 cells attached to the plate and completed two PD over 5 
days. However, the cells did not reach a log phase of growth. After 5 days, the number of cells 
remained constant indicating a growth arrest. 
In contrast, the growth curves with support of 3T3 feeder cells both showed significant 
growth. PCOC3 cells spent a longer time in lag phase compared to PCOC2 before entering the 
log growth phase. PCOC2 entered an exponential growth phase one day earlier than PCOC3 
(day 4 versus day 5). In the log phase, the PD times were similar for both lines, at around 2 
days. By day 10 PCOC2 had entered the plateau phase, this was not reached by PCOC3. 
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Figure 4.13: Growth curve of PCOC2 and PCOC3 cultured with and without 3T3 feeder cells 
Triplicates of cells counts (divided by 1000) are represented over a 9 days period. Error bars 
indicate the standard deviation. In the absence of 3T3 feeder cells neither PCOC2 nor PCOC3 
cells were able to sustain growth. In exponential growth, with the support of 3T3 feeder cells, 
the population doubling time of both cell line was approximately two days.  
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4.8 Discussion 
Biopsies were cultured using protocols to support the growth of explants. Two out of 13 
cultures produced cell lines that appear to be immortal. These cultures showed an ability to 
grow for over 30 PD, exceeding the growth span of normal keratinocytes. STR analysis 
confirmed these lines were derived from the original biopsies, and immunohistochemical 
analysis confirmed the cells were of the expected cell type (i.e. keratinocytes). Additional 
analyses demonstrated that these cells grew optimally when supported by post-mitotic 3T3 
feeder cells. 
The growth pattern of PCOC2 and 3 differed in the first passages, PCOC3 was slower to 
establish as a consistently growing cell culture. Such differences are likely to be due to 
individual genetic factors relating to the cells contained in the biopsy. This growth pattern 
changed as faster growing non-differentiating cells were selected. In the growth curves, the 
growth rate during the exponential phase was similar. Cells were seeded at low density in the 
growth curve experiment to reach confluence after 9 days or more. It is worth noting that the 
low density used likely contributed to the length of the lag phase. Culture without 3T3 feeder 
cells may be feasible if higher seeding densities were used. 
Several methods have been described to establish cell lines from tissue samples 
including enzymatic/chemical dissociation, mechanical dissociation and explant. The explant 
method as described in Stanley 2002 was selected as it was previously successfully used to 
develop HPV-positive gynaecological cell lines in our laboratory (Stanley 2002; Bryant et al. 
2014). The main drawback of this method was the lack of a single cell suspension, which 
reduced the number of cells able to grow in culture to the outside layer of the explant. To 
compensate for this, the biopsies were processed before culture to obtain fragments smaller 
than 2 mm. The advantage of the explant method was the reduced exposure to chemicals such 
as trypsin which could diminish cell viability. Even though mechanical disaggregation damaged 
some cells, the use of tissue fragments instead of single cells ensured some cells were still 
intact within each biopsy piece.  
In this study in 76.9% of biopsies processed produced new cell growth. This showed the 
adequacy of the technique to sustain the growth of tonsil epithelial cells. However, the overall 
success rate at establishing long-term cell culture was low (15.4%). Although, it should be 
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recognised that contamination was the primary cause of failure, with a single event affecting 5 
biopsies (38.4%). 
The advantages and disadvantages of single cell cloning and heterogeneous cell 
populations were considered. Single cell cloning could have led to the isolation of different 
clones from the same tumour especially if performed during the first passages. Characterised 
clones can be a useful tool to determine if different levels of HPV gene expression or 
integration status influence treatment response. However, tumours contain heterogeneous 
cell populations. As the main intended use of the cells was to study the impact of a relatively 
new drug, the use of heterogeneous populations seemed appropriate. Early aliquots are still 
available if there is a need for single clone isolation in the future. 
A drawback of long-term culture process is the selective pressure for the clones best 
suited to grow in tissue culture conditions. Using the lowest passage available reduced the 
impact of this process. Moreover, the use of the same stock in each experiment avoids clonal 
variations over time affecting the results. The selective pressure is likely to be greatest in the 
first few passages. Therefore the cell populations at p7 and p14 were probably already 
relatively homogenous. This could be assessed genetically using deep sequencing of multiple 
sub-clones, but this was not performed within the current study. However, the cultures were 
assessed microscopically, and alteration of colony morphology between p1 and 7 or 14 was an 
indication of the culture homogenisation (i.e. lateral growth instead of upwards). The peak-
shaped colonies which disappeared over time were likely to contain normal cells which after a 
few passages underwent senescence due to telomere shortening.  
In comparison to the already available HNSCC lines 93VU147T, UDSCC2, UPCISCC90, 
UMSCC47 and UMSCC104, the PCOC lines have several advantages. They originate from 
primary OPSCC tumours in treatment naive patients. One being a never-smoker and the other 
a ex-smoker, neither of them have a reported heavy drinking history. None of the other lines 
combine these characteristics. The main difference between the protocols used to develop 
PCOC2 and 3, and those used for the published lines, was the absence of 3T3 feeder cells to 
support the growth of the published lines. The type of media, washes and inversion of the 
plates to promote attachment also varied between protocols. A new method of establishing 
cell lines from head and neck tissue biopsy was recently described (Owen et al. 2016). 
Following enzymatic dissociation, cell surface markers including epithelial cell adhesion 
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molecules and fibroblast surface protein were used to sort keratinocytes and fibroblasts 
respectively using fluorescence associated cell sorting. This technique avoids the need for 
differential trypsinisation and washes to remove non-adherent cells. Fibroblast growth was not 
a major issue in the development of PCOC2 and PCOC3, possibly because the use of 3T3 feeder 
cells minimised their growth.  
The low success rate in establishing new lines is consistent with the low number of HPV-
positive head and neck, and more specifically OPSCC, cell lines already available. Other factors 
such as the relatively recent interest in HPV-positive head and neck SCC and the fact that not 
all developed lines are published also influences the amount of lines available.  
All SCC biopsies collected were HPV-positive, this is higher than expected in view of the 
published HPV prevalence rate in oropharyngeal cancers of around 51.8% reported in the UK 
between 2002 and 2011 and, 55% in South Wales between 2001 and 2006 (Evans et al. 2013; 
Schache et al. 2016). In South Wales, the percentage of HPV-positive cases might be higher 
now than previously. Based on p16 data between 2010 and 2013 of a small number of patients 
treated at Velindre Hospital, 75% of tumours were HPV-positive (unpublished data provided by 
Dr Mererid Evans). Transcription of the CDK inhibitor p16 (CDKN2A) is commonly up-regulated 
in HPV-positive tumours as a consequence of binding of Rb by HPV E7 protein. Hence p16 
expression is often used as a biomarker of HPV infection. The HPV positivity of the biopsies 
collected in the study could also be explained by a bias towards HPV-positive cases. Some 
patients were already known to be p16 positive before being consented for the study. Finally, 
the small cohort size could also have contributed an unrepresentative sample with regard to 
HPV prevalence.  
4.8.1 Strengths and weaknesses 
The culture method used had a high success of implants. The absence of explants in 
some biopsies suggested that only some tumour cells were able to grow in the culture 
environment provided. It also highlights the heterogeneity of the tumours, pieces containing a 
high number of necrotic cells are less likely to develop. The low take rate following explant 
growth was the main weakness. Contamination with environmental microbes contributed to 
the low success rate. Senescence observed after several passages indicated that the culture 
conditions were also suitable for normal cell growth.  
Chapter 4  Primary culture of oropharyngeal cells 
 
113 
 
Basic characterisation of the model was performed, including robust quality controls. 
STR profile combined with the HPV status and the keratinocytes staining provided substantial 
evidence of the cell type grown and confirmed their epithelial origin. However it should be 
noted that the cytokeratin panel used was not specific for tonsils or oropharyngeal tissue, and 
could be present in other types of epithelia. Loss of heterozygosity was identified in PCOC2 in 
comparison with the biopsy. Such events are known to occur in the development of tumour 
lines and to remain stable once cultures are established (Dracopoli and Fogh 1983). Genetic 
instability in culture has been described in several head and neck lines (Brenner et al. 2010). 
However this has not been tested in regards to PCOC2 and PCOC3. A strength of those models 
is the use of relatively low passages compared to what is often seen in immortalised lines, 
providing a closer representation to the original tumours than other available models.  
The cells were not weaned off the feeders over time. Such a process would have 
required a gradual reduction of 3T3 feeders amount over 3-4 passages. Cells were cultured 
with a feeder layer before cryopreservation, the cultures were revived in the same conditions, 
and used straight away in experiments. This culture method was more labour intensive. 
However, culture conditions were developed in accordance with it and used throughout the 
project.  
4.8.2 Conclusion 
Two new HPV-positive cell lines have been established from fresh biopsies of 
oropharyngeal cancer. The novel lines are from patients who are typical of the demographic 
affected by HPV-driven oropharyngeal cancers (i.e. relatively young and fit, with limited co-
morbidities associated with alcohol and tobacco use). These lines represent a valuable and 
scarce resource to support investigation of the biology of, and potential treatment of, HPV-
positive oropharyngeal cancers. 
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Chapter 5 - messenger RNA sequencing 
5.1 Introduction 
Whole transcriptome sequencing (also known as RNA-seq) is a quantitative and sensitive 
technique that shows all transcripts present at a particular time point (Mortazavi et al. 2008). 
In recent years, it has emerged as a valuable technique for tumour characterisation, and has 
had a huge impact on fundamental understanding of the biology of cancer (Parfenov et al. 
2014; Cancer Genome Atlas Network 2015). In the current study, mRNA-seq was used to 
investigate differences in gene expression between, and among, the HPV-positive and negative 
cell lines for following reasons: 
 To characterise and/or confirm the status of the cell lines with regard to HPV gene 
expression, HPV integration and p53 mutation.  
 To establish whether the HPV-positive cell lines are characteristic of typical HPV-driven 
tumours, and if our HPV-negative cell lines are typical of non-HPV-driven HNSCC. 
 To compare expression of different genes, including those involved in DNA repair, 
between HPV-positive and negative lines. This was fundamentally important in relation 
to differential responses to PARPi (described in the next chapter). 
5.2 Data and quality control 
Preliminary bioinformatic quality control analyses were performed by Dr Peter Giles and 
Dr Kevin Ashelford from the Wales Gene Park. A random selection of 10% of reads was used 
for data quality analysis. All cell lines passed quality control measures and were used for 
downstream analysis. Reads were mapped against human reference sequence hg19 (genome 
build 19) and HPV16 reference sequence NC_001526 (Table 5.1).  
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Table 5.1: Mapped reads to human and HPV sequences 
Cell line (HPV +/-) 
Median insert size 
(bp) 
Reference genome* Mapped reads 
UPCISC90 (+) 141 hg19 50339462 
HPV16 19831 
PCOC2 (+) 137 
hg19 34041846 
HPV16 5014 
PCOC3 (+) 151 
hg19 31352778 
HPV16 13087 
UMSCC47 (+) 150 
hg19 49239786 
HPV16 3969 
UMSCC4 (-) 151 
hg19 48897461 
HPV16 0 
UMSCC6 (-) 151 
hg19 47881266 
HPV16 0 
UMSCC19 (-) 148 
hg19 49508832 
HPV16 0 
UMSCC74 (-) 154 
hg19 51169790 
HPV16 12 
*: hg19 denotes human genome build 19; HPV16 denotes HPV16 reference genome 
NC_001526.2. 
 
5.3 Characterisation of novel and established cell lines 
5.3.1 Cell line panel 
Eight cell lines, 4 HPV-positives and 4 HPV-negatives, were selected to use as a study 
panel. The aim was to select lines representing the diversity of OPSCC. The main HPV-positive 
lines were the novel lines PCOC2 and PCOC3 (described in Chapter 4). Two commonly used 
lines, derived from heavy smokers, UMSCC47 and UPCISCC90 were also included. HPV-
negative lines varied in p53 status. UMSCC4 and UMSCC19 have previously described 
mutations in p53, whilst UMSCC6 and UMSCC74a harbour wild-type p53. 
UMSCC74a originated from a recurrent tumour, which was diagnosed after the patient 
had undergone chemoradiotherapy. This line is also described as having undergone epithelial-
mesenchymal transition, giving the culture a fibroblastoid appearance. UMSCC4 was also 
derived post-treatment from a patient who had undergone 2 rounds of chemotherapy: 
bleomycin, oncovin, mitomycin C, and methotrexate.(Brenner et al. 2010). 
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5.3.2 HPV gene expression in four HPV-positive cell lines 
Transcripts mapped to HPV16 sequence were visualised for each cell line using the 
Integrative Genomics Viewer (IGV Version 2.3.65, Broad Institute) as shown in Figure 5.1 
(Robinson et al. 2011). Expression of HPV encoded genes was quantified (expressed as Reads 
per kilobase of transcripts per Million mapped reads (RPKM)).The HPV gene expression pattern 
varied between the lines (Figure 5.2). Late genes L1 and L2 were not expressed in any of the 
lines, indicating the presence of non-productive HPV infection. This corresponds to the gene 
expression pattern commonly observed in HPV-driven tumours, where deregulation of HPV 
gene expression prevents completion of the viral life cycle, and hence the L1 and L2 capsid 
genes are not expressed. The highest levels of E6/E7 expression were observed in UPCISCC90 
and PCOC3. Proportionally higher expression of E4 was found in PCOC2 and PCOC3, and of E5 
in UMSCC47. UPCISCC90, PCOC2, and PCOC3 showed expression of E2/E4 and E5. 
5.3.3 Splicing of HPV encoded genes 
The HPV genome is highly spliced. The two main oncogenes E6 and E7 are of particular 
interest as they are transcribed from the P97 promoter as an E6E7 transcript that undergoes 
alternative splicing. The resulting transcripts have been associated with different oncogenic 
potential. Splicing patterns were investigated using the Sashimi plot function of IGV as 
illustrated in Figure 5.3, and were compared with the most common HPV16 transcripts as 
described on the Papillomavirus Episteme reference website (https://pave.niaid.nih.gov/). To 
avoid confounding by sequencing artefacts, only splice sites with at least 10 reads mapped 
were considered for the analysis. Different frequencies of distinct splicing sites were present 
across the cell line panel. Quantified levels of each transcript and their position are shown in 
Table 5.2. 
The most common oncogenic transcripts, E6*I and E6*II, were present in all lines. A 
splicing site across E1 and E4 was also found in all lines. This site is often present after the E6*I 
and E6*II transcripts. Less common splice sites located in E2 were present in UPCISCC90, 
PCOC2 and PCOC3, another less common site was found in E5 in PCOC2. UMSCC47 expressed a 
reduced variety of transcripts compared to the other lines. A splicing variant which has not 
been commonly described, across E6 and E7, was detected at a low level.  
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Figure 5.1: Mapping of reads against HPV16 
The left axis represents the raw number of reads; the horizontal axis represents the HPV16 
genome and the exons. For each cell line, the number of reads mapped to the HPV16 
NC_001526.2 sequence is indicated. Vertical coloured lines indicate mismatches with the 
reference sequence. 
 
Figure 5.2: HPV gene expression in UMSCC47, PCOC2, PCOC3, UPCISCC90 
Reads Per Kilobase of transcript per million Mapped reads (RPKM) are plotted for each HPV 
gene.  
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Figure 5.3: Splice junctions in UPCISCC90, PCOC2, PCOC3 and UMSCC47 
Showing reads with ends mapping at different sites of the HPV genome, visualised using IGV. 
 
Table 5.2: Description of HPV16 transcripts 
Cell line  Start (nt)* End (nt) Count Transcript 
UPCISCC90 
226 408 1928 E6*I 
226 525 362 E6*II 
880 3356 156 E1^E4 
880 2707 14 E2 
880 3359 12 E1^E4 
PCOC2 
226 408 180 E6*I 
226 525 13 E6*II 
226 3356 57 E5 
226 3359 10 E5 
880 2707 11 E2 
880 3356 162 E1^E4 
880 3359 26 E1^E4 
PCOC3 
226 408 801 E6*I 
226 525 147 E6*II 
880 2707 82 E2 
880 3356 132 E1^E4 
880 3389 19 E1^E4 
UMSCC47 
226 408 435 E6*I 
226 525 87 E6*II 
226 741 11 Novel 
*: Nucleotide (nt)  
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5.3.4 Identification of HPV variants 
Small differences in HPV16 sequence can be found in different geographic areas, these 
differences only involve a small number of nucleotides, and have been classified as HPV16 
variants (Burk et al. 2013). The main variants described are European, African, Asian and 
American, with subtypes in each group. Nucleotide mismatches in the highly conserved E6 and 
LCR regions, which characterise each variant have been described (Cornet et al. 2012). Using 
IGV, the E6 nucleotide sequence of each cell line was compared with the mismatched sites 
described for each HPV16 variants, the results are presented in Table 5.3. UPCISCC90, PCOC2 
and PCOC3 harbour infection by the main European variant of HPV16. This result was expected 
as all those lines originated from European patients. The HPV variant present in UMSCC47 was 
identified as African 2A (AF2A), this line was originally developed in the United States. 
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Table 5.3: Comparison of HPV16 E6 sequence in UPCISCC90, PCOC2, PCOC3 and UMSCC47 
with known HPV16 variants 
Variant or 
cell line 
Position and nucleotide* 
109 131 132 143 145 178 286 289 295 335 350 403 532 
Reference** T A G C G T T A T C T A A 
EUR /C /G - - - /A - - - - /G - - 
EAS - - - - - G/C - - - - - - - 
AF1a - - C G T - A G - T - - - 
AF1b - G - G T - A G G T G - - 
AF2a C - T G T - A G - T - G - 
AF2b - - - G T - A G - T - - - 
NA - - - - T - A G - T G - - 
AA1 - - - - T - A G - T G G - 
AA2 - - - - T - A G - T G - /G 
UPCISCC90 ND G G C G T ND A T C G A A 
PCOC2 ND A G C G T ND ND ND C T A A 
PCOC3 ND A G C G T ND ND ND C G ND A 
UMSCC47 ND A T ND T T ND ND T T T G A 
* For each nucleotide position, the mismatch is indicated or a dash when no nucleotides were 
changed from the HPV16 reference sequence. Nucleotides separated by a slash are different 
nucleotides that can be in the given position for the given sublineage. The top half of the table 
shows known HPV16 variants described by Cornet et al (Cornet et al, 2012). The lower part 
represents the sequence from the 4 lines characterised. Diagnostic SNPs are shown in red. 
** Abbreviations: EAS, European-Asian; EUR, European; AFR, African; NA, North American; AA, 
Asian-American; ND , no data - i.e. not transcribed at a sufficient level to allow detection. 
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5.3.5 HPV integration sites 
Integration of HPV DNA into the host genome confers a proliferative advantage in vitro, 
and integrated virus is present in the majority of HPV-positive head and neck cancers (Jeon et 
al. 1995; Parfenov et al. 2014). Viral integration can potentially disrupt the pattern of HPV gene 
expression as well as alter the expression of some human genes, leading to genetic instability 
and disease progression. It was therefore important to determine the integration status of the 
lines. Integrated virus had previously been described for UMSCC47 and UPCISCC90. Hence it 
was possible to compare the mRNA-seq data with existing publications (Olthof et al. 2015), 
thereby potentially validating our methodology. 
5.3.6 Fusion transcripts 
HPV integration sites in the host genome were detected by analysing paired-end reads 
that had one end mapped to HPV16 sequence and the other to a human sequence (these are 
referred to as fusion transcripts). Circos plots were used to visualise fusion transcripts (Figure 
5.4). Sites of insertions were further analysed using IGV (Table 5.4). The location of integration 
sites was determined to identify whether insertional mutagenesis was a likely factor in the 
development of the original tumour. Information on genes into which insertion was apparent, 
was obtained from the GeneCards Human Gene Database (http://www.genecards.org/).  
Relatively high numbers of fusion transcripts were observed in the UPCISCC90 line, 
these were further analysed using IGV. One main integration site was detected in exon 4 of 
gene C9orf156 in chromosome 9, with reads mapping in E1, E6 and E7. Reads also mapped in 
intron 2 of the same gene from E1. Another site of integration was detected around 200 bp 
before FOXE1 from E7. The point of fusion in the HPV gene E6 in the two most common fusion 
transcripts coincided with the ends of E6*I and E6*II transcripts suggesting that transcription 
of these mRNAs was driven by an HPV promoter. 
The analysis indicated integration upstream of, and production of a fusion transcript 
with, C9orf156 (Chromosome 9 Open Reading Frame 156). C9orf156 is a poorly characterised 
protein, also known as Nef Associated Protein 1. The suggested function of this protein, 
according to its GeneCards entry is a potential hydrolase, which hydrolyses acyl-CoA thioesters 
(in vitro). However, its physiological substrate is not known, and its only known disease 
association is with cleft lip. FOXE1 is a thyroid transcription factor involved in thyroid 
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morphogenesis. Several diseases have been associated with FOXE1 including cleft palate, 
thyroid associated conditions and thyroid cancers.  
Four integration sites were detected in PCOC2. The main integration site was located in 
chromosome 10, with reads originating in E2 and one read from L1. All reads mapped within 
the gene YMEL1 at two sites, introns 6 and 7. The function of YME1L1 is described as the 
human orthologue of yeast mitochondrial AAA metalloprotease, Yme1p. The protein is 
localised in the mitochondria, and it is proposed that this gene plays a role in mitochondrial 
protein metabolism and could be involved in mitochondrial pathologies. The only confirmed 
disease association is with pulmonary valve insufficiency. The presence of the E6^E4 splice 
products suggests that if integration had taken place, it had not separated the E6 and E4 ORFs, 
implying that E2 sequences likely remain intact. This has been confirmed by PCR with full 
amplification of both E2 and E1 genes indicating that intact copies of both are present. Two 
other minor integration sites were detected, from E2 into exon 7 of SUX22 in chromosome 15, 
and from E7 into exons 8 and 9 of DAGLB in chromosome 7.  
A number of integration sites were also observed in PCOC3. The main site of integration 
was located in chromosome 20. The majority of these fusion transcripts mapped to E7, with a 
minority mapping to E1. The site of integration was the gene CEBPB, which is formed of only 1 
exon. The analysis showed several fusion transcripts that appear to link between the E7 splice 
donor region and exonic sequences in the CEBPB gene. CEBPB gene encodes a transcription 
factor that contains a basic leucine zipper domain. The encoded protein functions as a 
homodimer and is important in the regulation of genes involved in immune and inflammatory 
responses. Mutations in CEBPB are associated with several diseases including acute 
promyelocytic leukemia and glioma (Du et al. 2016). 
Only two sites of integration were detected in UMSCC47. The main one was located in 
chromosome 3, with fusion transcripts originating from E7 and a few from E5. Within 
chromosome 3, the integration site was located in exon 11 of the TP63 gene. TP63 is a 
member of the p53 family of transcription factors. The encoded protein acts as a sequence-
specific DNA binding transcriptional activator or repressor. Activity may be required in 
conjunction with TP73/p73 for initiation of TP53/p53 dependent apoptosis in response to 
genotoxic insults and the presence of activated oncogenes. It may also be involved in Notch 
signalling. Diseases associated with TP63 include ectrodactyly, ectodermal dysplasia, cleft 
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lip/palate syndrome and split-hand/foot malformation. The other integration event detected 
spans from E6 to chromosome 11. This read maps to Exon 9 of the BIRC2 gene. BIRC2 is a 
member of a family of proteins that inhibits apoptosis by binding to tumour necrosis factor 
receptor-associated factors TRAF1 and TRAF2. Mutation of BIRC2 may be associated with lung 
cancer and lymphoma. However, given that only a single read mapped to this location, further 
validation would be required to view this as a robust finding. 
5.3.6.1 Consistency of HPV integration findings with published data 
Integration events present in UPCISCC90 and UMSCC47 have been previously described 
(Ragin et al. 2004; Olthof et al. 2015). In UPCISCC90, the same integration sites were detected 
in C9orf156 exon 4 and intron 2 as previously observed by Olthof et al. The mRNA-seq also 
detected additional sites of integration within this gene, which had not been reported 
previously. An additional integration site 200 bp before FOXE1, observed with mRNA-seq, was 
also novel. The detection of these extra sites could be explained by the higher sensitivity of 
mRNA-seq. However, these data differ from the integration sites published by Ragin et al., who 
used fluorescence in situ hybridization and spectral karyotyping, and reported chromosome 9 
at 9q31 as the main site of integration (Ragin et al. 2004). While located in the same 
chromosome, the location is not directly adjoining to the one found with mRNA-seq located at 
9q22.33. These differences might be due to the techniques used, alternatively, this could be an 
example of evolution and selection of subclones in cell lines grown in different laboratories.  
In UMSCC47, the mRNA-seq analysis identified one published integration event, 
previously detected using a rapid-amplification-of-cDNA-ends methodology, into exon 7 of 
TP63 (labelled exon 11 in the reference sequence used here). Using a ligation-mediated PCR 
method, another integration site, into intron 4 of TP63 was detected. This latter integration 
site was not observed in the mRNA-seq data. This could be explained by the proximity of the 
sites and also by differences in the techniques.  
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Figure 5.4: Circos plot showing fusion transcripts between HPV16 and human genome for 
UPCISCC90, PCOC2, PCOC3 and UMSCC47 
The circle consists of the HPV16 sequence in grey and the human chromosomes as coloured 
bars. Fusion transcripts are represented as grey lines joining their point of insertion in both 
human and HPV sequence. Thicker/darker lines are the result of multiple reads detected. 
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Table 5.4: Main HPV integration sites in UPCISCC90, PCOC2, PCOC3 and UMSCC47* 
Cell line HPV gene Human chromosome Human gene 
UPCISCC90 
E1 
9 C9orf156 Exon3 
9 C9orf156 Intron2 
E6 9 C9orf156 Exon3 
E7 
9 C9orf156 Exon3 
9 Non coding +- 200 bp before FOXE1 
PCOC2 E2 10 YMEL1 Intron 6 and 7 
PCOC3 E7 20 CEPBP 
UMSCC47 E7 3 TP63 Exon 11 
*: Sites with at least 5 mapped reads are represented in the table. 
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5.3.7 Validation of p53 status 
The p53 status of the established cell lines has been published: UPCISCC90, UMSCC6, 47 
and 74a are described as wild-type for p53, while UMSCC4 and 19 are described as mutated 
(Somers et al. 1992; Bradford et al. 2003; Ferris et al. 2005; Mandic et al. 2005). The p53 status 
of PCOC2 and PCOC3 was also analysed using PCR amplification and Sanger sequencing (data 
not shown). Wild-type p53 was detected in both lines. This was consistent with the mRNA-seq 
data, where no deletions or mutations were observed relative to the wild-type sequence. 
5.3.7.1 p53 SNPs and mutations 
The mRNA-seq data set was used to assess SNPs and mutations in the p53 gene. IGV was 
used to identify mismatches with the reference sequence hg19. Mismatches were only 
counted if they were present in over 5 reads (this was to avoid confounding by counting 
isolated sequencing errors). The identified mismatches were searched against the NCBI dbSNP 
database to determine allele frequency and clinical significance. Numbering relates to the 
human genome hg19 reference sequence. 
SNPs were identified in UPCISCC90, UMSCC47, UMSCC74a, PCOC2 and PCOC3. 
Comparing these with the NCBI dbSNP database showed no known clinically significant 
correlations. One pathogenic mutation in the DNA binding domain (a homozygous GA 
mutation in exon 6), and two SNPs were identified in UMSCC4. A deletion was identified in 
UMSCC19 consisting of a gap of 22 nucleotides in exon 8. This deletion was also located in the 
DNA binding domain, resulting in an inactive form of p53. 
One SNP, rs1042522, was detected in all lines except UMSCC6. This SNP has previously 
been associated with an increased risk of cervical cancer. However, its role is controversial as 
some large-scale studies found no association between this SNP and cancer (Klug et al. 2009). 
The role of rs1042522 has not been described in the context of head and neck tumours.  
5.3.7.2 Consistency of p53 mutation findings with published data 
Mutations and deletions were identified in UMSCC4 and UMSCC19. The localisation of 
the identified mutations in the DNA binding domain of UMSCC4 was consistent with previously 
published data (Mandic et al. 2005). A 10 bp deletion found in UMSCC19 has also been 
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described previously, this creates a frame shift (Somers et al. 1992). A non-pathogenic SNP has 
been reported by some papers in one allele of UMSCC47, this corresponds to what was 
observed in the current data set (Bradford et al. 2003). The PCR data previously obtained for 
PCOC2 and PCOC3 was also validated as the same SNPs were identified. Overall, the p53 status 
of all lines was confirmed. 
5.4 Differential gene expression between HPV-positive and HPV-negative 
cell lines 
5.4.1 Global unsupervised clustering 
Differential gene expression between the 4 HPV-positive and 4 HPV-negative cell lines 
was investigated. For each cell line, gene expression was quantified as RPKM and differentially 
expressed genes were identified using an edgeR analysis as described in section 2.10.3.4 
(Mortazavi et al. 2008; Robinson et al. 2010). Data was normalised and the P-values corrected 
for multiple testing and false discovery issues using the FDR method; a p<0.05 cut-off value 
was used (Benjamini and Hochberg 1995). 
The results are visualised as heatmaps based on unsupervised hierarchical clustering 
(using average linkage and Pearson's correlation as the similarity metric) to group similar data 
together and reveal any patterns within the dataset. The resultant values are represented as 
colours, where green is under-expressed (compared to median), black is the median 
expression and red is overexpressed (Figure 5.5).  
The heatmap demonstrates that the HPV-positive and negative samples form discrete 
groups, with further divisions visible within these groups. It also resulted in grouping of the 
PCOC lines relative to the other HPV-positive lines. To explore these differences further, a 
heatmap was generated to show differential gene expression between these groups (Figure 
5.6). In these analyses, the number of genes differentially expressed was too high to sort 
through manually, so a Gene Ontology (GO) analysis was used to identify groups of genes that 
were differentially expressed as described in section 2.10.3.5 (Figure 5.6). 
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Figure 5.5: Heatmap representing differential gene expression between HPV-positive and 
negative cell lines 
Gene expression was normalised across the lines and colour coded. Black represents the 
median, green a lower expression than the median value and red a higher expression. After 
correction for multiple testing, 211 transcripts were significantly differentially expressed 
between the two groups (FDR p<0.05). 
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Figure 5.6: Heatmap representing differential gene expression between the PCOC cell lines 
compared to already established HPV-positive lines 
Gene expression was normalised across the lines and colour coded. Black represents the 
median, green a lower expression than the median value and red a higher expression. After 
correction for multiple testing, 506 transcripts were significantly differentially expressed 
between the two groups (FDR p<0.05). 
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5.4.2 Differences in gene expression: Gene Ontology analyses 
Genes that showed differences in transcript levels between groups were further 
investigated using a GO Over Representation Analysis (GO-ORA) (Young et al. 2010). The data 
was corrected for multiple testing and false discovery using the FDR method. GO analyses use 
a controlled vocabulary to classify genes under three headings of 1) biological processes (BP) 2) 
molecular functions (MF) and 3) cellular component (CC).  
5.4.2.1 Comparison of GO subsets in HPV-positive and negative lines 
The results for the top 500 differentially expressed transcripts are presented. The 
partition of significant transcripts in to the GO categories after p-value correction for multiple 
testing was: 51 BP, 5 MF, and 5 CC. The sensitivity of the gene expression analyses was limited 
due to the lack of biological repeats. Hence these analyses should be regarded as exploratory. 
The most significantly regulated ontologies are shown below for the BP, MF and CC 
classifications (Table 5.5, Table 5.6 and Table 5.7). 
A variety of BP were differentially expressed between HPV-positive and negative cell 
lines. This included over-representation of pathways involved in several metabolic processes 
including glucoronidation, flavonoid and uronic acid metabolism. Several cellular processes 
including extracellular matrix (ECM) organisation and chromosome organisation were also 
significantly differentially regulated. Glucoronidation is the transfer of the glucuronic acid 
component of uridine diphosphate glucuronic acid to a substrate by UDP-
glucuronosyltransferase. It is of interest, as it is used in the detoxification of many xenobiotics 
and bioactive compounds including many drugs and hormones. This is achieved by increasing 
the polarity of the substrate and increasing efflux via ABC class transporter proteins (Mazerska 
et al. 2016). This pathway appears to be significantly more active in HPV-negative cell lines, 
and is also highlighted in the analysis of MF ontologies. Genes involved in the organisation and 
composition of the ECM were represented in the BP and CC analyses. 
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Table 5.5: Significant Biological Process ontologies (HPV-positive vs negative cell lines) 
GO ID Term p.fdr* value 
GO:2001029 regulation of cellular glucuronidation 5.07044E-11 
GO:0052696 flavonoid glucuronidation 1.21725E-08 
GO:0052695 cellular glucuronidation 1.31571E-07 
GO:0009812 flavonoid metabolic process 1.93747E-07 
GO:0006063 uronic acid metabolic process 5.02586E-07 
GO:0019585 glucuronate metabolic process 5.02586E-07 
GO:0030198 extracellular matrix organization 1.33965E-06 
GO:0043062 extracellular structure organization 1.33965E-06 
GO:0045922 negative regulation of fatty acid metabolic process 3.86198E-06 
GO:0051552 flavone metabolic process 4.55623E-06 
GO:0009813 flavonoid biosynthetic process 4.55623E-06 
GO:0045912 negative regulation of carbohydrate metabolic process 4.72082E-06 
GO:0042573 retinoic acid metabolic process 1.21982E-05 
GO:0010677 negative regulation of carbohydrate metabolic process 1.83022E-05 
GO:0045833 negative regulation of lipid metabolic process 0.000105032 
GO:0006805 xenobiotic metabolic process 0.000266518 
GO:0071466 cellular response to xenobiotic stimulus 0.000335597 
GO:0009410 response to xenobiotic stimulus 0.000434141 
GO:0009888 tissue development 0.000928789 
GO:0032787 monocarboxylic acid metabolic process 0.001857035 
GO:0006631 fatty acid metabolic process 0.001857035 
GO:0019217 regulation of fatty acid metabolic process 0.003262184 
GO:0022617 extracellular matrix disassembly 0.003525732 
GO:0001523 retinoid metabolic process 0.015858668 
GO:0045143 homologous chromosome segregation 0.019387946 
GO:0006109 regulation of carbohydrate metabolic process 0.019387946 
GO:0016101 diterpenoid metabolic process 0.025809632 
GO:0010511 regulation of phosphatidylinositol biosynthetic process 0.028288198 
GO:0070192 chromosome organization involved in meiotic cell cycle 0.030297076 
GO:0043436 oxoacid metabolic process 0.037869608 
*: The p-value represents data corrected for multiple testing and false discovery. 51 GO were 
significantly different (p.fdr <0.05) between the two groups. The 30 most significant categories 
are shown. 
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Table 5.6: Significant Molecular Function ontologies (HPV-positive  
vs negative cell lines)  
GO ID Term p.fdr* value 
GO:0015020 glucuronosyltransferase activity 1.10672E-06 
GO:0005501 retinoid binding 0.000106315 
GO:0019840 isoprenoid binding 0.000166721 
GO:0001972 retinoic acid binding 0.001408542 
GO:0008194 UDP-glycosyltransferase activity 0.01020897 
*: The p-value represents data corrected for multiple testing and false discovery. Five GO were 
significantly different (p.fdr <0.05) between the two groups. 
 
 
 
Table 5.7: Significant Cellular Component ontologies (HPV-positive vs 
negative cell lines) 
GO ID Term p.fdr* value 
GO:0005578 proteinaceous extracellular matrix 0.001857035 
GO:0031012 extracellular matrix 0.003534985 
GO:0044421 extracellular region part 0.013170708 
GO:0005576 extracellular region 0.017227438 
GO:0000795 synaptonemal complex 0.045361421 
*: The p-value represents data corrected for multiple testing and false discovery. Five GO were 
significantly different (p.fdr <0.05) between the two groups. 
  
Chapter 5  messenger RNA sequencing 
 
133 
 
5.4.2.2 Differential Gene Expression and Gene Ontology analysis between the PCOC lines and 
previously established HPV-positive lines 
The initial differential expression heatmap highlighted clusters of genes with reduced 
expression in the PCOC lines compared to the two other HPV-positive lines. To further 
investigate the gene expression profiles of these two groups, analyses of differential gene 
expression and GO were performed grouping PCOC2 and PCOC3 vs UPCISCC90 and UMSCC47.  
Results showing transcripts differentially expressed (p<0.05) are presented as a heatmap 
(Figure 5.6) This highlighted two clear groups of genes, one with higher and one with lower 
expression in PCOC2 and PCOC3 compared to UPCISCC90 and UMSCC47. A GO analysis was 
used to look further at which groups of genes were differentially expressed (Table 5.8). The 
analysis was based on the top 500 significantly differently expressed transcripts. Pathways in 
the BP ontologies that showed differences between the groups, mainly related to cell 
differentiation and tissue development, including development of skin. Among the MF 
ontologies, several pathways relating to fatty acid metabolism were present, along with some 
involved with glycoprotein binding. In the CC ontologies, the primary differences were in 
pathways involved with composition of the extracellular space and composition of vesicles. 
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Table 5.8: PCOC cells versus established HPV-positive cells: Top 10 significant ontologies by 
GO category 
Category* GO ID Term p.fdr** value 
BP GO:0009888 tissue development 8.13507E-07 
BP GO:0051239 regulation of multicellular organismal process 0.000188443 
BP GO:0048856 anatomical structure development 0.000188443 
BP GO:0030154 cell differentiation 0.000328706 
BP GO:0032502 developmental process 0.000328706 
BP GO:0044707 single-multicellular organism process 0.00047516 
BP GO:0048513 animal organ development 0.000710766 
BP GO:0043588 skin development 0.001004473 
BP GO:0048869 cellular developmental process 0.00156408 
BP GO:0009605 response to external stimulus 0.001613676 
MF GO:0050544 arachidonic acid binding 0.003218797 
MF GO:0050543 icosatetraenoic acid binding 0.004844659 
MF GO:0050542 icosanoid binding 0.005199383 
MF GO:1901567 fatty acid derivative binding 0.005199383 
MF GO:0005539 glycosaminoglycan binding 0.005686227 
MF GO:0008201 heparin binding 0.010460524 
MF GO:0050786 RAGE receptor binding 0.017387801 
MF GO:0005102 receptor binding 0.033216283 
MF GO:0035662 Toll-like receptor 4 binding 0.034214762 
MF GO:0001948 glycoprotein binding 0.034263345 
CC GO:0005576 extracellular region 5.9795E-05 
CC GO:0044421 extracellular region part 0.000188443 
CC GO:0005615 extracellular space 0.0007416 
CC GO:0031982 vesicle 0.001613676 
CC GO:0031988 membrane-bounded vesicle 0.00228527 
CC GO:0065010 extracellular membrane-bounded organelle 0.002649475 
CC GO:0070062 extracellular exosome 0.002649475 
CC GO:0005587 collagen type IV trimer 0.002649475 
CC GO:0043230 extracellular organelle 0.002649475 
CC GO:1903561 extracellular vesicle 0.002649475 
*: BP = biological process; MF = molecular function; CC = cellular component. 
**: The p-value represents data corrected for multiple testing and false discovery (p.fdr <0.05). 
Ninety-three BP GO were significantly different between the two groups. Thirteen MF GO were 
significantly different between the two groups. Fifteen CC GO were significantly different 
between the two groups. 
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5.4.3 Relative expression of genes of interest 
Based on the hypotheses under investigation, the mRNA levels of several genes and 
ontology groups were specifically assessed in the eight cell lines. These data are illustrated as 
histograms (with RPKM vs cell line) and heatmaps (where colour indicates fold-change 
between groups). Most of these genes and pathways of interest were not identified as 
significantly differentially expressed between the groups in previous unsupervised analyses. 
Therefore, this analysis is only exploratory. 
5.4.3.1 p53 mRNA level  
Considerably higher levels of p53 transcripts were observed in the HPV-positive cell lines 
than in HPV-negative lines (Figure 5.7). UMSCC74a showed higher levels of expression than 
other HPV-negative lines, which is consistent with the distinct pattern of gene expression 
compared to the other HPV-negative lines observed previously. In isolation, the difference 
between p53 transcript levels in the HPV-positive and negative lines is significant (T-test 
p=0.00567), but after correction for multiple tests the p-value dropped to 0.25. 
5.4.3.2 p21 mRNA level 
p21 (CDKN1A) is a well characterised p53 responsive gene. To gain insight into the likely 
levels of active p53 protein, mRNA levels of p21 were also assessed. The pattern of 
transcription of p21 was not similar to that observed for p53. There was no significant 
difference in expression between HPV-positive and negative lines (Figure 5.7). The highest 
levels of p21 transcription were present in UMSCC74a.  
5.4.3.3 p16 mRNA level 
mRNA for p16 was present in all the HPV-positive lines (Figure 5.7). However, the 
correlation between HPV status and p16 transcription was not perfect, as transcription of p16 
was also evident in the HPV-negative line UMSCC19. 
5.4.3.4 PARP1 mRNA level  
PARP1 is a gene of interest because the PARPi Olaparib is being investigated in clinical 
trials as a possible specific treatment for HNSCC (https://clinicaltrials.gov/ct2/show/ 
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NCT02308072) and in the current pre-clinical in vitro study as a potential treatment for HPV-
positive OPSCC cells. PARP1 transcripts were present in all cell lines tested. The highest levels 
of expression were observed in the HPV-positive cell line UPCISCC90, however, there was no 
obvious correlation between HPV status and PARP1 transcript levels (Figure 5.7). 
5.4.4 Pathways of interest 
The expression of genes in key DNA damage/repair pathways was investigated using GO 
directed analyses. The outputs relating to BER, Double Strand Break Repair (DSBR), and p53 
pathways are shown as heatmaps (Figure 5.8, Figure 5.9 and Figure 5.10). 
The BER heatmap (Figure 5.8) shows no difference in expression of genes involved in 
BER between the HPV-positive and negative cell lines. Similar trends were evident in the data 
for DSBR (Figure 5.9). Differential expression of genes involved in signalling via p53 in response 
to DNA damage was also assessed. This also showed no difference between the HPV-positive 
and negative cell lines in levels of mRNA for genes associated with p53 signalling (Figure 5.10). 
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Gene Gene ID Fold change P-value fdr p 
TP53 NM_000546 -4.26 0.00567 0.25279 
p21 (CDKN1A) NM_000389 1.1 0.83265 1 
p16 (CDKN2A) NM_000077 -5.5 0.08457 0.98212 
PARP1 NM_001618 -1.2 0.66105 1 
Figure 5.7: mRNA levels of specific genes of interest 
The number of reads (RPKM) for p53, p21, p16 and PARP1 are shown for the HPV-positive and 
HPV-negative lines. This is depicted as histograms in the upper panel and in tabulated form 
(showing fold change between the HPV-positive and negative groups, and signicance by T-test 
without and with fdr adjustment for multiple tests) in the lower panel. NB for comparison, a 
“highly expressed” gene eg. ACTB was transcribed at approximately 50,000 RPKM in these cell 
lines. 
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Figure 5.8: Differential gene expression in the BER pathway between HPV-positive and 
negative cells 
Gene expression was normalised across the lines and colour coded. Black represents the 
median, green a lower expression than the median value and red a higher expression. The 
block of differentially expressed transcripts in the centre of the figure are mainly p53 
transcripts. Heatmap based on analysis of 69 transcripts.   
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Figure 5.9: Differential gene expression in the DSB repair pathway between HPV-positive and 
negative cells 
Gene expression was normalised across the lines and colour coded. Black represents the 
median, green a lower expression than the median value and red a higher expression. 
Heatmap based on analysis of 133 transcripts. 
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Figure 5.10: Differential gene expression in the “DNA damage response, signal transduction 
by p53 class mediator” pathway between HPV-positive and negative cells 
Gene expression was normalised across the lines and colour coded. Black represents the 
median, green a lower expression than the median value and red a higher expression. 
Heatmap based on analysis of 27 transcripts. The botton two rows show transcript levels for 
NDRG1. 
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5.5 Discussion 
5.5.1 Main Findings 
The main findings of the mRNA-seq analyses are summarised below. The analyses: 
 Confirmed that all “HPV-positive” cell lines showed active expression of HPV encoded 
oncogenes. 
 Identified varying levels of expression of HPV encoded oncogenes (the highest levels 
were observed in UPCISCC90 and PCOC3). 
 Confirmed the HPV16 variants present: UPCISCC90, PCOC2 and PCOC3 are European; 
UMSCC47 is an African 2A variant. 
 Showed the presence of integrated HPV in the genomes of the HPV-positive lines. 
Some integrations occurred in sites with pathological associations. In PCOC3, 
integration occurred in the CEBPB gene, mutation of which is associated with acute 
promyelocytic leukaemia and glioma.  
 Confirmed p53 status for all lines. For the established lines, this was consistent with 
published data. For the novel lines, the RNA-seq data was consistent with DNA 
sequencing data. In summary: no inactivating mutations were present in the HPV-
positive lines, inactivating mutations were identified in two of the HPV-negative lines 
(UMSCC4 and UMSCC19). 
 Using differential gene expression showed clustering of HPV-positive and HPV-negative 
cell lines. It also showed different patterns of gene expression between the novel and 
established HPV-positive cell lines. 
 Using GO analysis between HPV-positive and HPV-negative cell lines primarily showed 
differences in: metabolic processes, including glucoronidation and in organisation and 
composition of the ECM. 
 Using GO analysis between novel PCOC HPV-positive cell lines, and the established 
HPV-positive cell lines primarily showed differences in: cell and tissue differentiation 
and development; and composition of the extracellular space. 
 Investigating expression levels of individual genes showed: 
o Higher transcript levels of p53 in HPV-positive lines, but no correlation 
between p21 and p53 transcript levels. 
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o Transcription of p16 in all HPV-positive lines, but also p16 transcription in one 
HPV-negative line (UMSCC19). 
o PARP1 was transcribed in all the lines. The highest levels were observed in 
UPCISCC90, but there was no correlation between PARP1 levels and HPV 
status. 
 Investigation of expression levels within specific pathways, based on GO analysis, 
showed no correlation between HPV status and transcription of genes involved in DNA 
repair pathways or p53 signalling. 
The pattern of expression of HPV genes was investigated. This confirmed that there was 
active HPV gene expression in all cell lines. This, along with the HPV DNA typing and p16 
complies with the “gold standard” definition of an HPV-positive tumour (Schache et al. 2011). 
The characteristics of the cell line panel were also validated, and matched previously published 
data regarding these lines. Splice site usage was investigated and confirmed the presence of 
the main oncogenic E6*I and E6*II transcripts. This supports the classification of the novel lines 
as deriving from true HPV-driven tumours and indicates that they are representative of 
“typical” HPV-positive OPSCC. 
The novel lines PCOC2 and PCOC3 were shown to contain wild-type p53 and infection by 
a European variant of HPV16. Information regarding the physical state of the virus was 
obtained through the identification of fusion transcripts and one integration site in each line. 
PCOC2 expressed high levels of E4 and E5, the presence of these transcripts indicates either 
the integration of the full HPV16 genome or a mixed infection (presence of HPV both as an 
episome and in integrated form, this could be determined by Southern blot). 
The sites of integration were assessed. Previous studies have suggested that integration 
of HPV into the host genome can result in insertional mutagenesis and loss of function of 
tumour suppressor genes (Schmitz et al. 2012). The sites of integration in the HPV-positive cell 
lines were therefore assessed. In PCOC3, insertion occurred in the CEBPB gene, which 
contributes to regulation of genes involved in immune and inflammatory responses. Mutations 
of CEBPB has been associated with acute promyelocytic leukaemia and glioma (Du et al. 2016). 
Hence, in this case, insertional mutagenesis may be relevant to disease aetiology. This may 
also be true for the insertion in TP63 in UMSCC47. 
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In HPV-positive head and neck cancer cells, p53 is degraded following the action of HPV 
E6 protein, the selective pressure for p53 mutation is therefore low in these cells, resulting in a 
wild-type p53 genotype in most cases (Stransky et al. 2011). In contrast, p53 mutations are 
often present in HPV-negative lines. p53 is the most commonly mutated gene in head and neck 
cancers, and clinically, mutation is significantly associated with shorter survival times and 
resistance to chemo and radiotherapy (Zhou et al. 2016). The mRNA-seq data confirmed the 
presence of published mutations in UMSCC4 and UMSCC19 (Somers et al. 1992; Mandic et al. 
2005). No mutations were observed in the data for PCOC2 or PCOC3, again suggesting that 
they are representative of “typical” HPV-driven OPSCC. 
The GO analysis comparing HPV-positive and negative cell lines identified primarily 
differences in levels of transcripts involved in metabolic pathways. This highlights the 
fundamental cellular differences associated with the differing aetiologies (HPV vs non-HPV). It 
was interesting that the glucoronidation pathway appeared more active in HPV-negative cells, 
as it could be speculated that greater detoxification of xenobiotics would be associated with 
poorer clinical outcomes (Mazerska et al. 2016). There was no significant up-regulation or 
down-regulation detected in major DNA damage response pathways or cell cycle regulation 
pathways. Such pathways have been previously identified as differentially expressed in HPV-
positive tumours in large datasets but this was not evident in the current data (W. Zhang et al. 
2016). This could be regarded as surprising, given the postulated deficiencies in DSBR 
associated with HPV-positive tumours (Kimple et al. 2013; Rieckmann et al. 2013). High levels 
of p16 have also been suggested to impair HR-mediated repair of DSB in HPV-positive HNSCC 
(Dok et al. 2014).  
Induction of BER enzymes in HPV-positive cells might also have been expected. This 
hypothesis was based on data from The Cancer Genome Atlas Project that showed that the 
APOBEC mutation pattern is common in several HPV mediated cancers including cervical, and 
head and neck cancers (Roberts et al. 2013). In these tumours, APOBEC-mediated mutagenesis 
is pervasive and correlates with APOBEC mRNA levels. This is believed to be a consequence of 
induction of APOBEC activity by HPV encoded genes. For instance, APOBEC3A is a member of 
the “apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like" family of RNA editing 
proteins, and is up-regulated in response to expression of the E7 oncoprotein (Warren et al. 
2015). As APOBEC mutations may be repaired via BER, it was surprising that the BER pathway 
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did not appear to be up-regulated in HPV-positive cells. This is however consistent with the 
lack of induction of APOBEC activities in the mRNA-seq dataset (data not shown). 
The relative expression of several specific genes of interest was assessed. p53 transcript 
levels were consistently higher in HPV-positive cells. Regulation of p53 activity at the protein 
level is relatively well understood. In normal circumstances, p53 mRNA is rapidly transcribed 
and translated, but p53 protein is then ubiquitinated by Mdm2, and rapidly degraded. This 
results in low “steady-state” levels of p53 protein, but allows for rapid accumulation if 
proteolysis is blocked. Regulation of transcription of p53 itself, is less well studied and less well 
defined. Transcription appears to be regulated in a cell cycle dependent manner, and peaks in 
mid-S-phase (Reisman et al. 2012) but is also stimulated by serum factors (Reich and Levine 
1984) and by c-Myc (Reisman et al. 1993). Interestingly, overexpression of Myc and HPV E7 has 
previously been shown to result in increased transcription of p53 (Liu et al. 2007) and 
numerous lines of enquiry suggest up-regulation of Myc in HPV infected cells and HPV 
associated tumours, hence it may be that these factors account for the increased p53 
transcript levels in the HPV-positive lines (Strickland and Vande Pol 2016; Zhang et al. 2016). 
An alternative explanation is that the difference between p53 mRNA levels in HPV-
positive and negative cells is consistent with evidence that p53 protein stimulates transcription 
of p53 mRNA (Deffie et al. 1993; Kishore et al. 2007). The work by Deffie et al. also 
demonstrated that mutated p53 could not transactivate transcription from the p53 promotor. 
Hence, if there was some residual p53 activity in the HPV-positive cells, then this could 
stimulate p53 transcription, but this effect would not be present in the cells carrying 
inactivating mutations in p53 (UMSCC4 and UMSCC19). However this would not explain low 
levels of HPV transcription in UMSCC6 where p53 is apparently wild-type.  
p21 (CDKN1A) is a relatively well characterised p53 responsive gene, and is often used a 
marker to indicate presence of active p53 (Riley et al. 2008; Abbas and Dutta 2009). The gene 
encodes a potent CDK inhibitor that binds to and inhibits the activity of CDK2 and CDK4 
complexes, and thus functions as a regulator of cell cycle progression at G1. p21 expression is 
tightly controlled by p53, and mediates p53-dependent cell cycle G1-phase arrest in response 
to a variety of stress stimuli. There was no significant difference in expression between HPV-
positive and negative lines, and no apparent correlation between transcript levels for p53 and 
p21. This suggests that although p53 was transcribed in the HPV-positive cell lines, functional 
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p53 protein appears not to be present. The highest levels of p21 transcription were present in 
UMSCC74a. This would be consistent with the presence of functional p53 in this line. 
p16 over-expression arises from increased activity of E2F transcription factors secondary 
to binding of Rb by HPV E7 protein. p16 IHC is used diagnostically in conjunction with HPV DNA 
testing to identify HPV associated tumours (Schache et al. 2011). It was therefore expected 
that p16 would be transcribed at a higher level in HPV-positive cell lines. However, it was 
important to confirm this and show that the cell lines reflected the p16 IHC status of the 
original tumours. The high levels of p16 in the HPV-positive lines also confirm that proliferation 
in these cells, and in the original tumour, was driven by HPV, and these are hence appropriate 
models for investigation of HPV-driven disease. Transcription of p16 in the HPV-negative line 
UMSCC19 was not expected, but does demonstrate the acknowledged limited specificity of 
p16 testing to identify HPV-driven tumours (Evans et al. 2013).  
Levels of PARP1 mRNA were assessed. This was relevant as PARP inhibition is one of the 
main themes of this thesis. PARP1 transcripts were present in all HPV-positive and negative cell 
lines. The lack of correlation with HPV status is consistent with the similar levels of other genes 
involved in BER between the two groups. UPCISCC90 showed very high levels of expression. 
This might suggest that this cell line may be more dependent upon ongoing PARP expression. 
Several specific potentially relevant pathways were also investigated using GO directed 
analyses including BER, DSBR, and p53. There were no substantial differences in these 
pathways according to HPV status. Based on the suggestion that APOBEC3A induced in HPV-
positive cells can induce DNA DSB, and activate the global DNA Damage Response (Landry et 
al. 2011), and high levels of reactive oxygen species in HPV mediated tumours (Marullo et al. 
2015), it might be expected that HPV-positive cells would show constitutive activation of DNA 
repair pathways, but this is not supported by the mRNA-seq data.  
Finally, mRNA levels for genes in the ontology “DNA damage response, signal 
transduction by p53 class mediator” were assessed. This was relevant to the question of 
whether functional p53 was present. The data appear consistent with the absence of p53 
signalling in all the lines. This could be caused by a genuine absence of stress and/or DNA 
damage in the cells examined, or by the absence of functional p53 protein, or a combination of 
these factors. 
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Taken together, these data do not suggest differences in the induction and repair of 
DNA damage, between HPV-positive and negative cells.  
5.5.2 Exclusion of UMSCC6 
The UMSCC6 cell line was included in the mRNA-seq analyses but not in the subsequent 
experiments. This was because this cell line is exceptionally slow growing, with a doubling time 
of several weeks. This made it unfeasible to include it in clonogenic assays. The mRNA-seq data 
has been included however as it provides a useful comparison with the HPV-positive lines. 
5.5.3 Strength and weaknesses 
mRNA seq is a very sensitive technique, it provided in-depth analysis of the panel of cell 
lines and enabled the validation of their characteristics prior to use in other assays. This 
represents the first characterisation of these lines as well as the first in-depth characterisation 
of the novel HPV-positive PCOC lines.  
The main weakness was the small sample size which limited the power to detect 
differences in gene expression between the groups. Similarly, the data was based on one 
sequencing reaction for each cell line, which again limits statistical power. Hence these results 
should be regarded as exploratory and not definitive. To confirm these differences would 
require replication in a larger data set. 
It is difficult to be certain how well the gene expression patterns observed in cells grown 
in culture represent the gene expression patterns present in the original tumour. However, it is 
important to note that the growth conditions were standardised as far as possible (e.g. 
identical concentrations of FBS and culture conditions), and the differences observed hence 
appear likely to reflect the different molecular biology, including mutational profile and HPV 
status, of the original cells. 
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5.5.4 Conclusion 
The main conclusions are that: 
 The novel PCOC cell lines show characteristics of “typical” HPV-driven tumours (HPV 
genes expressed from integrated virus, p53 wild-type, p16 positive). 
 There was no evidence for differences in induction or repair of DNA damage, between 
HPV-positive and negative cells. 
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Chapter 6 - Investigation of PARP inhibition in oropharyngeal 
cancer cell lines 
6.1 Introduction 
HPV-positive OPSCC patients tend to respond better than HPV-negative patients to 
radiotherapy (Dayyani et al. 2010). In vitro, some HPV-positive cell lines demonstrated an 
increased sensitivity to radiation compared to HPV-negative cells together with a G2 cell cycle 
arrest (Kimple et al. 2013; Rieckmann et al. 2013; Ziemann et al. 2015). This difference in 
response has been attributed to a deficiency in repair of DNA DSB in HPV-positive cells leading, 
to an accumulation of unrepaired breaks (Rieckmann et al. 2013). However, there are 
discrepancies in the literature with regards to the events following cell cycle arrest. One study 
reported observing apoptosis (Rieckmann et al. 2013) while others did not (Kimple et al. 2013; 
Ziemann et al. 2015). 
The DSB repair deficiency in HPV-positive cells could potentially be targeted using a 
synthetic lethal therapeutic strategy. This synthetic lethal approach has already been used in 
BRCA deficient breast and ovarian cancers (Evers et al. 2008; Audeh et al. 2010). This provides 
a precedent for a similar approach in other DNA repair deficient tumours. We hypothesised 
that synthetic lethality could be achieved via the combination of SSB repair inhibition by the 
PARPi Olaparib and defective DSB repair in HPV-positive HNSCC cells.  
In vitro studies in HNSCC cells lines have concentrated on the efficacy of combining 
PARPis with radiotherapy (Güster et al. 2014). Combination treatment is also being tested in an 
ongoing clinical trial regardless of HPV status (ORCA-2). However, there is still a lack of in vitro 
data for single treatment with Olaparib, especially with regard to a potential differential 
response between HPV-positive and negative cell lines. 
An alternative explanation for the greater sensitivity of HPV-positive tumours to 
radiotherapy, might be that these tumours have low levels of functional p53 protein present 
due to incomplete degradation mediated by the HPV E6 protein, as opposed to entirely 
inactive p53 protein following p53 gene mutation (Kimple et al. 2013). Levels of wild-type p53 
were therefore also assessed. 
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The work described in this chapter aimed to determine the sensitivity of a panel of HPV-
positive and negative cell lines to a single dose of Olaparib and to investigate the mechanism 
of sensitivity.  
It was hypothesised that: 
1. Sensitivity to Olaparib would correlate with HPV status, and HPV-positive lines would 
be more sensitive to Olaparib than HPV-negative lines. 
2. HPV-positive cells would accumulate higher levels of unrepaired DNA DSB than HPV-
negative lines following treatment with Olaparib, as a consequence of the conversion 
of SSB to DSB during replication, coupled with defective repair of DSB in these lines.  
3. The accumulation of DNA DSB would be associated with cell cycle arrest and possibly 
apoptosis.  
4. In HPV-positive cells, cell cycle arrest and apoptosis may be linked to activation of p53.  
5. High basal levels of PARP1 may correlate with sensitivity to Olaparib. 
6.2 Optimisation of the Olaparib dosing protocol 
A series of experiments were performed to optimise the various assays prior to 
investigating the main aims. 
6.2.1 DMSO concentration 
Olaparib is soluble in water below 0.002 mg/ml, which was lower than the 
concentrations needed for the experiments. Therefore the first dilution step was done in 
DMSO. However this led to residual DMSO in cell culture media and the possibility of DMSO 
mediated cytotoxicity irrespective of any drug action. The survival of PCOC2 cells cultured with 
0.1%, 0.5% and 1% DMSO was measured to select a permissible final DMSO concentration 
which did not reduce survival. Cells were cultured in triplicates until 80% confluence was 
reached in the untreated control. The number of viable cells in each plate was then counted 
(Figure 6.1). A 1% concentration of DMSO reduced the number of viable cell by 43%, while 
0.5% and 0.1% DMSO caused increases of 33% and 37% of viable cells respectively. A final 
concentration of 0.1% DMSO was selected for further experiments. DMSO concentrations 
were then standardised to 0.1% in all experiments to avoid variations in DMSO levels affecting 
the results.  
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Figure 6.1: Effect of DMSO on PCOC2 cell culture 
Viability counts of PCOC2 cells cultured with varying concentrations of DMSO were normalised 
to the untreated control. Data is represented as a box plot, indicating the median, minimum 
and maximum values. Cells were plated at 500000 cells per plate and incubated until the 
untreated plate reached approximately 80% confluence (c.7 days). 3T3 cells were removed by 
washing and viable cells were stained with trypan blue and counted manually using a 
haemocytometer. The median cell number was reduced by 43% in the presence of 1% DMSO. 
Concentrations of 0.1% and 0.5% DMSO caused a 37% and 33% increase of the median cell 
number respectively.  
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6.2.2 Seeding density  
The seeding density (i.e. the number of cells initially plated) was optimised for each cell 
line as it represents a key parameter of clonogenic assays. A higher density than necessary 
could result in colonies not emerging from single cells, and could also mean control plates 
became confluent too soon. Alternatively, too low a seeding density would hamper the colony 
formation and increase the assay duration. 
Some cell lines did not sustain growth at low density, as previously reported by 
Rieckmann et al. (Rieckmann et al. 2013). This issue was addressed through the use of 3T3 
feeder cells that can promote growth by providing cell-cell contact. Clonogenic assays vary in 
duration (from 10 days to over 3 weeks), influenced by the plating efficiency and population 
doubling time of each cell line. A wide range of seeding densities (50 - 500000 cells per plate) 
were tested using UMSCC47 and UMSCC4 (data not shown). A selected narrower range of 
densities was then tested with each cell line in triplicates, with or without the presence of 3T3 
feeder cells. The appropriate seeding density for PCOC2 and PCOC3 had already been 
determined in pilot experiments (4400 cells). Hence for these lines, only the 3T3 feeder cells 
requirements were tested. UMSCC4 was already known to grow very slowly at low densities 
without 3T3 feeder cells (Prof T. Carey, personal communication). Therefore, culture without 
3T3 feeder cells was not attempted for this line. Colony morphology and density were 
observed 7 days after seeding and the media replaced. From day 10 onwards, plates were 
observed daily until the experiment was stopped, and the cells stained at day 15. Wide 
variations in optimal seeding densities were observed across the cell line panel (2500-12500 
cells/plate). UMSCC47 and UPCISCC90 seeded at 20000 cells/plate were the only lines able to 
grow without 3T3 feeder cells. Overall cell growth at the lowest densities benefited from the 
support of 3T3 feeder cells (Figure 6.2). To homogenise conditions, it was decided to optimise 
all seeding densities with the presence of 3T3 feeder cells. Based on these results, seeding 
densities of 2500 cells for UMSCC47, 12500 cells for UPCISCC90, 7500 cells for UMSCC4, 7500 
cells for UMSCC19 and 3000 cells for UMSCC74a were selected. A 10-15 days assay duration 
resulted in countable colonies for all cell lines. 
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Figure 6.2: Effect of seeding density and presence of 3T3 feeder cells on colony formation 
with UMSCC47, UPCISCC90, UMSCC4, UMSCC19 and UMSCC74a 
Cells were seeded at densities between 20000 and 1000 cells with and without the support of 
3T3 feeder cells. Plates were incubated at 37°C for 10-15 days, then stained with crystal violet 
and photographed (images above). Colonies >50 cells were counted. UMSCC19 and UMSCC74a 
did not sustain growth without feeder cells. All lines had an enhanced capacity to form 
colonies with 3T3 feeder cells.  
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6.3 Colony formation capacity after a single dose of Olaparib 
The effect of treatment with Olaparib was assessed using clonogenic assays in a panel of 
4 HPV-positive and 3 HPV-negative cells lines (as described in Chapter 5). In addition, normal 
non-malignant keratinocyte cells (HEKn) were included as a control. One representative 
example of raw results using PCOC2 is shown in Figure 6.3. Examples for the remaining cell 
lines can be found in Appendix 2.  
A wide range of responses to treatment was evident across the cell line panel (Figure 
6.4). Within the HPV-positive lines, two groups with distinct colony formation capacity in 
response to Olaparib were present. PCOC2 and UPCISCC90 were the most sensitive lines. Their 
Surviving Fraction (SF) decreased in a dose-dependent manner with increasing exposure to 
Olaparib. A single treatment of 0.1 µM Olaparib reduced their mean SF by 30.85% and 45.8% 
respectively. The only significant difference between these lines was detected after 0.1 µM 
treatment (two way ANOVA p<0.05). PCOC2 and UPCISCC90 were also significantly more 
sensitive than the other HPV-positive lines at doses over 0.1 µM (p<0.05; two way ANOVA with 
Bonferroni post-test; Figure 6.4 A).  
PCOC3 and UMSCC47 demonstrated lower sensitivity to Olaparib treatment compared 
to UPCISCC90 and PCOC2. These lines followed a similar dose response with no significant 
differences between them detected below 5 µM. The sensitivity increased at high doses with 
mean SF at 10 µM of 41.3% for UMSCC47 and 21.4% for PCOC3. UMSCC47 was only sensitive 
at 5 and 10 µM Olaparib treatment (one way ANOVA p≤0.01). While PCOC3 was sensitive from 
1 µM (one way ANOVA p<0.05).  
HPV-negative lines also varied in their colony formation capacity following treatment 
with Olaparib (Figure 6.4 B). Two lines, UMSCC4 and UMSCC19, were not sensitive to 
treatment with doses below 5 µM. HEKn and UMSCC74a displayed higher Olaparib sensitivity 
compared to UMSCC4 and UMSCC19. They followed a similar dose response with no 
differences detected between the two curves (two way ANOVA p<0.05). Individually, 
UMSCC74a was significantly sensitive from 0.5 µM while HEKn displayed sensitivity at all doses 
(one way ANOVA p<0.05). This possibly suggested that UMSCC74a was an unusual case and did 
not behave like the other HPV-negative tumour cell lines included in the panel. The highest 
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doses of Olaparib tested (10 μM) caused a reduction of colony formation of nearly 100% in 5/8 
lines. 
In summary, three distinct categories of drug response were observed. These were 
defined according to sensitivity to Olaparib at 0.5-1 μM, at which the widest range of 
sensitivities were observed (Figure 6.5). Resistant cell lines (SF>80%) included the HPV-positive 
PCOC3 and UMSCC47 plus the HPV-negative lines UMSCC19 and UMSCC4, medium sensitivity 
cell lines (SF 40-80%) included HPV-negative HEKn and UMSCC74a, and sensitive cell lines 
(SF<40%) included HPV-positive cell lines PCOC2 and UPCISCC90. 
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Figure 6.3: Example of PCOC2 clonogenic assay result 
Cells were plated at low density, at 24 h media with/without Oparib was added, then plates 
were incubated for 10-15 days. Plates were stained using crystal violet and photographed 
(images above). Colonies of >50 cells were counted. The ability of PCOC2 to form colonies 
clearly decreased in a dose-dependent manner in response to increasing concentrations of 
Olaparib.  
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Figure 6.4: Surviving fractions of the cell line panel in response to Olaparib (by HPV status) 
The results presented are representative of at least 3 repeats, including triplicates within each 
experiment (i.e. there are a minimum of 9 data points per condition). Statistical significance 
between the lines was assessed using two-way ANOVA with Bonferroni post-test. Error bars 
indicate SD. 
Panel A (HPV-positive cell lines): The colony formation capacity of PCOC2 and UPCISCC90 was 
reduced compared to PCOC3 and UMSCC47 following a single dose exposure of Olaparib from 
0.1 μM to 10 μM. As an example the result of the comparaison between UPCISCC90 and 
UMSCC47 is illustrated (*** p0.001, *p<0.05).  
Panel B (HPV-negative cell lines): UMSCC19 and UMSCC4 were least sensitive to Olaparib. 
Their colony formation capacity was reduced starting at 5 μM and 10 µM, whilst UMSCC74a 
and HEKn were more sensitive at lower doses. As an example the result of the comparison 
between UMSCC19 and UMSCC74a is illustrated (*** p0.001, *p<0.05).   
A 
B 
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Figure 6.5: Surviving fractions of the cell line panel in response to Olaparib (all lines) 
All lines were sensitive to high doses of Olaparib (10 μM), however at doses between 0.5-1μM, 
the surviving fractions differed significantly between lines (ANOVA p<0.001). The cell lines 
were divided into 3 categories based on sensitivity at 0.5-1 μM. The “sensitive” (SF<40%) cell 
lines were two HPV-positive lines (UPCISCC90 and PCOC2); “intermediate” (SF 40-80%) cell 
lines were an HPV-negative line and normal human epidermal keratinocytes (UMSCC74a and 
HEKn); and “resistant” (SF>80%) lines included 2 HPV-positive and 2 HPV-negative lines 
(UMSCC19, 4, 47 and PCOC3). 
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6.4 DSB detection protocol development 
Measurement of phosphorylation of histone H2AX is a sensitive method for quantifying 
DNA DSB (Sharma et al. 2012). Following induction of DSB, serine 139 located on the C-
terminal tail of the H2AX histone is quickly phosphorylated by kinases including ATM and ATR. 
This modified histone is referred to as -H2AX. The presence of -H2AX facilitates chromatin 
re-organisation to allow access for DNA damage repair proteins. De-phosphorylation occurs 
once the DSB has been repaired. -H2AX can hence be used as an indirect marker for the 
presence of DSB (Bonner et al. 2008). To allow quantification of -H2AX, cells require lysis to 
release the nuclei, followed by staining with an anti-serine 139 -H2AX antibody and/or a DNA 
stain before analysis by flow cytometry. 
6.4.1 Lysis and staining specificity 
Whole cells and nuclei populations were stained and analysed separately by flow 
cytometry to evaluate the lysis efficiency and staining specificity. HeLa cells were used for 
protocol development experiments as they were easily available. For assay optimisation, cells 
were treated with Ionising radiation (IR), rather than Olaparib, as IR is a well-characterised 
inducer of DNA damage, including DNA DSB. Cells were left untreated or exposed to 10 Gy IR 
and used after 30 min. Visualisation of data on a forward versus side scatter plot resulted in 
two distinct populations (Figure 6.6 A). The population comprised of whole cells was larger and 
more granular than the nuclei. Staining patterns also differed between whole cells and nuclei. 
The staining of whole cells using the -H2AX antibody was minimal, indicating the presence of 
mostly intact cell membranes (Figure 6.6 B). Staining for -H2AX, indicating the presence of 
DSB, was detected in the nuclei population, and increased following 10 Gy radiation (Figure 6.6 
B).  
In summary, these experiments demonstrated that the cell lysis procedure was effective 
in producing a nuclei population, and that staining with the -H2AX antibody appeared to 
correlate with the presence of DNA DSB. 
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Figure 6.6: Visualisation of HeLa whole cells and nuclei population and quantification of DSB 
following irradiation 
A: The gated nuclei population (first panel) and the whole cells population (second panel) and 
both populations (third panel). Cells and nuclei are distinguished by their size and granulosity. 
B: Shows background and staining with -H2AX antibody in whole cells (first panel) and nuclei 
(second panel) untreated and after 10 Gy IR. Fluorecence is minimal in whole cells but 
detected in untreated in irradiated nuclei. This demonstrated increased antibody binding 
following induction of DSB.  
B 
A 
B 
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6.4.2 Selection of experimental time-points 
In order to observe unresolved DSB, present due to possible defects in DNA repair, the 
timeframe of the experiment was optimised. UPCISCC90 was selected for these experiments as 
it showed sensitivity to Olaparib in the clonogenic assay (HeLa would be inappropriate as its 
growth rate was much faster than the OPSCC lines). The cell cycle pattern and -H2AX 
response following treatment with 0.1, 1 and 10 µM Olaparib were measured after 12, 18, 24, 
and 48 h. Olaparib doses of 0.1, 1, and 10 µM were selected based on the clonogenic assay 
results as cell lines displayed a wide range of sensitivity at these doses. 
The topoisomerase II inhibitor Etoposide was used as a positive control. Etoposide acts 
by stabilising DNA/topoisomerase II complexes, thereby inhibiting the ligation step in repair of 
topoisomerase induced DSB. The use of this drug specifically creates DSB, which can 
potentially be repaired using either HR or NHEJ. High doses (25 µM) of Etoposide were used to 
specifically induce DSB and increase -H2AX levels in the assay.  
Variations in the amount of -H2AX were not detected following low dose treatment 
with Olaparib (0.1 and 1 µM) (Figure 6.7 A). However, treatment with 10 µM Olaparib resulted 
in 1.8 and 2.5 fold increases in -H2AX after 24 h and 48 h respectively (the most noticeable 
differences in the amount of -H2AX detected compared to the vehicle occurred after 24 h and 
48 h). The positive control Etoposide was shown to be an appropriate control, as it induced an 
accumulation of -H2AX detectable after 12 h and this increased over time.  
The effects of Olaparib on cell cycle distribution were also assessed. An increase in the 
proportion of cells in G2 and S-phase was observed after 24 h and 48 h for 10 µM Olaparib 
treatment whilst Etoposide caused a complete G2 arrest after 48 h (Figure 6.7 B). For further 
experiments, 24 h and 48 h were selected as appropriate time-points, as they showed the 
highest accumulation of -H2AX indicating the presence of unrepaired DSB. 
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Figure 6.7: -H2AX and cell cycle following Olaparib treatment 
A: The Mean Fluorescence Intensity (MFI) of the -H2AX FITC labelled antibody was measured 
12, 18, 24 and 48 h after Olaparib (0-10 μM) or Etoposide (25 μM) treatment. Each value was 
normalised against the vehicle control. Increased fluorescence was observed after 24 and 48 h, 
indicating unrepaired DSB.  
B: Fluorescence of 7-AAD versus cell count representing the cell cycle after 48 h of treatment 
with Olaparib or Etoposide. The proportion of cells in S and G2-phases increased after 
treatment with 1 and 10 μM Olaparib. Etoposide caused a G2 arrest. 
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B 
Chapter 6  Investigation of PARP inhibition in oropharyngeal cancer cell lines 
 
162 
 
6.4.3 Effect of 3T3 feeder cells in PCOC culture on -H2AX level 
PCOC2 and 3 were cultured with the support of 3T3 feeder cells. These cells were 
rendered post-mitotic by administration of a 60 Gy dose of IR which caused sufficient DNA 
damage to prevent replication in culture. Most 3T3 feeder cells were removed using 
differential trypsinisation but a small number may have remained mixed with PCOC cells. 
Levels of unrepaired DSB in the contaminating 3T3 feeder cells could therefore potentially 
have influenced the results of the PCOC experiments. To assess whether this was a significant 
influence, an experiment was performed to investigate the -H2AX and cell cycle staining 
patterns of feeder cells. The general gating strategy used for all lines is shown in Figure 6.8.  
The staining patterns were compared for nuclei populations obtained from: (1) PCOC2 
cultured with 3T3 feeder cells; (2) PCOC2 cultured without 3T3 feeder cells; and (3) 3T3 feeder 
cells alone. The scatter plot illustrating the DNA content versus amount of -H2AX enabled 
discrimination between PCOC2 and 3T3 feeder cells. 3T3 feeder cells had a higher DNA content 
and due to irradiation displayed a higher level of -H2AX (Figure 6.9 A and B). The mouse 
genome is smaller than the human one (2.8109 bp versus 3.3109 bp). However, the 3T3 cell 
line is tetraploid which is consistent with the higher amount of DNA observed in the 
experiment (Leibiger et al. 2013). The more precise gating of the PCOC2 population enabled 
the elimination of the extra peaks in the cell cycle pattern caused by the 3T3 feeder cells 
(Figure 6.9 C). The -H2AX antibody used has been described as human-specific by the 
manufacturer, but with a disclaimer that due to close similarities there might be cross-species 
reactivity. This has clearly been observed in this case. It was demonstrated in previous 
experiments that PCOC cells do not grow well, especially at low plating densities, without 3T3 
feeder cells. Hence removing them from the culture was therefore undesirable. The gating 
process shown here was used in all further PCOC experiments. 
6.5 DNA double-strand break repair 
6.5.1 Basal level of -H2AX and cell cycle distribution differs between cell lines 
All lines had a baseline -H2AX expression which indicated the formation and repair of 
DSB as part of the normal cell processes. Different levels of expression were observed between 
the lines. UMSCC19 showed a significantly higher level of -H2AX than PCOC3, UMSCC47, 
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UPCISCC90 and UMSCC4 (p<0.05, result of ANOVA and Bonferroni’s post-test). PCOC2, 
UMSCC74a and the normal keratinocyte line HEKn showed intermediate levels of -H2AX 
(Figure 6.10 A).  
The cell cycle was not synchronised prior to these experiments and, perhaps because of 
this, variations in distribution were present between cell lines, with HEKn and PCOC3 showing 
the highest proportion of cells in G1 (Figure 6.10 B).  
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Figure 6.8: General gating strategy 
The fluorescence in each channel was measured by flow cytometry (BD FACS Canto) and the 
data analysis carried out using FlowJo v10 software.  
A: Within each experiment, the gates were fitted to the untreated and unstained control 
before being applied to the other samples. The nuclei population was distinguished from 
debris on the forward vs side scatter plot (Panel 1). Doublets were excluded based on the 
forward scatter area vs height plot (Panel 2). The Gamma-H2AX + gate was fitted by excluding 
the basal fluorescence in the FITC channel (Panel 3). 
B: The MFI was calculated in the FITC-A channel and used as a representation of the Gamma-
H2AX level (Panel 1). The cell cycle pattern was visualised in the single nuclei population using 
the AmCyan channel (panel 2).  
A 
B 
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Figure 6.9: Gating strategy to reduce 3T3 feeder cells influence on measurement of the cell 
cycle 
A: Gating of a population of nuclei isolated from PCOC2 cells cultured alone. DAPI represents 
the DNA content and the FITC labelled -H2AX antibody the presence of DSB. 
B: Gating of a population of nuclei isolated from PCOC2 cells cultured with 3T3 feeder cells. 
Two populations can be distinguished; 3T3 feeder cells have a higher DNA content and 
elevated levels of DSB. 
C: The first panel shows the cell cycle pattern of PCOC2 and 3T3 feeder cells analysed together. 
Two extra peaks (black arrows) are visible on the cell cycle pattern. The middle panel shows 
the profile of 3T3 feeder cells. The G1 and G2 peaks indicated by black arrows correspond to 
the extra peaks visible in the first panel. The third panel shows the PCOC2 gate analysed on its 
own, with the extra peaks no longer visible. 
  
B A 
C 
B 
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Figure 6.10: Basal level of -H2AX and cell cycle distribution differed between cell lines 
A: -H2AX MFI representative of at least 3 experiments are plotted for each untreated cell line 
with the standard deviation. The basal -H2AX level differed between lines. UMSCC19 had an 
elevated level compared to PCOC3, UMSCC47, UPCISCC90 and UMSCC4 (ANOVA and 
Bonferroni’s post test p<0.05).  
B: Histogram showing cell cycle distribution for the cell line panel in untreated unsynchronised 
cells. Data is representative of at least 3 experiments. 
  
B 
A 
B 
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6.5.2 High doses of Olaparib lead to unrepaired DSB 
Low doses of Olaparib treatment (0.1 and 1 µM) did not lead to an increase in -H2AX in 
any of the cell lines, compared to the vehicle control. However increases in -H2AX after 10 
µM Olaparib treatment were observed, and these varied between cell lines and over time. 
Representative experiments for each cell line are shown in Figure 6.11 to Figure 6.14 A. The 
data are summarised in Figure 6.15 and Figure 6.16. A significant increase in the level of -
H2AX after 10 µM Olaparib compared to vehicle control was detected in the HPV-positive cell 
line UPCISCC90, and the HPV-negative cells UMSCC4, UMSCC19 and UMSCC74a both 24 h and 
48 h after treatment. The highest increase was observed in UPCISCC90, in which the level of -
H2AX was 1.5 and 2.3 fold higher than observed in the vehicle control after 24 h and 48 h 
respectively. Among the HPV-negative lines, the highest increase was seen in UMSCC74a with 
a 0.6 and 0.9 fold increase compared to vehicle after 24 h and 48 h.  
Levels of -H2AX were elevated in PCOC2 and PCOC3 24 h after treatment (there was 
also a tendency for -H2AX to increase after 48 h in PCOC2). Normal keratinocytes (HEKn) cells 
were included to give an indication of the rate of DNA repair in “normal” cells. The HEKn 
displayed significant -H2AX increase after 24 h 10 μM Olaparib compared to vehicle and 1 μM 
Olaparib, but this was no longer visible after 48 h. This appears to indicate functioning repair of 
DSB in these 3 cell lines. 
Following Etoposide treatment (25 µM), a significant increase in -H2AX was detected in 
all tumour cell lines (after both 24 h and 48 h). In HEKn -H2AX increased after 24 h but only in 
a non-significant tendency after 48 h. This confirmed the assay was functioning as expected, 
and that detected presence of unrepaired DSB in all lines. 
In summary, the quantification of -H2AX level following Olaparib treatment showed 
HPV-positive cells did not accumulate higher levels of unrepaired DNA DSB than HPV-negative 
lines. Forty-eight hours after 10 μM Olaparib treatment, substantial levels of unrepaired DSB 
were evident in 2/4 HPV-positive lines and 3/3 HPV-negative lines.   
A 
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Figure 6.11: PCOC2 and PCOC3 -H2AX and cell cycle analysis 
Histogram overlay representation of the -H2AX expression and cell cycle distribution 24 h and 
48 h after treatment of A: PCOC2 and B: PCOC3.  
A 
B 
A 
B 
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Figure 6.12: UMSCC47 and UPCISCC90 -H2AX and cell cycle analysis 
Histogram overlay representation of the -H2AX expression and cell cycle distribution 24 h and 
48 h after treatment of A: UMSCC47 and B: UPCISCC90.  
A 
B 
A 
B 
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Figure 6.13: UMSCC4 and UMSCC19 -H2AX and cell cycle analysis 
Histogram overlay representation of the -H2AX expression and cell cycle distribution 24 h and 
48 h after treatment of A: UMSCC4 and B: UMSCC19.  
A 
B 
A 
B 
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Figure 6.14: UMSCC74a and HEKn -H2AX and cell cycle analysis 
Histogram overlay representation of the -H2AX expression and cell cycle distribution 24 h and 
48 h after treatment of A: UMSCC74a and B: HEKn.  
B 
A A 
B 
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Figure 6.15: -H2AX measurement 24 h after Olaparib treatment 
Data is representative of at least 3 independent experiments. The MFI normalised to vehicle is 
shown for each cell line after treatment with 0.1 μM 1 μM and 10 μM Olaparib. 25 μM 
Etoposide was used as a positive control. Etoposide treatment resulted in a significant -H2AX 
increase in all lines (ANOVA and Tukey post-test, * P < 0.05, ** P<0.01, *** P<0.001). 
A: 10 μM Olaparib treatment caused a significant increase in the amount of -H2AX compared 
to the vehicle in the HPV-positive lines PCOC2, UPCISCC90 and PCOC3 but not in UMSCC47. 
B: Following 10 μM Olaparib, the amount of -H2AX significantly increased compared to 
vehicle in the HPV-negative lines UMSCC4, UMSCC19 and UMSCC74a.  
  
B 
A 
B 
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Figure 6.16: -H2AX measurement 48 h after Olaparib treatment 
Data is representative of at least 3 independent experiments. The MFI normalised to vehicle is 
shown for each cell line after treatment with 0.1 μM 1 μM and 10 μM Olaparib. 25 μM 
Etoposide was used as a positive control. Etoposide treatment resulted in a significant -H2AX 
increase in all lines except HEKn (ANOVA and Tukey post-test, * p<0.05, ** P<0.01, *** 
P<0.001). 
A: The highest increase in the amount of -H2AX detected compared to vehicle in HPV-positive 
lines occurred in UPCISCC90. A significant increase was observed in UMSCC47 after 10 μM 
compared to vehicle, which was not present after 24 h.  
B: Within the HPV-negative lines, a significant increase in -H2AX at 10 μM compared to 
vehicle was observed in UMSCC4, UMSCC19 and UMSCC74a. This was not detected in HEKn.  
  
A 
A 
B 
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6.5.3 High doses of Olaparib lead to cell cycle arrest 
The effect of the DNA damage caused by Olaparib treatment on progression through the 
cell cycle was investigated using flow cytometry. One representative experiment for each cell 
line is shown in Figures 6.11-6.14 B, and summarised in Figure 6.17 and Figure 6.18. 
The untreated samples showed some variations in cell cycle distribution among the cell 
lines. It was very noticeable that HEKn showed a much higher proportion of cells in G1 than 
the tumour lines, suggesting a lower proportion of actively cycling cells. Among the tumour 
lines, PCOC3 and UMSCC47 showed the highest G1 fractions, suggesting a lower rate of 
proliferation in these lines. 
For all the cell lines, cell cycle distribution was not affected by treatment with 0.1 and 1 
µM Olaparib for 24 h or 48 h. However, treatment with 10 µM Olaparib resulted in significant 
changes in cell cycle distribution in some cell lines. Olaparib treatment did not significantly 
affect the cell cycle distribution of PCOC3, or the HPV-negative lines UMSCC4, UMSCC19 and 
UMSCC74a. PCOC2 and HEKn cells accumulated in G2 24 h after treatment, however, the 
distribution was similar to the vehicle after 48 h. Significant effects on cell cycle distribution 
were detected in UPCISCC90, cells accumulated in S-phase after 24 h and G2 after 48 h. This 
pattern suggests cells slowing in the cycle to allow repair during S-phase, followed by G2 arrest 
due to the accumulation of unresolved DSB. UMSCC47 cells accumulated in G2 after 48 h 
treatment.  
In summary, only the HPV-positive cell lines UPCISCC90 and UMSCC47 showed evidence 
of significant cell cycle arrest 48 h after treatment with Olaparib.  
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Figure 6.17: Cell cycle distribution after 24 h Olaparib treatment 
Data is representative of at least 3 independent experiments. The percentage of cells in G1, S 
and G2-phases is shown for each cell line after treatment with 0.1 μM, 1 μM and 10 μM 
Olaparib. 25 μM Etoposide was used as a positive control.  
A: Within HPV-positive lines, significant variations in cell cycle distribution were detected in 
PCOC2 and UPCISCC90 after 10 μM Olaparib treatment. This was reflected by an increased 
proportion of cells in G2 for PCOC2 and in S-phase for UPCISCC90.  
B: Within the HPV-negative lines, a significant increase in cells in G2 was present in HEKn 
compared to vehicle . A tendency for cells to accumulate in S-phase was observed in UMSCC4 
but this was not statistically significant. 
  
A 
B 
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Figure 6.18: Cell cycle distribution after 48 h Olaparib treatment 
Data is representative of at least 3 independent experiments. The percentage of cells in G1, S 
and G2-phases is shown for each cell line after treatment with 0.1 μM 1 μM and 10 μM 
Olaparib. 25 μM Etoposide was used as a positive control.  
A: Within HPV-positive lines, significant changes in cell cycle distribution were detected in 
UPCISCC90 and UMSCC47 after 10 μM Olaparib treatment. This was reflected by an increased 
proportion of cells in both S and G2 in UPCISCC90 and of G2 in UMSCC47.  
B: Within the HPV-negative lines, no significant cell cycle alteration were detetced between 
vehicle and 10 µM treatment. A tendency of cell accumulation in both S and G2 was observed 
in UMSCC4 and of G2 accumulation in UMSCC74a without being statistically significant. 
  
B 
A 
B 
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6.6 Molecular effects of Olaparib treatment 
Cleavage of PARP1 by caspases is considered to be a hallmark of apoptosis (Kaufmann et 
al. 1993). Cleavage of PARP1, mediated by caspase 3, yields two fragments of 24 and 89 kDa. 
Detection of the 89 kDa cleaved PARP1 fragment provided an opportunity to assess apoptosis 
in the cell line panel. Levels of p53 and phospho-p53 (p-p53) were assessed to determine 
whether any response to Olaparib treatment was mediated through p53 dependent or 
independent pathways. 
6.6.1 Total and cleaved PARP1 expression in untreated cell lines  
PARP1 expression was first examined in cell lysates from untreated cell lines. This 
analysis was performed to determine whether the basal level of PARP1 correlated with 
sensitivity to Olaparib. Total PARP1 western blot images and densitometry quantification plots 
are presented in Figure 6.19. There was wide variation in the levels of PARP1 between 
individual cell lines. It appeared that the basal level of PARP1 in untreated cells was highest in 
the HPV-positive line UPCISCC90 and in the HPV-negative line UMSCC19, the other lines 
showed approximately equal levels of expression. PARP1 levels did not show an obvious 
correlation with the HPV status of the cell lines. 
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Figure 6.19: Basal PARP1 expression in untreated HPV-positive and negative cell lines 
A: PARP1 western blot image of PCOC2, PCOC3, UMSCC47, UPCISCC90, UMSCC4, UMSCC19, 
UMSCC74a, HEKn untreated and HEKn 10 Gy. β-actin was used as a loading control and 
indicated even loading between wells. 
B: The intensity of the western bloting bands as quantified in relation to β-actin level using 
Image studio Lite. The highest basal levels of PARP1 were seen in HPV-positive UPCISCC90 and 
HPV-negative UMSCC19 cells lines. 10 Gy treatment did not affect the HEKn PARP level. 
  
A 
B B 
A 
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6.6.2 Total and cleaved PARP1, p53 and p-p53 expression in Olaparib treated cell lines 
A condensed summary of the Western blot images (48 h only) is shown in Figure 6.20, 
and the full dataset in Figures 6.21 to 6.28. In PCOC2, PARP1 expression showed no changes 
after 24 h treatment. However after 48 h, PARP1 levels increased in concert with Olaparib 
concentration. PARP1 also appeared significantly induced following 10 Gy IR. The 89 bp 
cleaved form of PARP1 was not detected in either untreated or Olaparib treated cells. 
However, cleaved PARP1 was clearly present after 10 Gy IR indicating the induction of 
apoptosis in irradiated but not Olaparib treated cells. Neither p53 nor p-p53 were detected in 
treated or untreated PCOC2 cells, but both were present in the HEKn 10 Gy positive control. 
This showed the absence of a p53 dependant response to Olaparib treatment at these 
timepoints. 
No correlation between Olaparib dose and PARP1 expression was present in PCOC3. 
Cleaved PARP1 was not detected in this cell line under any condition (light unspecific bands 
were not taken into account). Neither p53 nor p-p53 expression were induced by Olaparib 
treatment or 10 Gy IR of PCOC3 but were present in the HEKn control. A similar pattern of 
expression was seen in UPCISCC90, indicating the absence of apoptosis or p53 dependent 
response in both of these lines after 24 h and 48 h Olaparib treatment. 
In UMSCC47, an increase in PARP1 expression was seen after 10 µM Olaparib (48 h) and 
following 10 Gy IR. Cleaved PARP1, p53 and p-p53 were not present. This also showed an 
absence of apoptosis or p53 dependent response. 
Among the HPV-negative cell lines, UMSCC4 and UMSCC19, there was no discernible 
dose-response relationship between Olaparib and PARP1. Cleaved PARP1 was not clearly 
detected. Some weak bands of variable sizes were visible around 89 kDa which are likely to be 
caused by the background and non-specific binding. Neither p53 nor p-p53 were detected. This 
indicated an absence of apoptosis or p53 dependent response in these cell lines. 
PARP1 levels did not change after Olaparib treatment in UMSCC74a. However, both p53 
and p-p53 appeared to be induced following 10 µM Olaparib (48 h) and 10 Gy IR, which 
suggests p53 mediated signalling was active in these cells but did not result in apoptosis. 
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In the HEKn cells, there was no dose-response relationship between Olaparib and 
PARP1, and PARP1 cleavage and p53 signalling were not induced by Olaparib. As previously 
observed, 10 Gy did result in accumulation of p53 and signalling via p-p53. This did not 
however result in apoptosis, as indicated by the absence of cleaved PARP1. 
In summary, there was no evidence for induction of apoptosis (cleaved PARP1) in any of 
the cell lines following treatment with Olaparib. Furthermore, treatment with Olaparib was not 
associated with p53 reactivation (accumulation of p53 or presence of p-p53) in HPV-positive 
cell lines. However, p53 and p-p53 protein did appear to accumulate in UMSCC74a (HPV-
negative) following treatment with 10 μM Olaparib. 
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Figure 6.20: Protein levels of PARP1, cleaved PARP1, p53 and phospho-p53 48 h following 
Olaparib treatment 
This figure shows PARP1, cleaved PARP1, p53 and phospho-p53 western blot images for all cell 
lines 48 h after Olaparib treatment. The cell lines treated with 10 Gy IR collected af 24 h 
following IR were included as controls. Two membranes were used, one for PARP1, cleaved 
PARP1 (18 min exposure each), p-p53 (25 min exposure) and β-actin 1 (2 min exposure) and 
the other for p53 (25 min exposure) and β-Actin 2 (2 min exposure).  
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Figure 6.21: PCOC2 PARP1, cleaved PARP1, p53 and p-p53 western blot images and intensity 
plots after 24 h and 48 h Olaparib treatment 
A: PARP1, cleaved PARP1, p53 and p-p53 western blot images of PCOC2 after 24 h and 48 h 
Olaparib treatment. The cell lines treated with 10 Gy and HEKn treated with 10 Gy collected 
after 24 h were used as controls. Two membranes were used, one for PARP1, cleaved PARP1 
(18 min exposure each), p-p53 (25 min exposure) and β-actin 1 (2 min exposure) and the other 
for p53 (25 min exposure) and β-Actin 2 (2 min exposure).  
B: The intensity of the western blotting bands as quantified in relation to β-actin level using 
Image studio Lite.   
A 
B 
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Figure 6.22: PCOC3 PARP1, cleaved PARP1, p53 and p-p53 western blot images and intensity 
plots after 24 h and 48 h Olaparib treatment 
A: PARP1, cleaved PARP1, p53 and p-p53 western blot images of PCOC3 after 24 h and 48 h 
Olaparib treatment. The cell line treated and HEKn treated with 10 Gy and collected after 24 h 
were used as controls. Two membranes were used, one for PARP1, cleaved PARP1 (18 min 
exposure each), p-p53 (25 min exposure) and β-actin 1 (2 min exposure) and the other for p53 
(25 min exposure) and β-Actin 2 (2 min exposure).  
B: The intensity of the western blotting bands as quantified in relation to β-actin level using 
Image studio Lite.  
A 
B 
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Figure 6.23: UMSCC47 PARP1, cleaved PARP1, p53 and p-p53 western blot images and 
intensity plots after 24 h and 48 h Olaparib treatment 
A: PARP1, cleaved PARP1, p53 and p-p53 western blot images of UMSCC47 after 24 h and 48 h 
Olaparib treatment. The cell line and HEKn treated with 10 Gy and collected after 24 h were 
used as controls. Two membranes were used, one for PARP1, cleaved PARP1 (18 min exposure 
each), p-p53 (25 min exposure) and β-actin 1 (2 min exposure) and the other for p53 (25 min 
exposure) and β-Actin 2 (2 min exposure).  
B: The intensity of the western blotting bands as quantified in relation to β-actin level using 
Image studio Lite.  
A 
B 
  
  
A 
B 
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Figure 6.24: UPCISCC90 PARP1, cleaved PARP1, p53 and p-p53 western blot images and 
intensity plots after 24 h and 48 h Olaparib treatment 
A: PARP1, cleaved PARP1, p53 and p-p53 western blot images of UPCISCC90 after 24 h and 48 
h Olaparib treatment. The cell line and HEKn treated with 10 Gy and collected after 24 h were 
used as controls. Two membranes were used, one for PARP1, cleaved PARP1 (18 min exposure 
each), p-p53 (25 min exposure) and β-actin 1 (2 min exposure) and the other for p53 (25 min 
exposure) and β-Actin 2 (2 min exposure).  
B: The intensity of the western blotting bands as quantified in relation to β-actin level using 
Image studio Lite.   
  
A 
B 
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Figure 6.25: UMSCC4 PARP1, cleaved PARP1, p53 and p-p53 western blot images and 
intensity plots after 24 h and 48 h Olaparib treatment 
A: PARP1, cleaved PARP1, p53 and p-p53 western blot images of UMSCC4 after 24 h and 48 h 
Olaparib treatment. The cell line and HEKn treated with 10 Gy and collected after 24 h were 
used as controls. Two membranes were used, one for PARP1, cleaved PARP1 (18 min exposure 
each), p-p53 (25 min exposure) and β-actin 1 (2 min exposure) and the other for p53 (25 min 
exposure) and β-Actin 2 (2 min exposure).  
B: The intensity of the western blotting bands as quantified in relation to β-actin level using 
Image studio Lite.  
A 
B 
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Figure 6.26: UMSCC19 PARP1, cleaved PARP1, p53 and p-p53 western blot images and 
intensity plots after 24 h and 48 h Olaparib treatment 
A: PARP1, cleaved PARP1, p53 and p-p53 western blot images of UMSCC19 after 24 h and 48 h 
Olaparib treatment. The cell line and HEKn treated with 10 Gy and collected after 24 h were 
used as controls. Two membranes were used, one for PARP1, cleaved PARP1 (18 min exposure 
each), p-p53 (25 min exposure) and β-actin 1 (2 min exposure) and the other for p53 (25 min 
exposure) and β-Actin 2 (2 min exposure).  
B: The intensity of the western blotting bands as quantified in relation to β-actin level using 
Image studio Lite.  
A 
B 
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Figure 6.27: UMSCC74a PARP1, cleaved PARP1, p53 and p-p53 western blot images and 
intensity plots after 24 h and 48 h Olaparib treatment 
A: PARP1, cleaved PARP1, p53 and p-p53 western blot images of UMSCC74a after 24 h and 48 
h Olaparib treatment. The cell line and HEKn treated with 10 Gy and collected after 24 h were 
used as controls. Two membranes were used, one for PARP1, cleaved PARP1 (18 min exposure 
each), p-p53 (25 min exposure) and β-actin 1 (2 min exposure) and the other for p53 (25 min 
exposure) and β-Actin 2 (2 min exposure).  
B: The intensity of the western blotting bands as quantified in relation to β-actin level using 
Image studio Lite.  
A 
B 
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Figure 6.28: HEKn PARP1, cleaved PARP1, p53 and p-p53 western blot images and intensity 
plots after 24 h and 48 h Olaparib treatment 
A: PARP1, cleaved PARP1, p53 and p-p53 western blot images of HEKn after 24 h and 48 h 
Olaparib treatment. The cell line treated 10 Gy and collected after 24 h was used as a control. 
Two membranes were used, one for PARP1, cleaved PARP1 (18 min exposure each), p-p53 (25 
min exposure) and β-actin 1 (2 min exposure) and the other for p53 (25 min exposure) and β-
Actin 2 (2 min exposure).  
B: The intensity of the western blotting bands as quantified in relation to β-actin level using 
Image studio Lite.  
A 
B 
  
  
A 
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6.7 Summary of results 
The results of the assays described in this chapter are summarised in Table 6.1. 
Table 6.1: Data summary 
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PCOC3                
UMSCC47                
UPCISCC90         +       
UMSCC4                
UMSCC19         +       
UMSCC74a                
HEKn                
aPurple HPV-positive, Blue HPV-negative, Grey normal. 
1Red indicates resistant cell lines (SF>80%); blue indicates medium sensitivity cell lines (SF 40-
80%); green indicates sensitive cell lines (SF<40%). Colours are specific to indicated dose and 
timepoint. 
2Green indicates that the relevant cell line accumulated DSB at the indicated dose and time-
point.  
3Green indicates that the relevant cell line showed significant changes to cell cycle distribution 
at the indicated dose and time-point.  
4Green indicates that the relevant cell line showed significant changes to cell cycle distribution 
at the indicated dose and time-point.  
5Green indicates that the relevant cell line showed an increase in PARP1 protein level at the 
indicated dose and time-point (+ indicates above average levels).  
6Green indicates that the relevant cell line accumulated p53 protein at the indicated dose and 
time-point.  
7Green indicates that the relevant cell line accumulated p-p53 protein at the indicated dose 
and time-point.  
8Green indicates that the relevant cell line accumulated cleaved PARP1 protein at the indicated 
dose and time-point.  
a Indicates dose of Olaparib. 
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6.8 Discussion 
6.8.1 Main findings 
With reference to the original hypotheses, these investigations established that: 
 The cell lines displayed a wide range of Olaparib sensitivities: 
o Two HPV-positive lines (PCOC2 and UPCISCC90), the HPV-negative line 
UMSCC74a and the normal keratinocytes HEKn were sensitive to the lowest 
dose tested (0.1 μM). 
o All lines were sensitive to 10 μM treatment. 
 Olaparib sensitivity did not correlate with HPV status, although the most sensitive lines 
were HPV-positive. Three groups were apparent after 0.5 μM and 1 μM treatment: 
o Sensitive: two HPV-positive lines. 
o Intermediate sensitivity: one HPV-negative line and normal keratinocytes. 
o Resistant: 2 HPV-positive and 2 HPV-negative lines. 
 Following treatment with Olaparib, HPV-positive cells did not accumulate higher levels 
of unrepaired DNA DSB than HPV-negative lines. Forty-eight hours after 10 μM 
Olaparib treatment, substantial levels of unrepaired DSB were evident in 2/4 HPV-
positive lines and 3/3 HPV-negative lines. 
 Among the five cell lines that accumulated DSB, only the HPV-positive cell lines 
UPCISCC90 and UMSCC47 showed evidence of significant cell cycle arrest 48 h after 
treatment.  
 There was a partial correlation between basal levels of PARP1 and sensitivity to 
Olaparib. UPCISCC90 showed the highest basal level and was the most sensitive cell 
line. However, UMSCC19 also showed relatively high basal level of PARP1 but was one 
of the least sensitive lines.  
 There was no evidence of apoptosis induction (cleaved PARP1) in any of the cell lines 
following treatment with Olaparib. 
 Treatment with Olaparib was not associated with p53 reactivation (accumulation of 
p53 or presence of p-p53) in HPV-positive cell lines. Although p53 and p-p53 protein 
did appear to accumulate in UMSCC74a (HPV-negative) following treatment with 10 
μM Olaparib.  
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6.8.2 Clonogenic assay 
The cell line panel showed a wide range in sensitivity to a single dose of Olaparib. 
Several of the HPV-positive lines demonstrated high sensitivity to low doses of Olaparib (0.1 
μM) whilst all lines were sensitive to 10 μM. The widest range of responses was observed at 
0.5 and 1 µM. These concentrations illustrated a clear distinction between the high sensitivity 
of some HPV-positive cells (PCOC2, UPCISCC90), the medium sensitivity of an HPV-negative 
line (UMSCC74a) and HEKn, and the low sensitivity of a mix of HPV-positive and negative lines 
(PCOC3, UMSCC47, UMSCC4 and UMSCC19). The dose range was chosen based upon studies 
testing the effects of Olaparib on BRCA2 mutant and proficient breast cancer cell lines. Doses 
up to 10 μM enabled the distinction between Olaparib sensitive (BRCA2 mutant) and non-
sensitive (BRCA2 proficient) cells (Evers et al. 2008). The 0.5 μM and 1 μM Olaparib treatments 
were in the range reported to be selective for cells with BRCA2 mutation.  
One unanticipated finding was that the normal keratinocytes (HEKn) were sensitive to 
relatively low doses of Olaparib. As these cells are presumed to be competent in DSB repair, 
Olaparib sensitivity was not expected after low dose treatment. Alternatively, this could be 
interpreted as indicating the presence of a functioning response to DNA damage, which may 
include arrest in G2-phase followed by effective DNA repair, that was absent in the majority of 
the cancer cell lines. This is consistent with expansion of the proportion of cells in G2 at 24 h 
following treatment but a return to a normal cell cycle distribution at 48 h. 
An overlap in sensitivity between HPV-positive and negative OPSCC cell lines has also 
been reported following IR (Rieckmann et al. 2013). The absence of a clear difference in radio-
sensitivity up to 6 Gy has also been confirmed in our laboratory using the same cell line panel 
as used in this study (Stefan Holzhauser, unpublished data). The main difference between 
Olaparib and radio-sensitivity was related to UMSCC47 which in the study by Rieckmann, was 
the most radio-sensitive of the HPV-positive lines but showed low sensitivity to Olaparib. 
Similarly, cisplatin treatment, as a single agent, did not highlight a clear difference between 
HPV-positive and negative HNSCC cell lines (Busch et al. 2016). It is noteworthy that several 
studies have observed correlations in cell line sensitivity between Olaparib and other DNA 
damaging chemotherapeutics including carboplatin, camptothecin and doxorubicin (testing 
undertaken by KuDOS Pharmaceuticals and reported in the European Medicine Agency (EMA) 
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report (Committee for Medicinal Products for Human Use 2014). Together, this suggests that 
responses to DNA damaging therapies may not show a clear correlation with HPV status. 
Three other studies have examined the effects of PARP1 inhibition in HNSCC cell lines 
(Güster et al. 2014; Weaver et al. 2015; Nickson et al. 2017). The study by Weaver et al. 
compared the response to Veliparib in two HPV-positive and one HPV-negative cell lines 
(UMSCC47, UPCISCC154 and UMSCC1 respectively). It showed the HPV-negative line to be the 
least sensitive (c. 1.5 fold difference). The paper by Nickson et al. is of particular interest, as it 
used the same drug (Olaparib) and four of the same cell lines as used in the current study 
(UMSCC 47, 6, 74a and UPCISCC90). They observed that the HPV-positive cell lines were most 
sensitive to IR, but reported Olaparib (up to 1 μM) as having no effect on cell proliferation 
(determined using clonogenic assays) in any line. 
The study by Guster et al. investigated the effects of Olaparib in a panel of 5 treatment-
naïve HPV-positive HNSCC (with one line, UMSCC47, in common with the current study). This 
showed broad variation in response to Olaparib (between approximately 10-45% inhibition 
following 5 days growth with 1 μM Olaparib). However, it was notable that the two lines with 
highest baseline PARP1 levels showed the greatest sensitivity to Olaparib. 
Taken together these reports show quite diverse findings. The reasons why other studies 
report very different results is unclear but may be related to differences in dose and the assay 
methodologies (e.g. differences in length of drug exposure) There is the suggestion that DSB 
repair is sub-optimal in some, but not all, HPV-positive cell lines, and that this may be 
associated with delayed resolution of DSB due to low levels of BRCA2, DNA-PK and associated 
proteins. There is also a suggestion that BER and SSB repair proteins may be up-regulated in 
HPV-positive cells, but levels of PARP1 do show variation. It also appears that high levels of 
basal PARP1 show some correlation with response to Olaparib.  
With regard to the strengths and weaknesses of the current study, the clonogenic data is 
very robust. This was achieved by thorough protocol development to optimise culture 
conditions including assay length and seeding density for all cell lines. This ensured reliable 
plating efficiency calculations which were the main measure of a clonogenic assay. To 
minimise the effects of Olaparib treatment on cell adhesion, plates were treated 24 h after 
seeding. In addition, an untreated plate was present in each experiment to assess the effect of 
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DMSO alone (this indicated that no individual cell line was differentially sensitive to DMSO, 
data not shown). Manual counting was reduced to a minimum by the use of an image analysis 
software thereby reducing subjectivity in the counting process. The software was based on 
pixel shade which could be affected by picture lighting. Hence three pictures were taken and 
counted for each plate. If manual counting was required (due to the growth characteristics of 
the individual cell line), two people performed independent counts.  
Several assays are available to measure drug sensitivity (e.g. MTT, cell count with dye 
exclusion, flow cytometric counting, etc.). Clonogenic assays were chosen primarily because 
the protocol was developed to test both radio and drug-sensitivity separately or in 
combination. Clonogenic assays are recognised as the assay of choice for radio-sensitivity as 
well as being adapted to determine the sensitivity of tumour cells to chemotherapy agents or 
other drugs (Rafehi et al. 2011). This assay measures the capacity of individual cells to divide 
following treatment and may detect  a higher level of sensitivity than other assays (Bird et al. 
1987). This effect has previously been observed in HNSCC cell lines which displayed sensitivity 
to chemotherapy agents at lower doses in clonogenic assays compared to MTT or counting 
assays (Henriksson et al. 2006). Similarly, no response to 0.1 μM or 1 μM treatment was 
detected by flow cytometry even in cell lines that were sensitive to these concentrations in the 
clonogenic assays. This could be an example of the greater potential sensitivity of the 
clonogenic assays. 
Overall, the clonogenic assays demonstrated the efficacy of Olaparib against our panel 
of OPSCC cell lines, including two novel lines. The main findings were efficacy at potentially 
therapeutic levels in some cell lines, but a lack of correlation between HPV status and Olaparib 
sensitivity. Hence it appears that HPV status is unlikely to provide a convenient predictive 
biomarker to guide the use of Olaparib in the context of OPSCC. The same appears likely to be 
true of basal levels of PARP1. However, these predictions clearly require validation in the 
context of well controlled clinical trials. Clinical trials may also provide the bio-resources and 
data to assess correlations between treatment response and other markers of a “BRCA-like” 
phenotype that may be associated with response to Olaparib (Lim and Ngeow 2016).  
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6.8.3 -H2AX and cell cycle analysis 
Levels of -H2AX, indicating the presence of DSB, and cell cycle distribution were 
assessed following treatment with Olaparib. Effects on these measures were only observed 
after 10 µM treatment. Lower doses of 0.1 μM and 1 μM did not lead to the formation of 
detectable DSB or cell cycle alterations. Cells were assessed at two timepoints (24 and 48 h), of 
these, 48 h is possibly a better indicator to the presence of delayed or suboptimal repair of 
DSB. Forty-eight hours after 10 μM treatment, substantial levels of unrepaired DSB were 
evident in 2/4 HPV-positive lines and 3/3 HPV-negative lines. Hence the data do not appear 
consistent with the hypothesis that HPV-positive cells would accumulate higher levels of 
unrepaired DNA DSB than HPV-negative lines due to defective DSB repair. Similarly, there was 
no correlation between HPV status and the degree of cell cycle perturbations in response to 
Olaparib (48 h after 10 μM Olaparib).  
The presence of unrepaired DSB did not appear to correlate with effect on the cell cycle. 
Among the five cell lines that accumulated DSB, only UPCISCC90 and UMSCC47 showed 
evidence of cell cycle arrest 48 h after treatment. Conversely, all three of the HPV-negative 
OPSCC lines showed evidence of DSB 24 and 48 h after 10 μM treatment but did not show 
significant changes to cell cycle distribution at 24 or 48 h (although some increase in G2 
fraction was apparent in UMSCC4 and 74a). This is consistent with delayed repair and impaired 
response to DNA damage in these lines. This possibility is supported by data from Kimple et al. 
that showed an absence of G2 arrest in several HPV-negative HNSCC cell lines following 4 Gy 
IR. However, they also reported significant G2 arrest in 4 HPV-positive lines (including 
UMSCC47 and UPCISCC90), which is not entirely consistent with our observations, where a 
clear distinction in response according to HPV status was not apparent.(Kimple et al. 2013).  
Of all the lines, UPCISCC90 accumulated the highest level of DSB (both after 24 h and 48 
h). After 24 h, this was associated with an increase in the proportion of cells in S-phase, which 
could be attributed to a pause in the cell cycle to allow DNA repair. After 48 h, a significant 
increase in the G2-phase was much more apparent, suggesting cell cycle arrest at this point, 
with cells unable to complete mitosis.  
The -H2AX level in normal keratinocytes HEKn was unaffected by 10 µM Olaparib 
treatment, but there was a slight increase in G2 fraction after 48 h, suggesting DNA damage 
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occurred below detectable levels, and was responded to. Following treatment with Etoposide, 
it was notable that levels of DSB induced were generally 1-5 fold higher in the cancer cell lines 
than in the normal cells. This might suggest less effective repair of DSB in both HPV-positive 
and negative cells than in normal cells, however as this observation is based on a single cell 
line, it should be treated with caution.  
The absence of significant differences between HPV-positive and negative HNSCC cell 
lines in basal level of -H2AX or cell cycle distribution has been observed in other studies. 
Nickson et al. found similar basal levels of -H2AX in 4 OPSCC cell lines, 3 of which were 
included in the panel used in this chapter (Nickson et al. 2017). They also reported faster repair 
of IR induced DSB (indicated by loss of -H2AX foci) in UMSCC47 compared to UMSCC6 and 
74a. The same patterns (lower -H2AX levels in UMSCC47 compared to UMSCC6 and 74a) were 
apparent in the current study. Weaver et al. published a study based on 3 HNSCC cell lines and 
reported slower resolution of IR induced -H2AX foci in the two HPV-positive lines (including 
UMSCC47) (Weaver et al. 2015). The findings reported in this thesis are broadly consistent 
with previously published data but are based on a greater number of cell lines. The study by 
Weaver et al. is also notable as it proposed a specific mechanism for defective repair of DSB in 
HPV-positive OPSCC i.e. that HPV-positive cells show reduced repair by both NHEJ and HR as a 
consequence of deficiencies in protein expression and recruitment of DNA-PK and BRCA2. In a 
separate study, low levels of DNA-PK and BRCA2 were shown in UPCISCC90 but not in 
UMSCC47 (Nickson et al. 2017).  
The strengths of this section included the thoroughly optimised and robust experimental 
methods. Experiments were performed in triplicate for each cell line using the same settings 
on a single flow cytometer. The main weakness was the absence of another technique to 
confirm the DNA damage caused by Olaparib. Such as Immunofluorescence to observe the 
formation and resolution of DSB, the main advantage of this technique is that the number of -
H2AX foci has been correlated with the number of DSB (Willmore et al. 1998). However, flow 
cytometry based approaches allow simultaneous observation of DSB and cell cycle distribution. 
Furthermore, some exposures, e.g. cisplatin, can lead to pan-nuclear staining associated with 
stalling of multiple replication forks, in which case flow cytometric assessment may be more 
appropriate (Busch et al. 2016). 
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6.8.4 Western blotting 
There was no apparent correlation between basal PARP1 level and HPV status. However, 
UPCISCC90 showed elevated PARP1 levels compared to the other lines. In the HPV-positive cell 
lines, following Olaparib treatment, there was no detectable p53, or p-p53 protein nor any 
induction of apoptosis. In the HPV-negative line UMSCC74a, p53 and p-p53 were detected 
following exposure to Olaparib. Cleaved PARP1, indicating apoptotic cells, was not detected in 
any of the cell lines in response to Olaparib.  
Whether p53 accumulates and causes apoptosis in HPV-positive HNSCC lines is 
controversial. A study by Kimple et al. reported accumulation of p53, caspase activation and 
increased annexin V binding in HPV-positive cells following IR. Although basal p53 protein and 
weak p-p53 protein in irradiated UPCISCC90 were only detected using western blots with what 
they describe as “long exposure”, and they reported absence an of p53 and p-p53 in UMSCC47 
(as observed in the current study) (Kimple et al. 2013). A similar study by Rieckmann et al. 
reported no accumulation of p53 and the absence of caspase activation and PARP1 cleavage 
(Rieckmann et al. 2013). It should be noted however that the 15 HNSCC lines assessed 
represented a very diverse group and only 3 were included in both studies. This highlights the 
pitfalls of drawing conclusions based on heterogeneous groups, and demonstrates the need 
for additional in vitro models. 
Another study examined cisplatin sensitivity in HPV-positive and negative HNSCC cell 
lines and showed only very low levels of caspase activity in response to cisplatin (Busch et al. 
2016). This study assessed only one cell line from the current panel (UMSCC47) in which no 
apoptosis was observed. The authors concluded that it was questionable whether apoptosis 
played a major role in response to cisplatin under the conditions investigated.  
The elevated PARP1 protein in untreated UPCISCC90 cells, and lower expression in 
UMSCC74a, was consistent with a previous study (Nickson et al. 2017). Basal PARP1 levels are 
relevant as, when Olaparib was tested against a broad panel of cancer cell lines, it was 
observed that low expression of PARP1 correlated with low sensitivity to Olaparib (testing 
undertaken by KuDOS Pharmaceuticals and reported in a European Medicine Agency (EMA) 
report (Committee for Medicinal Products for Human Use 2014). This is consistent with the 
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highest sensitivity to Olaparib in the current study being observed in line with the highest 
expression of PARP1 (UPCISCC90).  
There was no evidence to support the hypothesis that functional p53 was present in 
HPV-positive cells (i.e. that HPV conferred a less complete p53 phenotype than p53 mutation). 
It was interesting that accumulation and activation of p53 was not observed in UMSCC47, 
which supposedly expresses wild-type p53. This may suggest that either this line has an 
unidentified defect in p53 signalling, or that the stimuli used (Olaparib and IR) were not 
appropriate to stabilise p53. However, the latter seems unlikely as p53 was consistently 
induced by IR in HEKn cells.  
The strengths of these analyses include the use of well-validated assays with appropriate 
controls. Potential weakness included the absence of a positive control for p53 specific for 
each line. However, this was compensated for by the presence of irradiated HEKn on all 
membrane with visible p53 and p-p53. There are also some questions regarding whether the 
use of a more sensitive -H2AX detection assay would have been helpful. 
6.8.5 Further work 
The findings of this chapter could be extended and further validated by repeating the 
investigation of induction of DSB using immunohistochemical staining. The mechanism by 
which PARP1 inhibits cell proliferation could be further assessed using an RNA-seq based 
investigation of treated vs untreated cells. The findings regarding apoptosis could also be 
validated by using additional markers (e.g. a direct measure of caspase activity). Perhaps the 
highest priority however is the derivation and analysis of a greater number of OPSCC cell lines. 
The vulnerability of studies using a very limited number of cell lines has recently been 
highlighted by Busch et al. who observed complex patterns of response among a panel of 11 
cell lines (Busch et al. 2016). Using only a subset of these lines could easily lead to erroneously 
simplistic models. 
6.8.6 Conclusion 
There are several clear conclusions that can be drawn from the work described. The 
main one being that HPV status did not correlate with sensitivity to Olaparib. It was apparent 
that several lines were sensitive to Olaparib at doses that could be clinically relevant (by 
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analogy to the sensitivity of BRCA mutant breast cancer cell lines). However, it is difficult to 
discern any characteristic that would be adequate as a predictive marker. Regarding the 
mechanism of sensitivity, there was some evidence for an association with cell cycle arrest, but 
the correlation was not perfect. There was no evidence that sensitivity to Olaparib was 
associated with apoptosis.  
The results described in this chapter do not support the often repeated suggestion that 
there is a specific defect in repair of DSB in HPV-positive cells (Weaver et al. 2015; Nickson et 
al. 2017). Or at least, one that is therapeutically exploitable via synthetic lethal approaches. 
However, it is important to note, that in the current study we have predominantly investigated 
DSB arising from treatment with Olaparib, rather than DSB directly induced by IR, and there 
may be significant differences in response to lesions inflicted by different methods. The 
absence of cell cycle arrest in response to accumulation of DSB in the HPV-negative lines may 
suggest impaired surveillance of and/or response to DNA damage in these lines. 
Only the results for UPCISCC90 were consistent with the original hypothesis: that in 
HPV-positive cells treatment with Olaparib would cause accumulation of DSB, resulting in cell 
cycle  delays, and this would be associated with increased sensitivity to Olaparib demonstrated 
by clonogenic assays. For all the other cell lines, the data are more complex and difficult to 
interpret. The diverse responses across the cell line panel appears likely to be a true reflection 
of the biological heterogeneity of OPSCC and suggests that caution should be exercised with 
regard to conclusions drawn in studies including only a small number of cell lines. 
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Chapter 7 - Final discussion 
HPV-positive OPSCC is a relatively new disease entity, and the natural history of HPV 
infection in the oropharynx is poorly defined. The work described in Chapter 3 was the second 
phase of a natural history study, which aimed to determine whether HPV infection is common 
in non-malignant tonsil tissue, and identify premalignant lesions (analogous to cervical 
intraepithelial neoplasia). It was based on a sample of 511 non-malignant tonsils from patients 
representing the demographic groups most likely to harbour high-risk HPV infection. Three 
HPV detection techniques, including the most sensitive commercial test available at the time, 
failed to detect any HPV presence in the samples. This study showed that HPV infection is a 
very rare event in non-malignant tonsils. This finding has now been replicated in a similar study 
in France (Franceschi et al. 2015). The low prevalence of HPV infection, coupled with the 
absence of characterised premalignant lesions, and localisation of HPV within tonsillar crypts, 
renders early detection of OPSCC difficult. This suggests that for prevention of OPSCC, 
prophylactic vaccination, possibly including gender-neutral vaccination, may be a better 
investment of health resources. However, it will be approximately 30-40 years before 
vaccination results in reduced incidence of OPSCC. This is because, in the UK, vaccination of 12 
year-old girls began in 2008, while diagnosis of OPSCC most commonly occurs in men aged 55-
65 years. Hence there will be many OPSCC patients requiring treatment for many years to 
come. Patients are still likely to present with advanced lesions and suffer serious side effects 
and late toxicities from their treatment. This again highlights the need for improved therapies 
for this condition, and specifically treatments targeting the growing number of HPV-positive 
patients, who are likely to respond better to therapy, and live longer with the consequences of 
their treatment.  
Understanding of HPV-positive OPSCC at the molecular level, and development of 
aetiology-specific treatments, is hampered by a lack of in vitro models. In the current 
literature, approximately 5-8 HPV-positive OPSCC cell lines have been described. The study 
presented in Chapter 4 aimed to develop novel in vitro models of OPSCC. The 61.5% rate of 
explant growth showed the method used was appropriate to sustain growth of epithelial cells 
derived from oropharyngeal tissue. However, the lower overall success rate (15.4%) for cell 
line development illustrates the technical challenges and time commitment required for 
primary and early cell culture. Ultimately, two apparently immortal lines were produced 
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(PCOC2 and PCOC3), and the analyses undertaken on these lines confirmed that they: 
originated from the corresponding biopsies, were keratinocytes, and were positive for HPV16 
infection. Further characterisation using the mRNA-sequ data generated in Chapter 5, 
established that PCOC2 and PCOC3 contained wild-type p53 and that HPV had integrated into 
the host DNA (in chromosome 10 and 20 respectively). This validated the two cell lines as 
appropriate models to study HPV-positive OPSCC. The use of PCOC2 and PCOC3 for the rest of 
the investigations provided the advantage of low passage lines typical of the demographic 
affected by HPV-driven oropharyngeal cancers (i.e. relatively young and fit, with limited co-
morbidities associated with alcohol and tobacco). 
A panel composed of the two novel lines, plus two other HPV-positive lines and 4 HPV-
negative lines was selected to reflect some of the heterogeneity found in OPSCC. This included 
variables such as wild type versus mutated p53, treatment naive versus recurrent, and 
smoking versus non-smoking. The mRNA-seq analysis, described in chapter 5, was used to 
confirm the molecular characteristics of the panel and compare gene expression between 
HPV-positive and negative lines. This confirmed the p53 status, and in UMSCC4 and UMSCC19 
previously described mutations were identified (Somers et al. 1992; Bradford et al. 2003; Ferris 
et al. 2005). Integration events were identified in UMSCC47 and UPCISCC90 with an additional 
site in chromosome 9 detected in UPCISCC90. This descriptive data, together with the 
confirmed HPV status and STR typing, validated the cell line panel as appropriate for further 
experiments. 
The mRNA-seq analysis allowed comparison of the molecular characteristics of the HPV-
positive and negative groups. GO analysis highlighted several significantly differentially 
regulated ontologies, mostly relating to cellular metabolism. However none of these pathways 
had an obvious relation to viral oncogenesis or treatment response. The hypothesis that DDR 
pathways or expression of individual gene involved in DDR would be significantly different 
between HPV-positive and negative lines was not confirmed. This hypothesis was based on the 
suggestion that APOBEC3A, induced in HPV-positive cells (Landry et al. 2011), and high levels 
of reactive oxygen species in HPV-positive tumours (Marullo et al. 2015), would activate BER. 
Also, the utilisation of components of the DSB repair machinery for HPV replication, might 
result in up-regulation of DSB repair pathways. However, the mRNA-seq data did not provide 
evidence of differences in DNA damage response or repair pathways. This appears to 
contradict the suggestion that HPV-positive cell lines might be defective in DNA damage 
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response and/or repair (Kimple et al. 2013; Rieckmann et al. 2013; Weaver et al. 2015). 
Although it should be noted that these analyses were conducted using cells that had not 
received additional directly DNA damaging treatment. 
Concurrent with the mRNA-seq study, the cell line panel was used to evaluate the 
potential of synthetic lethal therapy using the PARPi Olaparib. Chapter 6 described the results 
of this study. The sensitivity of the lines to a single dose of Olaparib was assessed. Olaparib 
sensitivity showed only partial correlation with HPV status. Of the four HPV-positive lines, two 
were classed as sensitive and two as resistant; while the HPV-negative lines were classed as 
resistant, or showing intermediate sensitivity. Further investigation of Olaparib treated cells 
was undertaken and this showed no evidence to suggest less effective repair of DSB in HPV-
positive cells. In fact, the data seem to suggest the opposite trend. Three of the HPV-positive 
lines showed significantly increased levels of -H2AX 24 h after treatment with 10 μM Olaparib, 
but in two of these lines, levels had returned to baseline by 48 h. In contrast, all of the HPV-
negative OPSCC lines showed significantly increased levels of -H2AX at 24 h that were not 
repaired at 48 h. However, the presence of unrepaired DSB 48 h after 10 µM treatment did not 
uniformly induce G2 arrest as had been hypothesised. Significant G2 arrest only occurred in 
UPCISCC90.  
PARP1 expression, as measured by western blot and mRNA-seq, did not show obvious 
correlation with HPV status, or with drug sensitivity. Although it was notable that mRNA and 
protein levels of PARP1 were highest in UPCISCC90, and this line was also the most sensitive to 
Olaparib. This confirmed that high PARP1 level can be associated with Olaparib sensitivity, but 
only in some lines. The absence of p53 reactivation in HPV-positive cells seen in western blots 
was in accordance with the absence of differences in expression of “genes involved in DNA 
damage response, signal transduction by p53 class mediator” observed in the mRNA-seq data.  
It had previously been suggested that in HPV-positive cells, accumulation of DSB might 
be caused by a deficiency in DNA repair resulting in delayed repair (Rieckmann et al. 2013; 
Weaver et al. 2015). Kimple et al. however, suggested that re-activation of p53 was involved in 
the HPV-positive lines response to radiation, but this did not seem to be the case in response 
to Olaparib (Kimple et al. 2013). 
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The results presented are based on a small number of cell lines. But it should be noted 
that the number of cell lines used is similar to or higher than what was used in key publications 
within the field (Kimple et al. 2013; Rieckmann et al. 2013; Weaver et al. 2015; Ziemann et al. 
2015). Furthermore, the lines used in the current study may well represent better models 
(being exclusively OPSCC and including lines derived from HPV-positive non-smokers, rather 
than diverse HNSCC). The heterogeneity of the Olaparib sensitivity appears likely to be a 
reflection of the heterogeneity of the cell line panel. It may well also be a reasonable 
representation of the heterogeneity of OPSCC patients. Studies in HNSCC lines have previously 
reported wide variations in sensitivity to chemo and radio-therapy with overlap between HPV-
positive and negative lines (Kimple et al. 2013; Busch et al. 2016).  
Cell line studies, especially using novel and/or early passage cell lines may be limited in 
scale by the technical work necessary to maintain the lines in culture and their sometimes slow 
growth. However, perhaps the greatest limitations are the 2 dimensional nature of model and 
the absence of the microenvironment, especially with regard to the absence of cells of the 
immune system. Animal models could be seen as an intermediate level model. However, when 
conducted using immune compromised mice, they suffer from similar limitations.  
The data were not consistent with the original hypothesis (i.e. HPV-positive tumours will 
show greater sensitivity to Olaparib), but did suggest that monotherapy with PARPi might be 
useful in some OPSCC patients irrespective of HPV status. Consistent with this suggestion, pre-
clinical studies, described in the marketing authorisation of Lynparza, showed that several 
head and neck cell lines (HPV-negative, some non-oropharyngeal) were sensitive to Olaparib at 
similar concentrations as some ovarian lines.  
To determine whether Olaparib will be useful in clinical practise will ultimately depend 
on the results of clinical trials. In this context, it is pragmatic to evaluate Olaparib in 
combination with radiotherapy rather than as monotherapy. Combination of Olaparib with 
radiotherapy is the subject of investigation of several ongoing clinical trials. Nonetheless, 
complementary in vitro studies still have the potential to increase our understanding of the 
molecular effects of these therapies.  
None of the characteristics of the cell lines investigated in this study, such as HPV, p53 
or PARP1, were indicators of sensitivity to Olaparib. Given that treatment with Olaparib may 
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be effective in treating a subset of OPSCC patients, it would be desirable to identify predictive 
biomarker to guide its use. An mRNA-seq approach using treated and untreated lines would 
provide an exploratory method of investigating the transcriptional profile associated with 
Olaparib response. However, given that clinical trials using Olaparib are underway, there may 
be bio-resources associated with clinical outcome data, which would allow identification of 
predictive markers. Such investigations should also be informed by the results of studies 
seeking predictive biomarkers for Olaparib (i.e. markers of BRCA-ness) in other tumours (Lim 
and Ngeow 2016). 
There remains a pressing need for additional cell line models of HPV-positive OPSCC, 
which are required to increase understanding of this disease at the molecular level. It is also 
the case that understanding the natural history of HPV in the oropharynx is proving a 
challenging endeavour, and further well-designed epidemiological studies are required. It 
appears that the likely utility of Olaparib is best addressed empirically through appropriate 
clinical trials. In terms of aetiology-specific treatments for OPSCC, our data suggest that 
targeting DNA repair may not be the most fruitful avenue of investigation. Given the possible 
significance of the immune response in outcome of OPSCC, modulation of this response may 
be a more attractive option for ongoing investigation. 
7.1 Conclusion 
In conclusion, this investigation found little evidence to support the suggestion that HPV 
infection is associated with defects in DNA repair, and sensitivity to Olaparib. mRNA-seq did 
not show differences in basal transcription of genes involved in DNA repair (although these 
analyses were conducted in untreated cells). Similarly, there was no consistent trend in terms 
of sensitivity to Olaparib, and HPV-positive OPSCC cell lines did not appear to accumulate 
higher levels of DSB in response to the drug. Furthermore, there was no evidence for 
accumulation and activation of p53 in HPV-positive cells. This strongly suggests that improved 
survival in HPV-positive patients is likely to be due to alternative factors, most likely including 
the presence of a non-self immune target in HPV-positive tumours.  
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